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A B S T R A C T
Background
People with liver cirrhosis who have had one episode of variceal bleeding are at risk for repeated episodes of bleeding. Endoscopic
intervention and portosystemic shunts are used to prevent further bleeding, but there is no consensus as to which approach is preferable.
Objectives
To compare the benefits and harms of shunts (surgical shunts (total shunt (TS), distal splenorenal shunt (DSRS), or transjugular intrahepatic
portosystemic shunt (TIPS)) versus endoscopic intervention (endoscopic sclerotherapy or banding, or both) with or without medical
treatment (non-selective beta blockers or nitrates, or both) for prevention of variceal rebleeding in people with liver cirrhosis.
Search methods
We searched the CHBG Controlled Trials Register; CENTRAL, in the Cochrane Library; MEDLINE Ovid; Embase Ovid; LILACS (Bireme); Science
Citation Index - Expanded (Web of Science); and Conference Proceedings Citation Index - Science (Web of Science); as well as conference
proceedings and the references of trials identified until 22 June 2020. We contacted study investigators and industry researchers.
Selection criteria
Randomised clinical trials comparing shunts versus endoscopic interventions with or without medical treatment in people with cirrhosis
who had recovered from a variceal haemorrhage.
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Data collection and analysis
We used standard methodological procedures expected by Cochrane. When possible, we collected data to allow intention-to-treat analysis.
For each outcome, we estimated a meta-analysed estimate of treatment eJect across trials (risk ratio for binary outcomes). We used
random-eJects model meta-analysis as our main analysis and as a means of presenting results. We reported diJerences in means for
continuous outcomes without a meta-analytic estimate due to high variability in their assessment among all trials. We assessed the
certainty of evidence using GRADE.
Main results
We identified 27 randomised trials with 1828 participants. Three trials assessed TSs, five assessed DSRSs, and 19 trials assessed TIPSs.
The endoscopic intervention was sclerotherapy in 16 trials, band ligation in eight trials, and a combination of band ligation and either
sclerotherapy or glue injection in three trials. In eight trials, endoscopy was combined with beta blockers (in one trial plus isosorbide
mononitrate). We judged all trials to be at high risk of bias. We assessed the certainty of evidence for all the outcome review results as very
low (i.e. the true eJects of the results are likely to be substantially diJerent from the results of estimated eJects). The very low evidence
grading is due to the overall high risk of bias for all trials, and to imprecision and publication bias for some outcomes. Therefore, we are
very uncertain whether portosystemic shunts versus endoscopy interventions with or without medical treatment have eJects on all-cause
mortality (RR 0.99, 95% CI 0.86 to 1.13; 1828 participants; 27 trials), on rebleeding (RR 0.40, 95% CI 0.33 to 0.50; 1769 participants; 26 trials),
on mortality due to rebleeding (RR 0.51, 95% CI 0.34 to 0.76; 1779 participants; 26 trials), and on occurrence of hepatic encephalopathy,
both acute (RR 1.60, 95% CI 1.33 to 1.92; 1649 participants; 24 trials) and chronic (RR 2.51, 95% CI 1.38 to 4.55; 956 participants; 13 trials).
No data were available regarding health-related quality of life.
Analysing each modality of portosystemic shunts individually (i.e. TS, DSRS, and TIPS) versus endoscopic interventions with or without
medical treatment, we are very uncertain if each type of shunt has eJect on all-cause mortality: TS, RR 0.46, 95% CI 0.19 to 1.13; 164
participants; 3 trials; DSRS, RR 0.93, 95% CI 0.65 to 1.33; 352 participants; 4 trials; and TIPS, RR 1.10, 95% CI 0.92 to 1.31; 1312 participants;
19 trial; on rebleeding: TS, RR 0.28, 95% CI 0.14 to 0.56; 127 participants; 2 trials; DSRS, RR 0.26, 95% CI 0.11 to 0.65; 330 participants; 5
trials; and TIPS, RR 0.44, 95% CI 0.36 to 0.55; 1312 participants; 19 trials; on mortality due to rebleeding: TS, RR 0.25, 95% CI 0.06 to 0.96; 164
participants; 3 trials; DSRS, RR 0.31, 95% CI 0.13 to 0.74; 352 participants; 5 trials; and TIPS, RR 0.65, 95% CI 0.40 to 1.04; 1263 participants;
18 trials; on acute hepatic encephalopathy: TS, RR 1.66, 95% CI 0.70 to 3.92; 115 participants; 2 trials; DSRS, RR 1.70, 95% CI 0.94 to 3.08;
287 participants; 4 trials, TIPS, RR 1.61, 95% CI 1.29 to 1.99; 1247 participants; 18 trials; and chronic hepatic encephalopathy: TS, Fisher's
exact test P = 0.11; 69 participants; 1 trial; DSRS, RR 4.87, 95% CI 1.46 to 16.23; 170 participants; 2 trials; and TIPS, RR 1.88, 95% CI 0.93 to
3.80; 717 participants; 10 trials.
The proportion of participants with shunt occlusion or dysfunction was overall 37% (95% CI 33% to 40%). It was 3% (95% CI 0.8% to 10%)
following TS, 7% (95% CI 3% to 13%) following DSRS, and 47.1% (95% CI 43% to 51%) following TIPS. Shunt dysfunction in trials utilising
polytetrafluoroethylene-covered stents was 17% (95% CI 11% to 24%).
Length of inpatient hospital stay and cost were not comparable across trials.
Funding was unclear in 16 trials; 11 trials were funded by government, local hospitals, or universities.
Authors' conclusions
Evidence on whether portosystemic shunts versus endoscopy interventions with or without medical treatment in people with cirrhosis and
previous hypertensive portal bleeding have little or no eJect on all-cause mortality is very uncertain. Evidence on whether portosystemic
shunts may reduce bleeding and mortality due to bleeding while increasing hepatic encephalopathy is also very uncertain. We need
properly conducted trials to assess eJects of these interventions not only on assessed outcomes, but also on quality of life, costs, and
length of hospital stay.
P L A I N   L A N G U A G E   S U M M A R Y
Shunts compared with endoscopic intervention to prevent further episodes of variceal bleeding in people with liver cirrhosis
Background
People with scarring of the liver (cirrhosis) may develop high pressure in the portal vein (the vein that carries blood from the gut to the
liver). This high pressure results in abnormally dilated veins (varices) in the gullet (oesophagus), in the stomach, or in the intestine, which
may cause life-threatening bleeding. People who have bled once are at high risk of bleeding in the future, so it is important to prevent
further bleeding episodes in these people. DiJerent treatment options are available to prevent further bleeding. One option is endoscopic
treatment, which uses a flexible camera to examine the aJected area and to seal varices with elastic bands, or to inject the varices with a
substance to close the veins. A second option is 'shunting', which diverts blood flow away from the problematic vein, reducing pressure
and thereby reducing the chance of bleeding. There are three main types of shunts: total shunt, distal splenorenal shunt, and transjugular
intrahepatic portosystemic shunt. Total shunt and distal splenorenal shunt were more commonly used in the past and require invasive
surgical procedures. TIPS are now much more commonly used, as they do not require invasive surgery.
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Review question
The aim of this Cochrane Review was to compare shunts versus endoscopic treatments with or without further medications in people with
liver cirrhosis who had previously bled from varices, by collecting and analysing all relevant studies in this topic area and by reviewing
the evidence.
Study characteristics
In June 2020, we reviewed the evidence. We found 27 randomised clinical trials (trials where participants are allocated to groups at
random) involving 1828 participants. Three trials investigated total shunt (164 participants); five trials investigated distal splenorenal shunt
(352 participants); and 19 trials investigated transjugular intrahepatic portosystemic shunt (1312 participants). The source of funding was
unclear in 16 trials. Eleven trials were funded by the government or received grants from local hospitals or universities.
Results
Evidence suggesting whether shunt treatments compared with endoscopic treatments with or without further medications alter the overall
risk of death from any cause (all-cause mortality), reduce the risk of bleeding from varices, or reduce the risk of dying from bleeding varices
(death due to variceal bleeding) was very uncertain.
Evidence that people treated with shunts compared with endoscopic treatments with or without further medications are at increased risk
of acute hepatic encephalopathy (brain dysfunction associated with liver disease) or chronic hepatic encephalopathy (brain dysfunction
that occurs repeatedly or does not fully improve) was also very uncertain.
We could not conclude with certainty whether people treated with shunt stayed in hospital longer than people treated with endoscopy
with or without further medications, or which treatment was more expensive, as we were not confident that combining the results from
diJerent studies would produce a meaningful result. No trials reported on the impact of treatments on patient quality of life.
Risk of bias
The results of our analyses must be interpreted with caution due to concerns about the quality of included trials. Weaknesses in the design
of these studies could influence results, making them potentially misleading.
Conclusions
We cannot say for sure that portosystemic shunts when compared with endoscopic treatment associated sometimes with medical
treatment modify the risk of overall death (all-cause mortality), reduce the risk of repeated episodes of bleeding, or increase the risk of
developing hepatic encephalopathy. We need properly conducted trials assessing important outcomes for people with cirrhosis and health
providers.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Portosystemic shunts compared with endoscopic intervention with or without medical treatment for prevention of
rebleeding in people with cirrhosis
Portosystemic shunts compared with endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis
Patient or population: participants with cirrhosis and with previous oesophagogastric variceal bleeding
Setting: hospital; tertiary referral centres
Intervention: shunt intervention (total shunt (TS), distal splenorenal shunt (DSRS), or transjugular intrahepatic portosystemic shunt (TIPS))
Comparison: endoscopic intervention with or without medical treatment
Illustrative comparative risks (95% CI)Outcomes
Assumed risk with en-
doscopic intervention
















Follow-up: 32.9 months (range 11.7 to 98) 288 per 1000 286 per 1000 (248 to 325)








Follow-up: 33.8 months (range 13.5 to 98) 432 per 1000 173 per 1000
(143 to 216)







Health-related quality of life No data available No data
Medium-risk populationMortality due to rebleeding
Follow-up: 33.5 months (range 11.7 to 98) 95 per 1000 48 per 1000 (32 to 72)







Medium-risk populationAcute hepatic encephalopathy
Follow-up: 33.8 months (range 13.5 to 98) 185 per 1000 296 per 1000
(246 to 355)







Medium-risk populationChronic hepatic encephalopathy
Follow-up: 28.5 months (range 13.5 to 98) 27 per 1000 68 per 1000
(37 to 123)


















































































































































































The corresponding risk (risk of the intervention group) (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; OIS: optimal information size; RCT: randomised clinical trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded three levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); publication bias (-1 level).
bDowngraded three levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); publication bias (-1 level).
cDowngraded four levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); imprecision: optimal information size (OIS) as calculated by
GRADE was not met (-1 level); publication bias (-1 level).
dDowngraded four levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); imprecision: OIS as calculated by GRADE was not met (-1 level);
publication bias (-1 level).
eDowngraded four levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); imprecision: OIS as calculated by GRADE was not met (-1 level);
publication bias (-1 level).
 
 
Summary of findings 2.   Total shunt compared with endoscopic intervention for prevention of rebleeding in people with cirrhosis
Total shunt compared with endoscopic intervention for prevention of rebleeding in people with cirrhosis
Patient or population: participants with cirrhosis and with previous oesophagogastric variceal bleeding
Setting: hospital tertiary care centres
Intervention: total shunt
Comparison: endoscopic intervention
Illustrative comparative risks (95% CI)Outcomes
Assumed risk with en-
doscopic intervention











































































































































































































Follow-up: 42.8 months (range 20.4 to 65.1)
435 per 1000 122 per 1000
(61 to 244)
Health-related quality of life No data available No data
Medium-risk populationMortality due to rebleeding








Medium-risk populationAcute hepatic encephalopathy





















The corresponding risk (risk of the intervention group) (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RCT: randomised clinical trial; RR: risk ratio.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded three levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); imprecision: optimal information size (OIS) as calculated by
GRADE was not met (-1 level).
bDowngraded three levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); imprecision: OIS as calculated by GRADE was not met (-1 level).
cDowngraded three levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); imprecision: OIS as calculated by GRADE was not met (-1 level).
dDowngraded four levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); imprecision: OIS as calculated by GRADE was not met; there














































































































































































Summary of findings 3.   Distal splenorenal shunt compared with endoscopic intervention for prevention of rebleeding in people with cirrhosis
Distal splenorenal shunt (DSRS) compared with endoscopic intervention for prevention of rebleeding in people with cirrhosis
Patient or population: participants with cirrhosis and with previous oesophagogastric variceal bleeding
Setting: hospital tertiary care centres
Intervention: DSRS
Comparison: endoscopic intervention
Illustrative comparative risks (95% CI)Outcomes
Assumed risk with en-
doscopic intervention














Follow-up: 68.6 months (range 27.1 to 98) 469 per 1000 436 per 1000 (305 to 624)








Follow-up: 68.6 months (range 27.1 to 98) 458 per 1000 119 per 1000
(50 to 298)







Health-related quality of life   No data
available
Medium-risk populationMortality due to rebleeding
Follow-up: 68.6 months (range 27.1 to 98) 126 per 1000 39 per 1000 (16 to 93)







Medium-risk populationAcute hepatic encephalopathy
Follow-up: 68.6 months (range 27.1 to 98) 139 per 1000 236 per 1000
(131 to 428)







Medium-risk populationChronic hepatic encephalopathy
Follow-up: 62.5 months (range 27.1 to 98) 27 per 1000 68 per 1000
(37 to 123)







The corresponding risk (risk of the intervention group) (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).












































































































































































GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded four levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); imprecision: optimal information size (OIS) as calculated by
GRADE was not met; (-1 levels); heterogeneity (-1 level).
bDowngraded four levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); imprecision: OIS as calculated by GRADE was not met (-1 level);
heterogeneity (-1 level).
cDowngraded three levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); imprecision: OIS as calculated by GRADE was not met (-1 level).
dDowngraded three levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); imprecision: OIS as calculated by GRADE was not met (-1 level).
eDowngraded three levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); imprecision: OIS as calculated by GRADE was not met (-1 levels).
 
 
Summary of findings 4.   Transjugular intrahepatic portosystemic shunt compared with endoscopic intervention with or without medical treatment
for prevention of rebleeding in people with cirrhosis
Transjugular intrahepatic portosystemic shunt (TIPS) compared with endoscopic intervention with or without medical treatment for prevention of rebleeding in
people with cirrhosis
Patient or population: participants with cirrhosis with previous oesophagogastric variceal bleeding
Setting: tertiary care centres
Intervention: TIPS
Comparison: endoscopic intervention with or without medical treatment
Illustrative comparative risks (95% CI)Outcomes
Assumed risk with endo-
scopic intervention with
















Follow-up: 24.5 months (range 13.5 to 46.2) 252 per 1000 277 per 1000
(232 to 330)








Follow-up: 24.5 months (range 13.5 to 46.2) 425 per 1000 187 per 1000



















































































































































































Health-related quality of life   No data
available
Medium-risk populationMortality due to rebleeding
Follow-up: 24.9 months (range 13.5 to 46.2) 82 per 1000 53 per 1000
(33 to 85)







Medium-risk populationAcute hepatic encephalopathy
Follow-up: 24.5 months (range 13.5 to 46.2) 201 per 1000 324 per 1000
(259 to 400)







Medium-risk populationChronic hepatic encephalopathy
Follow-up: 22.5 months (range 13.5 to 46.2) 28 per 1000 53 per 1000
(26 to 106)







The corresponding risk (risk of the intervention group) (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RCT: randomised clinical trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty : We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
aDowngraded four levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); optimal information size (OIS) as calculated by GRADE was not
met (-1 level); publication bias (-1 level).
bDowngraded three levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); publication bias (-1 level).
cDowngraded four levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); OIS as calculated by GRADE was not met (-1 level); publication
bias (-1 level).
dDowngraded four levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); imprecision: OIS as calculated by GRADE was not met (-1 level);
publication bias (-1 level).
eDowngraded four levels because of within-study risk of bias: all trials were at overall high risk of bias (-2 levels); imprecision: OIS as calculated by GRADE was not met (-1 level);
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B A C K G R O U N D
Description of the condition
Portal hypertension is a common complication of liver cirrhosis,
usually defined as an increase in pressure within the portal
venous system. Portal hypertension leads to development of
portosystemic collateral vessels, and of these, gastro-oesophageal
varices are the most clinically relevant (Garcia-Tsao 2007; Cordon
2012). At the time of diagnosis of cirrhosis, around 30% of people
with cirrhosis have gastro-oesophageal varices; 90% of people with
cirrhosis will develop varices during their lifetime (D'Amico 2004;
Cordon 2012). The presence and extent of varices are related to
the severity of cirrhosis, and individuals with decompensated liver
cirrhosis are at highest risk (Garcia-Tsao 2007). Varices are at high
risk of rupture, oNen resulting in catastrophic haemorrhage ― a
major cause of death in people with cirrhotic liver disease. Other
causes of bleeding related to portal hypertension in cirrhosis are
hypertensive gastropathy and, less frequently, duodenopathy or
colopathy. Improved treatment protocols have improved survival;
however, mortality rates remain at around 15% to 20% for a
first bleed (Cabonell 2004). Early and vigorous resuscitation and
early endoscopy, preferably in specialist units, are essential for
these individuals (Grace 1997; Herrera 2014). However, people who
survive their first variceal bleed are at high risk of further episodes
of bleeding ('rebleeding'). The risk of variceal rebleeding is up to
60% within one year, with mortality around 33% (Garcia-Tsao 2007;
Bari 2012). Risk factors specifically for rebleeding have not been
well defined, and factors linked to the risk of initial bleeding include
the size of varices, the appearance of varices (i.e. red wale marks),
and variceal pressure (Zhao 2014).
Due to high risk of rebleeding, secondary prophylaxis is required for
individuals with a history of variceal haemorrhage.
Many tools have been used to reduce the risk of rebleeding,
such as surgical shunts to reduce portal hypertension, endoscopic
obliteration of varices, and drugs like beta blockers (EASL 2018).
Published guidelines recommend non-selective beta-blockers
(NSBBs) and endoscopic band ligation (EBL) as preferable first-
line treatment for secondary prevention of variceal haemorrhage
for cirrhotic portal hypertension (de Franchis 2015; Garcia-Tsao
2017; EASL 2018) because combination treatment decreases the
probability of rebleeding compared to monotherapy or either EBL
or drug treatment. Recommendations are based on recent meta-
analyses showing that combining EBL with NSBBs reduces overall
rebleeding, variceal rebleeding, and bleeding-related mortality
versus banding alone (Thiele 2012), and that adding NSBBs to EBL
improves survival, whereas adding EBL to NSBBs has no eJect on
mortality (Puente 2014).
Description of the intervention
Portosystemic shunts represent an alternative approach for
reducing portal hypertension and thereby the risk of rupture
of varices. The role of portosystemic shunts, above all TIPSs
in the last two decades, is usually limited to rescue treatment
for acute persistent bleeding or rebleeding despite conventional
treatment (i.e. endoscopic intervention and/or medical-vasoactive
drugs) and is limited for secondary prevention of bleeding. Current
international guidelines suggest TIPSs for prevention of rebleeding
in patients intolerant to beta blockers, or with contraindications
to their use and/or concomitant refractory ascites (de Franchis
2015; EASL 2018), or in selected individuals due to patient choice
(Tripathi 2015). However, shunting following the first episode of
variceal bleeding could provide more eJective treatment earlier
in a person's disease pathway, potentially avoiding repeated
admissions with variceal bleeding, and thereby possibly reducing
mortality. In addition, portosystemic shunts confer the further
advantage of being a 'once-only treatment', potentially preventing
repeated hospital visits.
Therapeutic portosystemic shunts are artificial conduits
connecting the portal and systemic circulation; they may be
inserted surgically or via interventional radiology. Shunts may
be classified according to their haemodynamic consequences:
the total surgical shunt (TS) has no prograde hepatopetal flow
through the portal vein and, therefore, all portal blood is diverted
into the systemic circulation (Collins 1995). In contrast, selective
or partial shunts preserve pre-existing hepatopetal portal vein
flow (Collins 1995). The distal splenorenal shunt (DSRS) is a
surgically placed selective shunt that has been associated with
improved preservation of liver function and hence lower morbidity
as compared to TS, although lower mortality has not been
conclusively demonstrated (D'Amico 1995). The selectivity of DSRSs
can be further improved if the venous collaterals between the
splenic vein and the pancreas are disconnected - an additional
procedure that is particularly important for alcoholics (Warren
1986). Since the early 1990s, the radiologically placed transjugular
intrahepatic portosystemic shunt (TIPS) has grown in popularity
(LaBerge 1993). It is inserted radiologically by minimal access and
can usually be placed more quickly than a surgical shunt (Brown
1997). In essence, it is a side-to-side portosystemic shunt. TIPSs
can, however, lead to serious acute and chronic complications
and small but significant mortality (Casado 1998). Stenosis and
occlusion rates have been reported to exceed 75% at two years in
randomised trials using TIPSs (Papatheodoridis 1999), although the
use of polytetrafluoroethylene-coated stents in modern practice
greatly reduces rates of stent dysfunction (Bureau 2007).
Endoscopic treatments are well established, and various
techniques may be practised. Among these interventions,
sclerotherapy represents an approach by which varices are
obliterated through injection of sclerosants (such as ethanolamine
oleate, polidocanol, sodium morrhuate, or other agents) (Cordon
2012). A further alternative is endoscopic glue injection,
whereby tissue adhesives (n-butyl-2-cyanoacrylate (Histoacryl)
or isobutyl-2-cyanoacrylate (Bucrylate)) are injected into varices
(Cordon 2012) - a technique that is of particular use in the
management of gastric varices (Garcia-Tsao 2007). An alternative
is variceal band ligation ('variceal banding'): varices are obliterated
by application of elastic bands via endoscopy (Cordon 2012;
Tripathi 2015). It is important to note that eJective endoscopic
intervention generally requires multiple treatments; typically,
varices are banded with an interval of one to four weeks
until eradication of varices has been achieved (Garcia-Tsao
2007; Tripathi 2015). Endoscopic intervention does carry risk of
complications, such as provocation of further bleeding episodes,
oesophageal ulcers, or bacteraemia (Terblanche 1983; McIntyre
1996; Cordon 2012). However, endoscopic techniques are well
established, are usually well tolerated, and significantly reduce
rates of rebleeding compared with controls (Graham 1981). Current
consensus suggests that variceal banding is the endoscopic method
of choice (Garcia-Tsao 2007; de Franchis 2010; Tripathi 2015)
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because it is more eJective and has lower complication rates than
sclerotherapy (Laine 1995; Dai 2015).
Endoscopic treatments serve to locally obliterate varices. By
obliterating varices, variceal rupture and haemorrhage may be
prevented. However, endoscopic treatment alone does not combat
portal hypertension; therefore, it does not target the underlying
pathophysiology of varices formation (Villanueva 2008). As a result,
endoscopic treatment is generally combined with pharmacological
treatment, typically long-term treatment with non-cardioselective
beta blockers (NSBBs), such as propranolol (Bernard 1997, Tripathi
2015), with or without nitrates. Beta blockade acts to reduce
portal pressure by decreasing cardiac output (blockade of beta1
receptors), promoting splanchnic vasoconstriction (blockade of
beta2 receptors), and reducing blood flow through collateral
vessels (Garcia-Tsao 2007; Villanueva 2008), hence reducing the risk
of variceal bleeding. Combining pharmacological and endoscopic
treatments has a synergistic eJect by targeting both localised and
decompressing varices (Bernard 1997; Villanueva 2008; Tripathi
2015).
How the intervention might work
Portosystemic shunts directly target portal hypertension.
Portosystemic shunts act to divert blood from the portal circulation
to the systemic circulation, decompressing varices and hence
preventing rebleeding. By diverting blood flow, portosystemic
shunts might provide a more eJective treatment option than
endoscopy.
Historically, surgical creation of a shunt (e.g. distal splenorenal
shunt, portacaval shunt) was performed to control bleeding and
prevent recurrent haemorrhage if other methods failed. However,
placement of TIPSs has become the preferred intervention in this
setting because covered stents have favourable long-term patency
and the risks and morbidity associated with major abdominal
surgery are avoided.
Why it is important to do this review
This current review represents an update of a Cochrane Review
first published in 2006 (Khan 2006), based on a protocol originally
published in 1997 (Khan 1997).
As stated above, shunts provide a once-only treatment modality
for prevention of variceal rebleeding and could potentially
be more eJective than endoscopic treatment for preventing
repeated episodes of variceal bleeding. However, portosystemic
shunting does have potential drawbacks. Portosystemic shunting,
particularly with surgical shunts, represents a more invasive option
than endoscopic treatment. Also, by diverting blood flow away
from the liver, portosystemic shunts carry increased risk of hepatic
encephalopathy, and portosystemic shunts pose a risk for shunt
failure or dysfunction (Luca 1999; Papatheodoridis 1999; Burroughs
2002; Garcia-Tsao 2007). Therefore, it is important to ask whether a
case can be made for more widespread use of shunting, and also to
assess the relative safety and risk of complications of portosystemic
shunting compared with endoscopic treatment.
In one meta-analysis in Spina 1992a, DSRSs significantly reduced
the risk of rebleeding compared to endoscopic sclerotherapy
without increasing the risk of chronic hepatic encephalopathy.
However, DSRSs did not significantly aJect overall death risk.
In D'Amico 1995, a comparison of TSs and DSRSs is reported
without diJerences between the two treatments. Several published
meta-analyses have assessed TIPSs versus endoscopic intervention
(Luca 1999; Papatheodoridis 1999; Burroughs 2002; Zheng
2008), all showing no diJerences in mortality, reduction in
rebleeding, and increased incidence of hepatic encephalopathy.
More recently, a multiple-treatments meta-analysis compared
TIPSs, endoscopic treatment modalities, pharmacotherapies, and
combination treatments (Shi 2013), showing that endoscopic band
ligation combined with argon plasma coagulation resulted in the
best profile of reduction in rebleeding rate and all-cause mortality,
and TIPSs had the greatest impact on reducing mortality rate due to
rebleeding. Further, a 2019 meta-analysis compared portosystemic
shunts (including transjugular portosystemic shunt) to endoscopy,
but in this review, authors also included trials utilising emergency
shunts to treat active bleeding (Zhou 2019).
In the current work, we examined portosystemic shunts in the
elective setting for patients with previous episodes of variceal
bleeding. To comprehensively address the question, we have
conducted a systematic review to compare shunts (TSs, DSRSs,
and TIPSs) versus endoscopic interventions (sclerotherapy or
banding, or both) with or without medical treatment for long-term
prophylaxis of rebleeding.
The current update, along with updated Cochrane standards,
incorporates new trials (Lo 2007; Ferlitsch 2012; Luo 2015;
Holster 2016; Lv 2018; Dunne 2020) and results of updated trials
(Santambrogio 2006).
O B J E C T I V E S
To compare the benefits and harms of shunts (surgical shunts
(total shunt (TSs), distal splenorenal shunt (DSRS), or transjugular
intrahepatic portosystemic shunt (TIPS
)) versus endoscopic interventions (endoscopic sclerotherapy or
banding, or both) with or without medical treatement (non-
selective beta blockers or nitrates, or both) for prevention of
variceal rebleeding in people with liver cirrhosis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We endeavoured to identify all possible randomised clinical trials
(published and unpublished) in which shunts were compared with
endoscopic interventions with or without medical treatment.
Types of participants
People known to have cirrhosis who had bled from
oesophagogastric varices but had subsequently stabilised
(before randomisation), either spontaneously or via non-surgical
approaches, including vasoactive drugs or balloon tamponade,
or endoscopic measures, or a combination of any two or three
together.
Types of interventions
Surgical shunts (total shunt (TS), distal splenorenal shunt (DSRS),
or transjugular intrahepatic portosystemic shunt (TIPS)) versus
endoscopic interventions (endoscopic sclerotherapy or banding, or
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both) with or without concomitant long-term medical treatment
(e.g. non-selective beta-blockers, nitrates, both).
Types of outcome measures
All outcomes were evaluated at the maximum available follow-up.
Primary outcomes
• All-cause mortality, defined as death due to any cause
• Rebleeding, defined as a clinically significant episode of
bleeding (i.e. requiring transfusion) from oesophagogastric
varices or portal hypertensive gastropathy. The diagnosis
should ideally have been confirmed by endoscopic examination
to distinguish variceal bleeding or bleeding from portal
hypertensive gastropathy from other causes of non-portal
hypertensive gastrointestinal haemorrhage
• Health-related quality of life, as measured by trial authors
Secondary outcomes
• Mortality due to rebleeding, defined as death resulting from a
further episode of bleeding from oesophagogastric varices or
portal hypertensive gastropathy following the primary (index)
bleeding
• Acute hepatic encephalopathy, defined by classical signs
detected on physical examination, signs unequivocally
described by participants' relatives, psychometric testing, or
electroencephalogram (EEG)
• Chronic hepatic encephalopathy, defined by recurrent episodes
of acute hepatic encephalopathy or inability of the individual
to attain previous level of function because of post-treatment
hepatic encephalopathy
• Complications, defined by untoward events reported by trial
authors (aside from hepatic encephalopathy, which is reported
separately)
• Hospital stay, defined by total days spent in hospital when
treatments are applied
• Cost analysis, defined by actual financial costs of treatment
complications of cirrhotic portal hypertension or of
complications during the follow-up period
Search methods for identification of studies
Electronic searches
We searched the Cochrane Hepato-Biliary Group Controlled
Trials Register (maintained and searched internally by the CHBG
Information Specialist via the Cochrane Register of Studies Web;
22 June 2020); the Cochrane Central Register of Controlled Trials
(CENTRAL; 2020, Issue 2), in the Cochrane Library (searched 22 June
2020); MEDLINE Ovid (1946 to 22 June 2020); Embase Ovid (1974 to
22 June 2020); Latin American Caribbean Health Sciences Literature
(LILACS; Bireme; 1982 to 22 June 2020), and Science Citation Index
- Expanded (Web of Science; 1900 to 22 June 2020), as well as the
Conference Proceedings Citation Index - Science (Web of Science;
1990 to 25 February 2020) (Royle 2003). For the current update, we
reviewed all records arising from Conference Proceedings Citation
Index and LILACS, as these databases had not been included in the
previous permutation of this review. CENTRAL, MEDLINE, Embase,
and Science Citation Index - Expanded had all been included in
the previously published version of the review, and we reviewed
all records from September 2006 (inclusive) onwards from these
databases for the current update. We performed an all language
search, evaluating only human studies. Appendix 1 presents the
search strategies with time spans for the searches.
Searching other resources
We investigated the reference lists of identified trials for
relevant trials. We searched conference proceedings/abstracts for
European Association for the Study of the Liver (EASL), American
Association for the Study of Liver Disease (AASLD), and British
Society of Gastroenterology. When practicable, authors of studies
identified to be pertinent were asked to review the list of
identified trials and to add any unidentified trials. Manufacturers
(TIPSs, pharmacological firms) were contacted. We also searched
ClinicalTrials.gov to identify protocols and any ongoing trials.
Data collection and analysis
Selection of studies
Searches for the original updated review were conducted by at
least two review authors (SK and CTS for the 1st version; and
RGS, GP, and HR for the update), who independently applied
the inclusion criteria to all identified studies. At least two review
authors independently extracted data from publications of interest,
and for the update, data were extracted in greater detail and were
rechecked by RGS, GP, and HR. We selected studies for inclusion
no matter whether they reported on outcomes of interest to our
review. Unpublished data were sought by writing to study authors
(see notes under Characteristics of included studies). Review
authors collected data for intention-to-treat analysis. We resolved
any discrepancies or diJerences among us by discussion.
Data extraction and management
We extracted data using standardised forms, which captured
data related to participant characteristics. Three review authors
(RGS, GP, and HR) independently extracted data. We resolved
disagreements by discussion. Data extraction encompassed
comparability between groups randomised to alternative
treatments regarding baseline prognostic variables, including
aetiology of cirrhosis; mean age; proportion of males/females;
participants with Child-Pugh stage A, B, or C (Pugh 1973);
completeness and length of follow-up of treatment groups and
reasons for withdrawals; presence of, absence of, or unknown for-
profit support; and trial design, exclusions, losses to follow-up,
and cross-over of patients. Review authors also extracted data
of particular interest for shunt intervention, including whether
assessments had been made to assess the suitability of shunt
intervention, and whether splenopancreatic disconnection was
undertaken in people undergoing DSRS. We also extracted data
related to the timing and method of assessing shunt patency.
We collected data for all-cause mortality, rebleeding, health-
related quality of life, death due to rebleeding, development of
acute hepatic encephalopathy, development of chronic hepatic
encephalopathy, complications, hospital stay, and financial cost.
When a trial had more than two groups, we extracted data only
from groups that corresponded to the treatments compared in this
review.
When possible, we measured outcomes as 'time-to-event'. To
prevent loss of data, we assessed outcomes as dichotomous
variables, using raw incidence over the entire follow-up period
reported by study authors (or the longest time point reported
whenever multiple time points were reported).
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For the outcomes of health-related quality of life, complications, in-
hospital stay, and cost, we extracted data directly 'as reported' by
study authors.
Assessment of risk of bias in included studies
Two review authors (RS and GP) independently assessed the
risk of bias of included studies. In light of changes to Cochrane
methods, we updated the risk of bias assessment using an adapted
Cochrane risk of bias tool (adapted from the Cochrane Handbook
for Systematic Reviews of Interventions - Higgins 2011; Higgins 2019 -
and the Cochrane Hepato-Biliary Group Module). Due to changes to
the Cochrane risk of bias tool since conduct of the previous review,
we reassessed the risk of bias in previously included trials, with any
discrepancy resolved by discussion between review authors.
Allocation sequence generation
• Low risk of bias: sequence generation was achieved using
computer random number generation or a random numbers
table. Drawing lots, tossing a coin, shuJling cards, and throwing
dice were adequate if performed by an independent person not
otherwise involved in the trial
• Unclear risk of bias: the method of sequence generation was not
specified
• High risk of bias: the sequence generation method was not
random
Allocation concealment
• Low risk of bias: participant allocations could not have been
foreseen in advance of, or during, enrolment. Allocation was
controlled by a central and independent randomisation unit; or
the allocation sequence was unknown to the investigators (e.g.
the allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes)
• Unclear risk of bias: the method used to conceal the allocation
was not described, so that intervention allocations may have
been foreseen in advance of, or during, enrolment
• High risk of bias: the allocation sequence was likely to be known
to investigators who assigned participants
Blinding of participants and treatment providers
• Low risk of bias: any of the following - no blinding or incomplete
blinding, but review authors judge that the outcome is not
influenced by lack of blinding; or blinding of participant and
study personnel ensured, and it is unlikely that blinding could
have been broken
• Unclear risk of bias: insuJicient information to permit
judgement of 'low risk' or 'high risk'
• High risk of bias: no blinding or incomplete blinding, and
outcome likely to be influenced by lack of blinding; or, blinding
of key study participants and personnel attempted, but likely
that blinding could have been broken, and outcome is likely to
be influenced by lack of blinding
Blinding of outcome assessment
• Low risk of bias: any of the following: blinding of participants and
key study personnel ensured, and unlikely that blinding could
have been broken; or rarely no blinding or incomplete blinding,
but review authors judged that the outcome was not likely to be
influenced by lack of blinding
• Unclear risk of bias: any of the following: insuJicient information
to permit judgement of 'low risk' or 'high risk'; or the trial did not
address this outcome
• High risk of bias: any of the following: no blinding of outcome
assessment, and outcome measurement likely to be influenced
by lack of blinding; or blinding of outcome assessment, but
likely that blinding could have been broken, and the outcome
measurement was likely to be influenced by lack of blinding
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make treatment
eJects depart from plausible values. The study used suJicient
methods, such as multiple imputation, to handle missing data
• Unclear risk of bias: information was insuJicient to assess
whether missing data in combination with the method used to
handle missing data were likely to induce bias on the results
• High risk of bias: results were likely to be biased due to missing
data
Selective reporting
• Low risk of bias: if the original trial protocol was available,
outcomes should be those called for in that protocol. If the
trial protocol was obtained from a trial registry, outcomes
sought should have been those enumerated in the original
protocol. If no protocol was available, the trial should
have reported the following outcomes: all-cause mortality,
rebleeding, mortality due to rebleeding, complications, acute
hepatic encephalopathy, and chronic hepatic encephalopathy
• Unclear risk of bias: information insuJicient to permit
judgement of 'low risk' or 'high risk'
• High risk: not all of the study's pre-specified primary outcomes
have been reported; one or more primary outcomes are
reported via measurements, analyses, or subsets that were
not pre-specified; one or more primary outcomes were not
pre-specified; one or more outcomes of interest are reported
incompletely; study fails to include results for a key outcome
that would be expected to have been reported for such a study
Other bias
• Low risk of bias: the trial appeared to be free of other factors that
could put it at risk of bias
• Unclear risk of bias: the trial may or may not have been free of
other factors that could put it at risk of bias
• High risk of bias: other factors in the trial could put it at risk of
bias
Overall risk of bias
We assessed the overall risk of bias in a trial as:
• low risk of bias: if all bias domains in a trial, as described in the
above paragraphs, are judged at 'low risk of bias'; or
• high risk of bias: if one or more of the bias domains in a trial, as
described in the above paragraphs, are judged at 'unclear risk of
bias' or 'high risk of bias'.
Measures of treatment e;ect
We assessed all outcomes through a combined analysis of all
shunt types together ('shunt therapy pooled'; i.e. TS, DSRS, and
TIPS combined) and repeated the analysis for each shunt type
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individually (TS, DSRS, TIPS). We calculated hazard ratios (HRs)
for time-to-event outcomes and calculated risk ratios (RRs) for
binary outcomes, and we planned to use mean diJerences (MDs)
for continuous outcomes. For the outcomes all-cause mortality,
rebleeding, death due to rebleeding, development of acute
hepatic encephalopathy, and development of chronic hepatic
encephalopathy, when possible, we carried out analyses to allow
reporting of time-to-event outcomes. Therefore, for each outcome
in each comparison (shunts versus endoscopic intervention with
or without medical treatment: TS versus endoscopic intervention
with or without medical treatment; DSRS versus endoscopic
intervention with or without medical treatment; TIPS versus
endoscopic intervention with or without medical treatment), we
planned to calculate a pooled estimate of treatment eJect as an
HR. If estimates of log HR and its variance were not quoted directly
in trial reports, we used alternative aggregate data (e.g. log rank
test P values) to estimate log(HR) and its variance utilising methods
proposed by Parmar 1998 and Williamson 2002, and summarised by
Tierney 2007. When possible, we planned to calculate variance and
observed-expected (O-E) rank from reported HRs and confidence
intervals (CIs) (Tierney 2007, Section 3 to 6). However, in most cases,
we planned to estimate log(HR) and its variance and O-E using the
quoted P value of the log-rank test (Tudur 2001, Section 2.3; Tierney
2007, Sections 7 to 9). If no P value was quoted for the log-rank test,
we planned to estimate log(HR) and its variance from Kaplan-Meier
survival curves (Tudur 2001, Sections 2.4 and 2.5; Tierney 2007,
Section 10). Full details and discussion of the reliability of results
are given in Tudur 2001.
We were not able to extract suJicient data to allow time-to-
event analysis from all reports. Therefore, to prevent loss of data,
we also reported the same outcomes (i.e. all-cause mortality,
rebleeding, death due to rebleeding, development of acute
hepatic encephalopathy, and development of chronic hepatic
encephalopathy) as dichotomous outcomes, using binary data to
calculate the RR. We decided to report only the results of analysis
of dichotomous data because they were available for all trials, and
because we used dichotomous data to grade the evidence (see
below) and to perform Trial Sequential Analysis, while avoiding
redundant information. We planned to report results of time-to-
event analysis if discrepancies with the main analysis were found.
For high variability on continuous outcomes (inpatient stay and
costs), we did not meta-analyse the results and reported mean
diJerences for each trial when available.
To ensure consistency across studies identified in the initial review
and in the current update, calculations from the initial review
were reviewed and any discrepancies were resolved by discussion
between review authors.
For this update, we decided to report 'financial cost' and 'length
of hospital stay' as the raw data published by trialists in light of
considerable inter-trial variability in the definitions and methods
used; therefore, overall, it was judged that reported data were not
comparable across all trials.
Unit of analysis issues
Participants as randomised to an intervention group of a clinical
trial are the unit of analysis. In trials of two–parallel group design,
we compared the experimental intervention group versus the
control. In trials with a parallel group design with more than
two intervention groups of interest to our review, we planned to
compare separately each of the experimental groups with each half
of the control group.
To avoid repeated observations on trial participants, we used
participant trial data at the longest follow-up (Higgins 2011; Higgins
2019).
We identified no cluster-randomised trials.
Dealing with missing data
Whenever possible, we performed all calculations according
to intention-to-treat principles (i.e. with all randomised trial
participants included in the analysis within the group into which
they were randomised). In some trials, results were presented on
a per-protocol basis, or the given information was insuJicient to
assess whether data had truly been presented with use of the
'intention-to-treat' principle (GDEAIH 1995; García-Villarreal 1999).
When this was the case, we contacted study authors to retrieve
pertinent data. As further information was not given, we used all
data that were available to us.
Assessment of heterogeneity
We assessed heterogeneity by visual examination of forest plots
and overlapping CIs, and through use of the I2 statistic. The I2
statistic was interpreted as follows: 0% to 40% heterogeneity may
not be important; 30% to 60% moderate heterogeneity; 50% to 90%
heterogeneity may be substantial; 75% to 100% heterogeneity may
be considerable (Higgins 2011).
Assessment of reporting biases
Whenever we had 10 or more trials, we drew funnel plots to assess
reporting biases from individual trials by plotting the risk ratio
(RR) on a logarithmic scale against its standard error (Egger 1997;
Higgins 2011; Higgins 2019). We examined the degree of asymmetry
of the funnel plot.
Data synthesis
We performed meta-analyses using the soNware package Review
Manager 5.4 (Review Manager 2014). We used a random-eJects
model meta-analysis approach because we expected that the trials
were heterogeneous. When data were available from only one trial,
we used Fisher's exact test for dichotomous data (Fisher 1992). We
planned to use Student's t-test for continuous data such as 'health-
related quality of life' (Student 1908).
Subgroup analysis and investigation of heterogeneity
We performed all analyses with all shunt types but also with
individual shunt types: TS, DSRS, and TIPS.
We planned subgroup analyses according to risk of bias, analysing
separately randomised clinical trials at low risk of bias compared to
trials at high risk of bias. We did this because trials at high risk of
bias can overestimate the benefits and underestimate the harms.
We also analysed trials with for-profit funding; without for-profit
support; and with unknown for-profit support to evaluate whether
for-profit funding is associated with greater intervention benefit.
No other subgroup analyses were planned a priori, and none were
undertaken due to the small sample size in each group.
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Robustness of conclusions was assessed using sensitivity analyses
(see below). When there was substantial heterogeneity, we
considered and discussed the appropriateness of performing the
meta-analysis. We did not perform a meta-analysis if viewed as
inappropriate. We explored reasons for possible heterogeneity,
while examining characteristics of trials.
Sensitivity analysis
We employed sensitivity analyses within each type of
portosystemic shunt to test the robustness of our results.
• Excluding trials examining participants with previous bleeding
from gastric varices, as they were likely more diJicult to treat
with endoscopy.
• Including only trials specifying use of polytetrafluorethylene
(PTFE)-covered TIPSs, as this could reduce the risk of occlusion
of the stent.
• Including only trials in which the PTFE-covered TIPSs were not
used, or in which the type of TIPS was not specified.
• Including only trials combining endoscopic interventions with
medical therapies, as these medical interventions could
influence the eJects of endoscopy.
• Excluding trials combining endoscopic interventions with
medical therapies to see if there are diJerences in the
intervention eJects.
• Including only trials using endoscopic banding exclusively
(i.e. excluding those using glue injection, sclerotherapy, or
combination treatments) as use of the mentioned example
interventions could modify eJects of endoscopic intervention.
As further sensitivity analyses, we compared evaluation of
imprecision with GRADE based on the GRADE Handbook, with
GRADE based on our choice of plausible RRR and multiplicity
correction, and according to our Trial Sequential Analysis
(described below), with a similar choice of a plausible RRR and
multiplicity correction, in addition to considering the choice of a
meta-analytic model and diversity (Jakobsen 2014; Castellini 2018;
Gartlehner 2019).
Trial Sequential Analysis
Trial Sequential Analysis considers the choice of statistical
model (fixed-eJect or random-eJects meta-analysis) and diversity
(Thorlund 2011; TSA 2011). We calculated the diversity-adjusted
required information size (DARIS, i.e. the number of participants
needed in a meta-analysis to detect or reject a certain intervention
eJect) (Brok 2008; Wetterslev 2008; Brok 2009; Wetterslev 2009;
Thorlund 2010; Wetterslev 2017).
The underlying assumption of Trial Sequential Analysis is that
testing for statistical significance may be performed each time a
new trial is added to the meta-analysis. We added trials according
to the year of publication, and if more than one trial was published
in a year, we added trials alphabetically according to the last name
of the first author. On the basis of the DARIS, we constructed the trial
sequential monitoring boundaries for benefit, harm, and futility
(Wetterslev 2008; Wetterslev 2009; Thorlund 2011; Wetterslev 2017).
These boundaries determine the statistical inference one may draw
regarding the cumulative meta-analysis that has not reached the
DARIS; if the trial sequential monitoring boundary for benefit or
harm is crossed before the DARIS is reached, firm evidence may be
established and further trials may be superfluous. However, if the
boundaries for benefit or harm are not crossed, it is most probably
necessary to continue doing trials to detect or reject a certain
intervention eJect. However, if the cumulative Z-curve crosses the
trial sequential monitoring boundaries for futility, no additional
trials may be needed.
In our Trial Sequential Analysis of the two primary dichotomous
outcomes, we based the DARIS on event proportions in the control
group assuming a plausible relative risk reduction (RRR) for all-
cause mortality of 10% and for rebleeding of 20%; risk of type I
error of 2.5% due to the three primary outcomes (Jakobsen 2014);
risk of type II error of 20%; and the diversity of trials included
in the meta-analysis. We repeated the analysis with a plausible
RRR of 40% for rebleeding. For the continuous outcome, health-
related quality of life, we planned to estimate the DARIS using a
minimal relevant diJerence of the standard deviation/2; type I error
risk of 2.5% due to the three primary outcomes (Jakobsen 2014);
risk of type II error of 20%; and diversity as estimated from trials
in the meta-analysis (Wetterslev 2009). We also calculated Trial
Sequential Analysis–adjusted confidence intervals (CIs) (Thorlund
2011; Wetterslev 2017).
In our Trial Sequential Analysis of secondary outcomes, we based
the DARIS for dichotomous outcomes on the event proportion
in the control group; we made an assumption of an RRR of
20% for death due to rebleeding, development of acute hepatic
encephalopathy, development of chronic hepatic encephalopathy
and complications; type I error risk of 1.4% due to the six secondary
outcomes (Jakobsen 2014); risk of type II error of 20%; and the
diversity of trials included in the meta-analysis. We repeated the
analysis with a plausible RRR or increase of 40% for mortality
due to rebleeding, development of acute hepatic encephalopathy,
and development of chronic hepatic encephalopathy. For the
continuous outcome, hospital stay and cost, we planned to
estimate the DARIS using a minimal relevant diJerence of the
standard deviation/2; type I error risk of 1.4% due to the six
secondary outcomes (Jakobsen 2014); beta of 20%; and diversity as
estimated from trials in the meta-analysis (Wetterslev 2009).
We reported results of the comparison of GRADE and Trial
Sequential Analysis. We downgraded imprecision in Trial
Sequential Analysis by two levels if the accrued number of
participants was below 50% of the diversity-adjusted required
information size (DARIS), and one level if between 50% and 100%
of DARIS. We did not downgrade if the cumulative Z curve crossed
the monitoring boundaries for benefit, harm, or futility, or if DARIS
was reached.
A more detailed description of Trial Sequential Analysis and the
soNware programme can be found at www.ctu.dk/tsa/ (Thorlund
2011).
'Summary of findings' tables and GRADE
We constructed 'Summary of findings' tables for the update of
the review. We created 'Summary of findings' tables for the
pooled analysis of all shunt interventions ('shunt therapy pooled')
versus endoscopic intervention with or without medical treatment
(Summary of findings 1), and we presented individual tables for
TS (Summary of findings 2), DSRS (Summary of findings 3), and
TIPS (Summary of findings 4) for the following outcomes: all-cause
mortality, rebleeding, health-related quality of life, mortality due
to rebleeding, acute hepatic encephalopathy, and chronic hepatic
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encephalopathy. We used dichotomous data to assess absolute
eJects.
We created 'Summary of findings' tables using GRADEpro soNware
and GRADE Interactive soNware (www.gradepro.org; GRADEpro
GDT), in accordance with Cochrane guidelines and the GRADE
Handbook (Grade Handbook). GRADE appraises the certainty of
evidence, assessing the degree to which we can be confident that
the estimate of eJect truly reflects the eJect being assessed. The
GRADE factors for assessing the evidence are trial risk of bias
(methodological quality), indirectness of the evidence (population,
intervention, control, outcomes), heterogeneity or inconsistency
of results, imprecision of eJect estimates (considering width
of confidence intervals, optimal information size, and whether
confidence intervals exclude important benefit or important harm),
and possible publication bias (including use of funnel plots) (Grade
Handbook). To calculate the optimal information size (OIS), we
used the conservative estimates of a RRR of 25%, beta 20%, and
alpha 0.05.
Overall, we graded the level of evidence as 'high', 'moderate', 'low',
or 'very low' (Grade Handbook; GRADEpro GDT).
• High certainty: we are very confident that the true eJect lies
close to that of the estimate of the eJect.
• Moderate certainty: we are moderately confident in the eJect
estimate: the true eJect is likely to be close to the estimate of the
eJect, but there is a possibility that it is substantially diJerent.
• Low certainty: our confidence in the eJect estimate is limited:
the true eJect may be substantially diJerent from the estimate
of the eJect.
• Very low certainty: we have very little confidence in the eJect
estimate: the true eJect is likely to be substantially diJerent
from the estimate of eJect.
R E S U L T S
Description of studies
Results of the search
The updated search identified in total 210 records of possible
interest for our review (Figure 1). Three additional records were
identified through other sources (Figure 1).
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Figure 1.   Study flow diagram. Searches performed up to June 2020
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Figure 1.   (Continued)
 
Of these 213 records, 25 were screened further for inclusion.
We excluded ten records reporting six trials based on reading
the full-text publications, as they did not fulfil the inclusion
criteria of our review (OrloJ 2009; Garcia-Pagan 2010; Li 2015;
Sauerbruch 2015; OrloJ 2015; Wang 2015). Two further records
were later publications of two other trials already included
in the previous review version (Merli 1998: a full report of a
previous abstract; Santambrogio 2006: long-term follow-up of the
Spina 1990 trial). We listed these two references within their
trial identifiers in Characteristics of included studies. One record
reported a randomised clinical trial (Lv 2019) which is under
evaluation (Studies awaiting classification), because it is not clear if
participants with active uncontrolled bleeding aNer randomisation
were included. A letter was sent to the study authors to request
more information. Two records described the protocols of two
ongoing trials for which we did not find related publications at the
time of our analysis (NCT02477384; NCT03094234) (Characteristics
of ongoing studies). Ten records reported on six new trials, which
we have included in the present review update (Lo 2007; Ferlitsch
2012; Luo 2015; Holster 2016; Lv 2018; Dunne 2020).
From the previous review version with 22 included trials, we had to
reassess fulfilment of the inclusion criteria of two trial publications
(Cello 1987; Sauer 1998). Most participants in the Cello 1987
trial had acute uncontrolled bleeding at randomisation; hence,
we excluded the trial from the current review version. The trial
publication Sauer 1998 and the trial publication Sauer 2002 seemed
to be reports of the same trial, which was confirmed through
personal communication with the trial authors (see the notes field
of the Characteristics of included studies table). In addition, for the
previous version of the review (Khan 2006), 14 trial publications
have been excluded. Among these records, two publications (Rossi
1994 and Krieger 1997) were recognised as ancillary studies of trials
that were already included, i.e.Sauer 1997 and Merli 1998. We listed
these two references within their trial identifiers in Characteristics
of included studies. One trial was reclassified and was added to the
current version of the review (Urbistondo 1996).
For the current review version, we rechecked or updated extracted
data with data found in the most recent multiple publications of
five trials (Rikkers 1993; Merli 1998; Pomier-Layrargues 2001; Sauer
2002; Santambrogio 2006). Furthermore, we found data on cost-
eJectiveness presented in one conference abstract (see Holster
2016); and we extracted data on hepatic encephalopathy from
Warren 1986 (see Henderson 1990), as the most recent publication
- Henderson 1990 - did not report data on hepatic encephalopathy.
The Characteristics of excluded studies tables provides the reasons
for exclusion of identified publications from the previous and
current review versions (i.e. 18 trials with 24 references) (Cello 1982;
Cello 1987; Escorsell 2002; Garcia-Pagan 2010; Kitano 1992; Li 2015;
Meddi 1999; OrloJ 1994; OrloJ 2009; OrloJ 2015; Paquet 1990;
Resnick 1974; Reynolds 1981; Sanyal 1994; Sauerbruch 2015; Terés
1987a; Tripathi 2001; Wang 2015).
As a result, 27 randomised clinical trials (three of which described
results in abstract format (Korula 1987; GDEAIH 1995; Ferlitsch
2012) were included in this review update. The results of all trials
were available in English.
Included studies
Trial design and setting
All of the 27 included trials were parallel-group randomised clinical
trials. These trials were carried out in 14 countries: the United States
(n = 5) (Korula 1987; Henderson 1990; Rikkers 1993; Cello 1997;
Sanyal 1997), Germany (n = 4) (Rossle 1997; Sauer 1997; Gülberg
2002; Sauer 2002), Spain (n = 4) (Terés 1987; Planas 1991; Cabrera
1996; García-Villarreal 1999), Italy (n = 2) (Merli 1998; Santambrogio
2006), China (n = 2) (Luo 2015; Lv 2018), United Kingdom (n = 2)
(Jalan 1997; Dunne 2020), France (n = 1) (GDEAIH 1995), Austria (n =
1) (Ferlitsch 2012), The Netherlands (n = 1) (Holster 2016), Sweden
(n = 1) (Isaksson 1995), Canada (n = 1) (Pomier-Layrargues 2001),
Japan (n = 1) (Narahara 2001), Puerto Rico (n=1) (Urbistondo 1996),
and Taiwan (n = 1) (Lo 2007).
Interventions
Three trials compared total shunt (TS) versus endoscopic
intervention (164 participants) (Korula 1987; Planas 1991; Isaksson
1995), five trials compared distal splenorenal shunt (DSRS)
versus endoscopic intervention (352 participants) (Terés 1987;
Henderson 1990; Rikkers 1993; Santambrogio 2006; Urbistondo
1996). Ten trials compared transjugular intrahepatic portosystemic
shunt (TIPS) versus endoscopic intervention (Cabrera 1996; Cello
1997; Jalan 1997; Sanyal 1997; Merli 1998; García-Villarreal 1999;
Narahara 2001; Pomier-Layrargues 2001; Gülberg 2002; Lo 2007),
and nine trials compared transjugular intrahepatic portosystemic
shunt (TIPS) versus endoscopic intervention combined with beta
blockers (GDEAIH 1995; Sauer 1997; Rossle 1997; Sauer 2002;
Ferlitsch 2012; Luo 2015; Holster 2016; Lv 2018; Dunne 2020). The
19 TIPS trials included 1312 participants.
Comparisons
Eight trials employed banding in the endoscopic intervention
group (Jalan 1997; Pomier-Layrargues 2001; Gülberg 2002; Sauer
2002; Ferlitsch 2012; Luo 2015; Lv 2018; Dunne 2020). Sixteen
trials employed endoscopic sclerotherapy (Korula 1987; Terés 1987;
Henderson 1990; Planas 1991; Rikkers 1993; GDEAIH 1995; Isaksson
1995; Cabrera 1996; Urbistondo 1996; Cello 1997; Sanyal 1997;
Sauer 1997; Merli 1998; García-Villarreal 1999; Narahara 2001;
Santambrogio 2006). Three trials used combinations of banding
and either sclerotherapy or glue injection: one employed either
sclerotherapy or band ligation (or combined sclerotherapy and
banding) of oesophageal varices, with sclerotherapy of gastric
varices (Rossle 1997); one treated oesophageal varices with
banding and treated gastric varices with injection of cyanoacrylate/
lipiodol (Holster 2016); one utilised glue injection of gastric varices,
followed by banding when there were concomitant oesophageal
varices (Lo 2007).
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In summary, three trials compared TS versus sclerotherapy without
drugs (Korula 1987; Planas 1991; Isaksson 1995), and five trials
compared DSRSs with sclerotherapy without drugs (Terés 1987;
Henderson 1990; Rikkers 1993; Urbistondo 1996; Santambrogio
2006). Among the 19 trials comparing TIPSs versus endoscopy, beta
blockers were used in the endoscopic group in nine trials (two
sclerotherapy (GDEAIH 1995; Sauer 1997), five band ligation (Sauer
2002; Ferlitsch 2012; Luo 2015; Lv 2018; Dunne 2020), and two band
ligation and sclerotherapy (Rossle 1997; Holster 2016)). Ferlitsch
2012 specifically examined trial participants with rebleeding from
oesophageal varices under suJicient pharmacological treatment
(propranolol and isosorbide mononitrate) and continued medical
treatment in the endoscopic banding group. In 10 trials, only
endoscopic interventions were used in the control group (in three
trials band ligation (Jalan 1997; Pomier-Layrargues 2001; Gülberg
2002), in six trials sclerotherapy (Cabrera 1996; Cello 1997; Sanyal
1997; Merli 1998; García-Villarreal 1999; Narahara 2001), and in
one trial glue injection into gastric varices and band ligation of
oesophageal varices were used (Lo 2007)).
Participants
Full details of the 27 included trials are given in the Characteristics
of included studies tables. All trials included 1828 participants
with cirrhosis, with a history of variceal bleeding. Twenty-three
publications reported on participant age: mean age in 22 of the
trials was 53.5 years, and median age in one trial was 49 years for
participants treated with TIPS and 46 years for those treated with
endoscopic intervention. The same 23 publications reported on
sex, with a predominance of men in all trials (68.9% of participants
were male) (Korula 1987; Terés 1987; Planas 1991; Isaksson 1995;
Cabrera 1996; Urbistondo 1996; Cello 1997; Jalan 1997; Rossle
1997; Sanyal 1997; Sauer 1997; Merli 1998; García-Villarreal 1999;
Narahara 2001; Pomier-Layrargues 2001; Gülberg 2002; Sauer 2002;
Santambrogio 2006; Lo 2007; Luo 2015; Holster 2016; Lv 2018;
Dunne 2020).
Among trials assessing TSs, one trial included only participants
with Child-Pugh class A (Korula 1987), and two trials excluded
participants in class C (Terés 1987; Planas 1991). Ferlitsch 2012 did
not provide information on trial participants' Child-Pugh class. Luo
2015 included participants in Child-Pugh classes B and C.
All other trials included participants in all Child-Pugh classes in
diJerent proportions. Merli 1998 excluded participants in Child-
Pugh class C with a score > 13. The Child-Pugh score in the trials
in which it was reported ranged from 6.6 in Rikkers 1993 to 9.8 in
Pomier-Layrargues 2001.
Urbistondo 1996 randomised participants in Child's classes A and B
to DSRS, sclerotherapy, or propranolol, and participants in Child's
C class to sclerotherapy or propranolol.
Eighteen trials specifically either included participants with
oesophageal variceal bleeding only or excluded those with isolated
gastric varices or gastric variceal bleeding (Henderson 1990; Rikkers
1993; GDEAIH 1995; Isaksson 1995; Cabrera 1996; Urbistondo 1996;
Cello 1997; Jalan 1997; Sanyal 1997; Sauer 1997; Merli 1998; García-
Villarreal 1999; Gülberg 2002; Sauer 2002; Santambrogio 2006;
Ferlitsch 2012; Luo 2015; Dunne 2020). One further trial excluded
participants with 'large fundal varices' (Pomier-Layrargues 2001).
One trial was unique in focusing on gastric variceal bleeding (Lo
2007), excluding participants with acute oesophageal bleeds. One
trial included participants with oesophageal or gastric variceal
bleeding (or both) (Holster 2016). In four trial publications, the
source of variceal bleeding was not specified (Korula 1987; Rossle
1997; Narahara 2001; Lv 2018), although Rossle 1997 discusses
treatment of both oesophageal and gastric varices. Two trials
included participants with both oesophageal and gastric variceal
bleeding; however, participants with gastric varices were excluded
from the endoscopic intervention group aNer randomisation (Terés
1987; Planas 1991).
Five trials did not provide information on the cause of cirrhosis
(Korula 1987; Planas 1991; GDEAIH 1995; Isaksson 1995; Ferlitsch
2012). Of the remaining trials, alcohol was judged to be the specific
cause of cirrhosis in 55.9% of trial participants (Terés 1987; Cabrera
1996; Urbistondo 1996; Cello 1997; Jalan 1997; Rossle 1997; Sanyal
1997; Sauer 1997; Merli 1998; García-Villarreal 1999; Narahara 2001;
Pomier-Layrargues 2001; Gülberg 2002; Sauer 2002; Santambrogio
2006; Lo 2007; Luo 2015; Holster 2016; Lv 2018; Dunne 2020).
The Merli 1998, Lo 2007, and Lv 2018 trials reported that alcohol
contributed to liver cirrhosis in only 25.9%, 16.6%, and 2.0%,
respectively, of trial participants. Viral aetiology was reported in 13
trials (Cello 1997; Jalan 1997; Rossle 1997; Sanyal 1997; Sauer 1997;
Narahara 2001; Pomier-Layrargues 2001; Gülberg 2002; Sauer 2002;
Luo 2015; Holster 2016; Lv 2018; Dunne 2020), and this ranged from
3% in Dunne 2020 to 90% of participants in Lv 2018.
Portal vein thrombosis was an explicit exclusion criterion in at
least 11 trials (Cello 1997; Jalan 1997; Sanyal 1997; Sauer 1997;
García-Villarreal 1999; Pomier-Layrargues 2001; Gülberg 2002;
Sauer 2002; Lo 2007; Holster 2016; Dunne 2020); three further
trials excluded individuals with complete portal vein thrombosis
or cavernous portal vein thrombosis (Rossle 1997; Merli 1998;
Narahara 2001). In contrast, Luo 2015 and Lv 2018 specifically
included only individuals with coexistent liver cirrhosis and portal
vein thrombosis.
We provide full details of the included trials in the Characteristics of
included studies tables.
For-profit funding
Among 11 trials in which information on funding was reported,
no trials were funded by industry or received any other type of
for-profit support. For the remaining 16 trials, no information on
funding was available.
Total shunt (TS) versus endoscopic intervention
Isaksson 1995, which assessed TS versus endoscopic intervention,
was funded by the National Research Council. For all other trials,
no information on the source of funding was available (Korula 1987;
Planas 1991).
Distal splenorenal shunt (DSRS) versus endoscopic intervention
Terés 1987,, Henderson 1990, and Rikkers 1993,,which assessed
DSRS versus endoscopic intervention, were supported by grants
provided by public research bodies. No information on the source
of funding was available in Santambrogio 2006 nor Urbistondo
1996.
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Transjugular intrahepatic portacaval shunt (TIPS) versus
endoscopic intervention
Cabrera 1996 and Lo 2007, which assessed TIPS versus endoscopic
intervention, were supported by local institutional grants: Pomier-
Layrargues 2001 and Holster 2016 were supported by national
research organisations; and Cello 1997, Sanyal 1997, and Lv 2018
were supported by regional and institutional grants. The remaining
12 trials provided no information (GDEAIH 1995; Jalan 1997; Rossle
1997; Sauer 1997; Merli 1998; García-Villarreal 1999; Narahara 2001;
Gülberg 2002; Sauer 2002; Ferlitsch 2012; Luo 2015; Dunne 2020).
Excluded studies
Overall, we excluded 18 trials.
In brief, the reasons for exclusion of the six trials identified in the
last search performed for the present review version were absence
of randomised design (Li 2015; Wang 2015), comparisons not
relevant to the review (Sauerbruch 2015), shunts and endoscopic
interventions were performed as emergency treatment in an
acute setting (OrloJ 2009; OrloJ 2015), and participants with
uncontrolled bleeding were included (Garcia-Pagan 2010).
We provide the reasons for exclusion in the Characteristics of
excluded studies tables.
Risk of bias in included studies
Please see Figure 2 and Figure 3.
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Cabrera 1996 + ? ? ? + + -
Cello 1997 ? + ? ? ? - -
Dunne 2020 + + ? ? + ? -
Ferlitsch 2012 ? ? ? ? ? ? -
García-Villarreal 1999 + ? ? ? + - +
GDEAIH 1995 ? ? ? ? - - ?
Gülberg 2002 ? ? ? ? + ? -
Henderson 1990 ? ? ? ? + - -
Holster 2016 + + ? + + + +
Isaksson 1995 ? ? ? ? - + +
Jalan 1997 ? ? ? ? + + -
Korula 1987 ? ? ? ? + - ?
Lo 2007 + + ? + + + +
Luo 2015 + + ? ? + - -
Lv 2018 + + ? ? + + -
Merli 1998 ? ? ? ? + + -
Narahara 2001 + + ? ? + + +
Planas 1991 ? ? - ? + + -
Pomier-Layrargues 2001 ? ? ? ? ? - -
Rikkers 1993 + ? ? ? + - -
Rossle 1997 + + ? ? + + -
Santambrogio 2006 + ? ? ? + - +
Sanyal 1997 + + ? ? + + -
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Figure 2.   (Continued)
Santambrogio 2006 + ? ? ? + - +
Sanyal 1997 + + ? ? + + -
Sauer 1997 + ? ? ? + + -
Sauer 2002 + ? ? ? + ? ?
Terés 1987 + ? ? ? - - -
Urbistondo 1996 + ? - ? - - -
 
 
Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
 
Portosystemic shunts versus endoscopic intervention
As expected, due to the nature of the intervention, no trial blinded
participants or personnel. We acknowledge that blinding could
have been unrealistic in trials of surgical shunts versus endoscopic
treatment. Perhaps evaluation of mortality was not aJected, but
assessment of the other outcomes could have been influenced.
In addition, the rate of protocol deviations in each trial for non-
clinical reasons could have been influenced by knowledge of the
assignment. We judged trials with a large number of protocol
deviations to be at high risk of bias, as assignment of participants to
treatments groups could have been distorted, whereas we judged
trials with a small number of protocol deviations to be at unclear
risk of bias.
For the domain 'other bias', we judged trials to be at high risk of
bias if they reported a large number of participants being crossed-
over because of bleeding, and it is not known when the data were
censored.
As we performed quantitative analysis according to shunt type
(TS, DSRS, or TIPS), we also presented risk of bias according to
shunt type to allow clearer conclusions when each shunt type was
individually examined.
Total shunt (TS) versus endoscopic intervention
Random sequence generation and allocation concealment (selection
bias)
All three trials had unclear generation of the randomisation
sequence and unclear allocation concealment (Korula 1987; Planas
1991; Isaksson 1995) (Figure 2; Characteristics of included studies).
Blinding (performance bias and detection bias)
For blinding of participants and personnel (performance bias), two
trials were at unclear risk of bias (Korula 1987; Isaksson 1995),
whereas Planas 1991 was at high risk (Figure 2; Characteristics of
included studies).
None of the trials reported blinding of outcome assessors (to
minimise detection bias) (Korula 1987; Planas 1991; Isaksson 1995)
(Figure 2; Characteristics of included studies).
Incomplete outcome data (attrition bias)
Two trials were at low risk of bias (Planas 1991; Korula 1987),
and one trial was at high risk of bias (Isaksson 1995) (Figure 2;
Characteristics of included studies).
Selective reporting (reporting bias)
Two trials were at low risk of bias (Isaksson 1995; Planas 1991),
and one trial was at high risk risk of bias (Korula 1987) (Figure 2;
Characteristics of included studies).
Other sources of bias
One trial was at low risk of bias (Isaksson 1995). One trial, published
as a conference abstract, was at unclear risk of bias (Korula 1987).
This is why we cannot exclude other potential sources of bias.
One trial was at high risk of bias because of the large number
of participants who were crossed-over from one treatment group
to another when a participant bled (Planas 1991). It is unknown
whether they were censored at the time of cross-over (Planas 1991)
(Figure 2; Characteristics of included studies).
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Distal splenorenal shunt (DSRS) versus endoscopic intervention
Random sequence generation and allocation concealment (selection
bias)
For random sequence generation, four trials were at low risk of bias
(Terés 1987; Rikkers 1993; Santambrogio 2006; Urbistondo 1996),
and one trial was at unclear risk of bias (Henderson 1990) (Figure 2;
Characteristics of included studies).
For allocation concealment, all five trials were at unclear risk of bias
(Terés 1987; Henderson 1990; Rikkers 1993; Santambrogio 2006;
Urbistondo 1996) (Figure 2; Characteristics of included studies).
Blinding (performance bias and detection bias)
For blinding of participants and personnel, four trials were at
unclear risk of bias (Terés 1987; Henderson 1990; Rikkers 1993;
Santambrogio 2006), whereas one trial was at high risk of bias
(Urbistondo 1996) (Figure 2; Characteristics of included studies).
For blinding of outcome assessors, all five trials were at unclear risk
of bias (Terés 1987; Henderson 1990; Rikkers 1993; Santambrogio
2006; Urbistondo 1996) (Figure 2; Characteristics of included
studies).
Incomplete outcome data (attrition bias)
Three trials were at low risk of bias (Henderson 1990; Rikkers
1993; Santambrogio 2006), and two trials were at high risk of bias
(Terés 1987; Urbistondo 1996) (Figure 2; Characteristics of included
studies).
Selective reporting (reporting bias)
We judged all five trials to be at high risk of reporting bias
(Terés 1987; Henderson 1990; Rikkers 1993; Santambrogio 2006;
Urbistondo 1996) (Figure 2; Characteristics of included studies).
Other bias
One trial was at low risk (Santambrogio 2006), and four trials were
at high risk of bias (Terés 1987; Henderson 1990; Rikkers 1993;
Urbistondo 1996) (Figure 2; Characteristics of included studies).
Transjugular intrahepatic portacaval shunt (TIPS) versus
endoscopic intervention
Random sequence generation and allocation concealment (selection
bias)
For random sequence generation, 12 trials were at low risk of
bias (Cabrera 1996; Rossle 1997; Sanyal 1997; Sauer 1997; García-
Villarreal 1999; Narahara 2001; Sauer 2002; Lo 2007; Luo 2015;
Holster 2016; Lv 2018; Dunne 2020), and seven trials were at unclear
risk of bias (GDEAIH 1995; Cello 1997; Jalan 1997; Merli 1998;
Pomier-Layrargues 2001; Gülberg 2002; Ferlitsch 2012) (Figure 2;
Characteristics of included studies).
For allocation concealment, nine trials were at low risk of bias
(Cello 1997; Sanyal 1997; Rossle 1997; Narahara 2001; Lo 2007; Luo
2015; Holster 2016; Lv 2018; Dunne 2020), and 10 trials were at
unclear risk of bias (GDEAIH 1995; Cabrera 1996; Jalan 1997; Sauer
1997; Merli 1998; García-Villarreal 1999; Pomier-Layrargues 2001;
Gülberg 2002; Sauer 2002; Ferlitsch 2012) (Figure 2; Characteristics
of included studies).
Blinding (performance bias and detection bias)
For blinding of participants and personnel, all trials were at unclear
risk of bias (GDEAIH 1995; Cabrera 1996; García-Villarreal 1999;
Cello 1997; Jalan 1997; Rossle 1997; Sanyal 1997; Sauer 1997; Merli
1998; Narahara 2001; Pomier-Layrargues 2001; Gülberg 2002; Sauer
2002; Lo 2007; Ferlitsch 2012; Luo 2015; Holster 2016; Lv 2018;
Dunne 2020) (Figure 2; Characteristics of included studies).
For blinding of outcome assessors, two trials were at low risk of
bias (Lo 2007; Holster 2016). The other 17 trials were at unclear
risk of bias (GDEAIH 1995; Cabrera 1996; García-Villarreal 1999;
Cello 1997; Jalan 1997; Rossle 1997; Sanyal 1997; Sauer 1997; Merli
1998; Narahara 2001; Pomier-Layrargues 2001; Gülberg 2002; Sauer
2002; Ferlitsch 2012; Luo 2015; Lv 2018; Dunne 2020) (Figure 2;
Characteristics of included studies).
Incomplete outcome data (attrition bias)
FiNeen trials were at low risk (Cabrera 1996; García-Villarreal 1999;
Jalan 1997; Rossle 1997; Sanyal 1997; Sauer 1997; Merli 1998;
Narahara 2001; Gülberg 2002; Sauer 2002; Lo 2007; Luo 2015;
Holster 2016; Lv 2018; Dunne 2020), and three trials were at
unclear risk of bias (Cello 1997; Pomier-Layrargues 2001; Ferlitsch
2012). One trial was at high risk of bias (GDEAIH 1995) (Figure 2;
Characteristics of included studies).
Selective reporting (reporting bias)
Ten trials were at low risk of bias (Cabrera 1996; Jalan 1997; Sanyal
1997; Sauer 1997; Merli 1998; Rossle 1997; Narahara 2001; Lo 2007;
Holster 2016; Lv 2018). Four trials were at unclear risk of bias
(Gülberg 2002; Sauer 2002; Ferlitsch 2012; Dunne 2020). Five trials
were at high risk of bias (GDEAIH 1995; Cello 1997; García-Villarreal
1999; Pomier-Layrargues 2001; Luo 2015) (Figure 2; Characteristics
of included studies).
Other bias
Four trials were at low risk of bias (García-Villarreal 1999; Narahara
2001; Lo 2007; Holster 2016), two trials were at unclear risk of
bias (GDEAIH 1995; Sauer 2002), and 13 trials were at high risk of
bias (Cabrera 1996; Cello 1997; Jalan 1997; Rossle 1997; Sanyal
1997; Sauer 1997; Merli 1998; Pomier-Layrargues 2001; Gülberg
2002; Ferlitsch 2012; Luo 2015; Lv 2018; Dunne 2020) (Figure 2;
Characteristics of included studies).
Overall judgement
We judged all trials to be at unclear or high risk of bias in at least one
domain. As a result, all trials were at overall high risk of bias, which
could result in systematic errors (Figure 2; Figure 3; Characteristics
of included studies).
However, in Lo 2007 and Holster 2016, the judgement of high risk is
based exclusively on lack of blinding of participants and personnel,
which is not feasible for the kind of treatments, but did not exclude
deviations of intended interventions (i.e. additional interventions
given). In Narahara 2001, the judgement of high risk is based only on
the lack of blinding of participants and personnel and of outcome
assessors, which could influence all outcomes assessed.
We classified trials as having risk of 'other bias' when participants
were crossed over to the alternative treatment aNer bleeding
and it is not reported when they were censored. For this reason,
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rebleeding is not influenced by the cross-over. On the contrary,
mortality, mortality due to rebleeding, and hepatic encephalopathy
could have been influenced by the cross-over.
E;ects of interventions
See: Summary of findings 1 Portosystemic shunts compared with
endoscopic intervention with or without medical treatment for
prevention of rebleeding in people with cirrhosis; Summary of
findings 2 Total shunt compared with endoscopic intervention
for prevention of rebleeding in people with cirrhosis; Summary
of findings 3 Distal splenorenal shunt compared with endoscopic
intervention for prevention of rebleeding in people with cirrhosis;
Summary of findings 4 Transjugular intrahepatic portosystemic
shunt compared with endoscopic intervention with or without
medical treatment for prevention of rebleeding in people with
cirrhosis
Results of the meta-analysis of all shunt types (i.e. TS, DSRS,
and TIPS) versus endoscopic intervention with or without medical
treatment are summarised in Summary of findings 1.
Results of the meta-analysis of total shunt (TS) versus endoscopic
intervention with or without medical treatment are summarised in
Summary of findings 2.
Results of the meta-analysis of distal splenorenal shunt (DSRS)
versus endoscopic intervention with or without medical treatment
are summarised in Summary of findings 3.
Results of the meta-analysis of transjugular intrahepatic
portosystemic shunt (TIPS) versus endoscopic intervention with or
without medical treatment are summarised in Summary of findings
4.
Time-to-event data for mortality could be obtained for only 23
trials, for rebleeding in only 16 trials, and for acute hepatic
encephalopathy only in 12 trials. These results were similar to those
obtained by the analysis of dichotomous data. No information on
the other outcomes could be obtained. So, we decided to report
only the dichotomous results. Morever, there was no pre-defined
time point for reporting time-to-event outcomes across all trials.
All shunt types (i.e. TS, DSRS, and TIPS) versus endoscopic
treatment
All-cause mortality
Twenty-seven trials reported all-cause mortality (3 trials using TS, 5
trials using DSRS, 19 trials using TIPS). Mortality data were available
for time-to-event analysis in 23 trials (2 trials used TS, 4 trials
used DSRS, and 17 trials used TIPS). When we meta-analysed data
for all shunt modalities, we found no evidence of a diJerence
between shunts and endoscopic interventions with or without
medical treatment in all-cause mortality (risk ratio (RR) 0.99, 95%
confidence interval (CI) 0.86 to 1.13; 1828 participants; 27 trials; I2 =
3%; very low-certainty evidence; Analysis 1.1). We downgraded the
evidence by three levels because all trials were at overall high risk of
bias (-2 levels), and because of publication bias (-1 level) (Summary
of findings 1; Table 1; Figure 4).
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Figure 4.   Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical
treatment, outcome: 1.1 All-cause mortality
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Sensitivity analysis
Assessment of imprecision with Trial Sequential Analysis and
comparison with GRADE
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis by using
the default relative risk reduction (RRR) of 25% for GRADE as
suggested in the GRADE Handbook (Grade Handbook), along with
the plausible RRR of 10% for GRADE and for Trial Sequential
Analysis.
Trial Sequential Analysis of this comparison was constructed with
28.8% for all-cause mortality in the endoscopic intervention with
or without medical treatment group; an RRR of 10% with the
portosystemic shunt; type I error of 2.5%; and type II error of
20% (80% power). There was no diversity (D2 = 0%). The diversity-
adjusted required information size (DARIS) was 9111 participants.
In Trial Sequential Analysis, the cumulative Z-curve (blue line) did
not approach the monitoring boundaries (red lines) for benefit,
harm, or futility (figure not shown).
The GRADE optimal information size (OIS) was met by using the
default RRR of 25% as suggested in the GRADE Handbook, but not
when we used a more realistic RRR of 10% chosen by review authors
for GRADE and Trial Sequential Analysis (Table 1).
Rebleeding
Across all shunt modalities, 26 trials reported on rebleeding (2
trials using TS, 5 trials using DSRS, 19 trials using TIPS). Data
on rebleeding were available for time-to-event analysis in 16
trials (0 trials using TS, 1 trial using DSRS, 15 trials using TIPS).
When all shunt modalities were meta-analysed and compared with
endoscopic interventions with or without medical treatment, shunt
intervention reduced rebleeding (RR 0.40, 95% CI 0.33 to 0.50;
1769 participants; 26 trials; I2 = 31%; very low-certainty evidence;
Analysis 1.2). We downgraded the evidence by three levels because
all trials were at overall high risk of bias (-2 levels), and because of
publication bias (-1 level) (Summary of findings 1; Table 1; Figure 5).
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Figure 5.   Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical
treatment, outcome: 1.2 Rebleeding
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Sensitivity analysis
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis by using
the default RRR of 25% for GRADE as suggested in the GRADE
Handbook, as well as a plausible RRR of 20% and 40% for GRADE
and for Trial Sequential Analysis.
Trial Sequential Analysis of this comparison was constructed on
a rebleeding risk of 43.2% in the endoscopic intervention with
or without medical treatment group; type I error of 2.5%; and
type II error of 20% (80% power). The cumulative Z-curve crossed
the monitoring boundary for benefit before reaching the required
information size both when RRR with portosystemic shunt was set
to 40% (D2 = 35%, DARIS 441 participants), and when it was set to
20% (D2 = 35%, DARIS 1854 participants) (figures not shown).
The OIS was met by using the default RRR of 25% as suggested in
the GRADE Handbook, and when we used an RRR of 40% and 20%
for GRADE and 40% for TSA, but not when the RRR was 20% for TSA
(Table 1).
Health-related quality of life
No trials examined health-related quality of life.
Mortality due to rebleeding
We were able to extract data on death caused by rebleeding from
26 trials across all shunt modalities (3 trials using TS, 5 trials using
DSRS, and 18 trials using TIPS). No data could be extracted to allow
analysis of death due to rebleeding as a time-to-event outcome.
Portosystemic shunts reduced mortality due to rebleeding (RR 0.51,
95% CI 0.34 to 0.76; 1779 participants; 26 trials; I2 = 0%; very low-
certainty evidence; Analysis 1.3). We downgraded the evidence by
four levels because all trials were at overall high risk of bias (-2
levels) due to imprecision, because OIS as calculated by GRADE
was not met (-1 level), and because of publication bias (-1 level)
(Summary of findings 1; Table 1; Figure 6).
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Figure 6.   Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical
treatment, outcome: 1.3 Mortality due to rebleeding









TS vs endoscopic intervention
DSRS vs endoscopic intervention
TIPS vs endoscopic intervention
 
Sensitivity analysis
Assessment of imprecision with Trial Sequential Analysis and
comparison with GRADE
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis by using the
default RRR of 25% as suggested in the GRADE Handbook and the
plausible RRR of 20% and 40% for GRADE and for Trial Sequential
Analysis.
Trial Sequential Analysis of this comparison was constructed
on mortality due to rebleeding risk of 9.5% in the endoscopic
intervention with or without medical treatment group; type I error
of 1.4%; and type II error of 20% (80% power). The cumulative
Z-curve reached the futility area before reaching the required
information size when RRR with portosystemic shunt was set to
40% (D2 = 0%, DARIS 2117 participants). When RRR was set to
20%, the cumulative Z-curve did not approach the monitoring
boundaries for benefit or harm or futility (D2 = 0%; DARIS 9429
participants) (figures not shown).
The optimal information size was not reached by using the default
RRR of 25% as suggested in the GRADE Handbook, by using an RRR
of 40% and 20% for GRADE, or by using an RRR of 40% and 20% for
Trial Sequential Analysis (Table 1).
Acute hepatic encephalopathy
Across all shunt modalities, 24 trials reported on development of
acute hepatic encephalopathy as a dichotomous outcome (2 trials
using TS, 4 trials using DSRS, 18 trials using TIPS). Portosystemic
shunts increased acute hepatic encephalopathy (RR 1.60, 95% CI
1.33 to 1.92; 1649 participants; 24 trials; I2 = 10%; Analysis 1.4;
very low-certainty evidence). We downgraded the evidence by four
levels because all trials were at overall high risk of bias (-2 levels),
because of imprecision - the OIS as calculated by GRADE was
not met (-1 level), and because of publication bias (Summary of
findings 1; Table 1; Figure 7).
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Figure 7.   Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical
treatment, outcome: 1.4 Acute hepatic encephalopathy
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Sensitivity analysis
Assessment of imprecision with Trial Sequential Analysis and
comparison with GRADE
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis by using the
default RRR of 25% as suggested in the GRADE Handbook and the
plausible RRR of 20% and 40% for GRADE and for Trial Sequential
Analysis.
Trial Sequential Analysis of this comparison was constructed on
an incidence of acute hepatic encephalopathy of 18.5% in the
endoscopic intervention with or without medical treatment group;
type I error of 1.4%; and type II error of 20% (80% power).
The cumulative Z-curve approached the monitoring boundary for
harm before reaching the required information size when the RRR
with portosystemic shunt was set to 40% (D2 = 14%, DARIS 1160
participants), and when the RRR was set to 20% (D2 = 14%, DARIS
5108 participants) (figures not shown).
The optimal information size was not reached by using the default
RRR of 25% as suggested in the GRADE Handbook, by using an RRR
of 20% for GRADE, or by using an RRR of 20% for Trial Sequential
Analysis. It was reached with an RRR of 40% for GRADE and for Trial
Sequential Analysis (Table 1).
Chronic hepatic encephalopathy
Across all shunt modalities, 13 trials reported on development
of chronic hepatic encephalopathy (1 trial using TS, 2 trials
using DSRS, 10 trials using TIPS). No time-to-event data
could be extracted for chronic hepatic encephalopathy for any
shunt type. Portosystemic shunts versus endoscopic intervention
with or without medical treatment increased chronic hepatic
encephalopathy (RR 2.51, 95% CI 1.38 to 4.55; 956 participants;
13 trials; I2 = 0%; very low-certainty evidence; Analysis 1.5). We
downgraded the evidence by four levels because all trials were at
overall high risk of bias (-2 levels), because of imprecision - the
OIS as calculated by GRADE was not met (-1 level), and because of
publication bias (-1 level) (Summary of findings 1; Table 1; Figure 8).
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Figure 8.   Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical
treatment, outcome: 1.5 Chronic hepatic encephalopathy
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Sensitivity analysis
Assessment of imprecision with Trial Sequential Analysis and
comparison with GRADE
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis by using the
default RRR of 25% as suggested in the GRADE Handbook and the
plausible RRR of 20% and 40% for GRADE and for Trial Sequential
Analysis.
Trial Sequential Analysis of this comparison was constructed on
an incidence of chronic hepatic encephalopathy of 2.7% in the
endoscopic intervention with or without medical treatment group;
type I error of 1.4%; and type II error of 20% (80% power). The
cumulative Z-curve did not approach the monitoring boundaries
for benefit, harm, or futility when RRR with portosystemic shunt
was set to 40% (D2 = 0%, DARIS 7888 participants). The Trial
Sequential Analysis curve was not constructed due to little
information (2.7%, DARIS) when RRR was set to 20% (D2 = 0%, DARIS
35,394 participants) (figures not shown).
The required information size was not reached by using the default
RRR of 25% as suggested in the GRADE Handbook, by using an RRR
of 20% and 40% for GRADE, or by using an RRR of 20% and 40% for
Trial Sequential Analysis (Table 1).
Complications
Full details of complications are summarised according to each
individual shunt modality in Table 2, Table 3, and Table 4.
It was not possible to perform a meta-analysis of all complications
because trialists oNen reported the number of events and not the
number of participants who had events. As some complications
are treatment-specific (e.g. shunt occlusion or thrombosis in shunt
intervention, oesophageal ulcers or thoracic pain in endoscopic
intervention), they cannot be compared in the two treatment
groups. Below we report the number of cases of shunt dysfunction
or occlusion (thrombosis) in the shunt group. For the endoscopy
group, see details in Table 2, Table 3, and Table 4.
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
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Shunt occlusion or dysfunction
The overall incidence of shunt occlusion or dysfunction was 37%
(95% CI 33 to 40).
Inpatient stay
For the update of this review, we decided that because of the
variability of definitions and of time periods measured, data for
length of stay could not be combined across trials; therefore, we
presented this outcome in a tabular format. The impact of shunt
intervention on duration of inpatient stay remains unclear, and
only limited conclusions may be drawn, with results summarised in
Table 5.
Full details are summarised according to each individual shunt
modality (please see relevant sections).
Cost analysis
There was variation in the methods and definitions used to
estimate cost of treatment, with results summarised in Table 6.
Full details are summarised according to each individual shunt
modality.
Total shunt (TS) versus endoscopic intervention
All-cause mortality
All-cause mortality was reduced with total shunt (RR 0.46, 95% CI
0.19 to 1.13; 164 participants; 3 trials; I2 = 1%; very low-certainty
evidence; Analysis 1.1.1). We downgraded the evidence by three
levels because all trials were at overall high risk of bias (-2 levels)
and because of imprecision - the OIS as calculated by GRADE was
not met (-1 level) (Summary of findings 2; Table 7).
Sensitivity analysis
We did not perform sensitivity analyses according to site of variceal
bleeding, modality of endoscopy, or association with beta blockers
because no trials were restricted to prevention of rebleeding of
gastric varices; sclerotherapy was the endoscopic intervention in
all trials; and no trials combined endoscopic intervention with
medical treatment.
Assessment of imprecision with Trial Sequential Analysis and
comparison with GRADE
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis, by using the
default RRR of 25% as suggested in the GRADE Handbook and the
plausible RRR of 10% for GRADE and for Trial Sequential Analysis.
Trial Sequential Analysis was constructed with risk of 19.7% for
all-cause mortality in the endoscopic intervention group; an RRR
of 10% with the TS; type I error of 2.5%; and type II error of 20%
(80% power). There was no diversity (D2 = 0%). The DARIS was
14,904 participants. Due to the fact that only 164 participants were
recruited (which is 1.1% of the DARIS of 14,904 participants), the
Trial Sequential Analysis figure was not drawn by the programme
because too little information was available (figure not shown).
The optimal information size was not reached by using the default
RRR of 25% as suggested in the GRADE Handbook or when we used
a more realistic RRR of 10% as chosen by review authors for GRADE
and for Trial Sequential Analysis (Table 7).
Rebleeding
Risk of rebleeding was reduced by TS (RR 0.28, 95% CI 0.14 to
0.56; 127 participants; 2 trials; I2 = 0%; very low-certainty evidence;
Analysis 1.2.1). We downgraded the evidence by three levels
because all trials were at overall high risk of bias (-2 levels) and
because of imprecision - the OIS as calculated by GRADE was not
met (-1 level) (Summary of findings 2; Table 7).
Sensitivity analysis
We did not perform sensitivity analyses according to site of variceal
bleeding, modality of endoscopy, or association with beta blockers
because no trials were restricted to prevention of rebleeding of
gastric varices; sclerotherapy was the endoscopic intervention in
all trials, and no trials combined endoscopic intervention with
medical treatment.
Assessment of imprecision with Trial Sequential Analysis and
comparison with GRADE
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis by using the
default RRR of 25% as suggested in the GRADE Handbook and the
plausible RRR of 20% and 40% for GRADE and for Trial Sequential
Analysis.
Trial Sequential Analysis of this comparison was constructed on risk
of rebleeding, with 43.5% in the endoscopic intervention group;
type I error of 2.5%; and type II error of 20% (80% power). The
cumulative Z-curve crossed the monitoring boundary for benefit
before reaching the required information size when RRR with TS
was set to 40% (D2 = 0%, DARIS 285 participants) - not when RRR was
set to 20% (D2 = 0%, DARIS 1197 participants) (figures not shown).
The optimal information size was not reached by using the default
RRR of 25% as suggested in the GRADE Handbook and an RRR of
20% and 40% as chosen by review authors for GRADE and TSA
(Table 7).
Mortality due to rebleeding
Mortality due to rebleeding was reduced with TS (RR 0.25, 95% CI
0.06 to 0.96; 164 participants; 3 trials; I2 = 0%; very low-certainty
evidence; Analysis 1.3.1). We downgraded the evidence by three
levels because all trials were at overall high risk of bias (-2 levels)
and because of imprecision - the OIS as calculated by GRADE was
not met (-1 level) (Summary of findings 2; Table 7).
Sensitivity analysis
We did not perform sensitivity analyses according to site of
variceal bleeding, modality of endoscopy, or association with beta
blockers because no trials were restricted to prevention of gastric
variceal rebleeding; sclerotherapy was the endoscopic intervention
in all trials, and no trials combined endoscopic intervention with
medical treatment.
Assessment of imprecision with Trial Sequential Analysis and
comparison with GRADE
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis by using the
RRR of 25% as suggested in the GRADE Handbook and the plausible
RRR of 20% and 40% for GRADE and for Trial Sequential Analysis.
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
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Trial Sequential Analysis of this comparison was constructed on
a risk of mortality due to rebleeding of 13.6% in the endoscopic
intervention group; type I error of 1.4%; and type II error of
20% (80% power). The cumulative Z-curve did not cross the
sequential boundaries for benefit, harm, or futility before reaching
the required information size when RRR with TS was set to 40% (D2
= 0%, DARIS 1427 participants); the Trial Sequential Analysis figure
was not obtained due to the fact that only 164 participants were
recruited (2.59% of the DARIS) when the RRR was set to 20% (D2 =
0%, DARIS 6321 participants) (figures not shown).
The optimal information size was not reached by using the default
RRR of 25% as suggested in the GRADE Handbook, by using an RRR
of 40% and 20% for GRADE, or by using an RRR of 40% and 20 % for
Trial Sequential Analysis (Table 7).
Acute encephalopathy
There was no diJerence between TS and endoscopic intervention
in the development of acute hepatic encephalopathy (RR 1.66, 95%
CI 0.70 to 3.92; 115 participants; 2 trials; I2 = 0%; very low-certainty
evidence; Analysis 1.4.1). We downgraded the evidence by four
levels because all trials were at overall high risk of bias (-2 levels),
because of imprecision - the OIS as calculated by GRADE was not
met - and because there were very few events and CI included
appreciable benefit and harm (-2 levels) (Summary of findings 2;
Table 7).
Sensitivity analysis
We did not perform sensitivity analyses according to site of
variceal bleeding, modality of endoscopy, or association with beta
blockers because no trials were restricted to prevention of gastric
variceal rebleeding; sclerotherapy was the endoscopic intervention
in all trials, and no trials combined endoscopic intervention with
medical treatment.
Assessment of imprecision with Trial Sequential Analysis and
comparison with GRADE
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis by using
the default RRR of 25% as suggested in the GRADE Handbook
and the plausible RRR of 20% and 40% for GRADE and for Trial
Sequential Analysis. Trial Sequential Analysis of this comparison
was constructed on an incidence of acute encephalopathy of 12.3%
in the endoscopic intervention group; type I error of 1.4%; and type
II error of 20% (80% power). The cumulative Z-curve did not reach
the monitoring boundaries for benefit, harm, and futility when RRR
with TS was set to 40% (D2 = 0%, DARIS 1596 participants). When
the RRR was set to 20% (D2 = 0%, DARIS 7082 participants), the
figure could not be constructed because of the small number of
participants (1.62% of the DARIS). The optimal information size was
not reached by using the default RRR of 25% as suggested in the
GRADE Handbook,and the RRR of 20% and 40% for GRADE and for
Trial Sequential Analysis (Table 7).
Chronic hepatic encephalopathy
Only one trial reported on development of chronic hepatic
encephalopathy, with 3 out of 34 participants in the TS group
compared with none out 35 in the endoscopic intervention group
(Fisher's test P = 0.11; 69 participants) (Planas 1991).
Sensitivity analysis
We did not perform sensitivity analyses according to site of
variceal bleeding, modality of endoscopy, or association with beta
blockers because no trials were restricted to prevention of gastric
variceal rebleeding; sclerotherapy was the endoscopic intervention
in all trials, and no trials combined endoscopic intervention with
medical treatment.
Complications
Complications are summarised in Table 2.
Two of the trials reported shunt occlusion or dysfunction, which
developed in 3% (95% CI 0.8% to 10%) of participants (Planas 1991;
Isaksson 1995).
Inpatient stay
Only Planas 1991 reported mean (± standard deviation) inpatient
stay (days) (MD between groups 3.1 days, 95% CI -2.3 to 8.5 days).
Isaksson 1995 reported the median inpatient stay in the TS group as
34.5 days (range 9 to 122 days) and in the endoscopic intervention
group as 33 days (range 15 to 64 days).
Cost analysis
Details of cost analyses are provided in Table 6. Two trials
reported cost analyses (Planas 1991; Isaksson 1995). Isaksson 1995
calculated hospital costs by including costs of laboratory, radiology,
transfusions, drugs, graNs, hotel service, endoscopy, and surgical
procedures. Planas 1991 reported data but did not provide details
on how costs were calculated. Both trials reported comparable
costs between patients treated with TS and patients treated with
endoscopic intervention.
Distal splenorenal shunt (DSRS) versus endoscopic
intervention
All-cause mortality
No diJerences were found between the two groups for all-cause
mortality (RR 0.93, 95% CI 0.65 to 1.33; 352 participants; 5
trials; I2 = 56%; very low-certainty evidence; Analysis 1.1.2). There
was heterogeneity because two trials reported an increase in
mortality with DSRS versus endoscopic intervention (Henderson
1990; Urbistondo 1996), whereas the other three trials reported a
reduction (Terés 1987; Rikkers 1993; Santambrogio 2006). The large
number of participants randomised to sclerotherapy who were
treated by DSRS when they bled (35% in Henderson 1990) prevent
us from considering this result as due to DSRS alone. In Urbistondo
1996, there was an unbalanced selection of participants because
DSRS was performed in Child's class A and B, whereas sclerotherapy
was performed also in Child's class C. We downgraded the evidence
by four levels because all trials were at overall high risk of bias (-2
levels), because of imprecision - the OIS as calculated by GRADE was
nor met (-1 level), and because of heterogeneity (-1 level) (Summary
of findings 3; Table 8).
Sensitivity analysis
We did not perform sensitivity analyses according to site of variceal
bleeding, modality of endoscopy, or association with beta blockers
because no trials were restricted to prevention of rebleeding of
gastric varices; sclerotherapy was the endoscopic intervention in all
trials, and no trials combined endoscopy with medical treatment.
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Assessment of imprecision with Trial Sequential Analysis and
comparison with GRADE
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis by using the
default RRR of 25% as suggested in the GRADE Handbook and the
plausible RRR of 10% for GRADE and for Trial Sequential Analysis.
Trial Sequential Analysis of this comparison was constructed on a
risk of all-cause mortality of 46.8% in the endoscopic intervention
group; an RRR of 10% with DSRS; type I error of 2.5%; and type
II error of 20% (80% power). There was diversity (D2 = 78%).
The DARIS was 13,538 participants. Due to the fact that only
324 participants were recruited (which is 2.45% of the DARIS of
13,538 participants), the Trial Sequential Analysis figure was not
constructed by the programme because too little information was
available.The optimal information size was not reached by using the
default RRR of 25% as suggested in the GRADE Handbook, or when
we used a more realistic RRR of 10% chosen by review authors for
GRADE and for Trial Sequential Analysis (Table 8).
Rebleeding
Rebleeding was reduced by DSRS (RR 0.26, 95% CI 0.11 to 0.65; 330
participants; 5 trials; I2 = 66%); very low-certainty evidence; Analysis
1.2.2). We downgraded the evidence by four levels because all trials
were at overall high risk of bias (-2 levels), because of imprecision -
the OIS as calculated by GRADE was not met (-1 level), and because
of heterogeneity (-1 level) (Summary of findings 3; Table 8).
Sensitivity analysis
We did not perform sensitivity analyses according to site of variceal
bleeding, modality of endoscopy, or association with beta blockers
because no trials were restricted to prevention of rebleeding of
gastric varices; sclerotherapy was the endoscopic intervention in
all trials, and no trials combined endoscopic intervention with
medical treatment.
Assessment of imprecision with Trial Sequential Analysis and
comparison with GRADE
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis by using the
default RRR of 25% as suggested in the GRADE Handbook and the
plausible RRR of 20% and 40% for GRADE and for Trial Sequential
Analysis.
Trial Sequential Analysis of this comparison was constructed on a
rebleeding risk of 45.8% in the endoscopic intervention group; type
I error of 2.5%; and type II error of 20% (80% power). The cumulative
Z-curve crossed the monitoring boundary for benefit when RRR
with DSRS was set to 40% (D2 = 72%, DARIS 928 participants).
When RRR was set to 20% (D2 = 72%, DARIS 3878 participants), the
cumulative Z-curve did not cross the boundaries for benefit, harm,
or futility (figures not shown). Overall, as the observed RRR greatly
exceeded 40% (observed RRR of 81%), Trial Sequential Analysis
would tend to support conclusions that DSRS shunt reduce the rate
of rebleeding compared with endoscopic treatment.
The optimal information size was not reached by using the default
RRR of 25% as suggested in the GRADE Handbook nor when we
used an RRR of 20% for GRADE and an RRR of 20% and 40% for Trial
Sequential Analysis. It was reached when we used a plausible RRR
of 40% chosen by the review authors for GRADE (Table 8).
Mortality due to rebleeding
Cause of death was reported in four trials (Terés 1987; Henderson
1990; Rikkers 1993; Santambrogio 2006). Mortality from rebleeding
was reduced by DSRS (RR 0.31, 95% CI 0.13 to 0.74; 352 participants;
5 trials; I2 = 0%; very low-certainty evidence; Analysis 1.3.2). All four
trials included death from gastrointestinal bleeding of all causes
(Terés 1987; Henderson 1990; Rikkers 1993; Santambrogio 2006).
We downgraded the evidence by three levels because all trials were
at overall high risk of bias (-2 levels) and because of imprecision -
the OIS as calculated by GRADE was not met (-1 level) (Summary of
findings 3; Table 8).
Sensitivity analysis
We did not perform sensitivity analyses according to site of
variceal bleeding, modality of endoscopy, or association with beta
blockers because no trials were restricted to prevention of gastric
variceal rebleeding; sclerotherapy was the endoscopic intervention
in all trials, and no trials combined endoscopic intervention with
medical treatment.
Assessment of imprecision with Trial Sequential Analysis and
comparison with GRADE
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis by using the
default RRR of 25% as suggested in the GRADE Handbook and the
plausible RRR of 40% and 20% for modified GRADE and for Trial
Sequential Analysis.
Trial Sequential Analysis of this comparison was constructed on
a risk of mortality due to rebleeding of 12.6% in the endoscopic
intervention group; type I error of 1.4%; and type II error of 20%
(80% power). The cumulative Z-curve did not cross the monitoring
boundaries before reaching the required information size when
RRR with DSRS was set to 40% (D2 = 0%, DARIS 1554 participants)
nor when RRR was set to 20% (D2 = 0%, DARIS 6892 participants)
(figures not shown).
The optimal information size was not reached by using the default
RRR of 25% as suggested in the GRADE Handbook, by using an RRR
of 40% and 20% for GRADE, or by using an RRR of 40% and 20% for
Trial Sequential Analysis (Table 8).
Acute hepatic encephalopathy
Acute hepatic encephalopathy was increased by DSRS (RR 1.70,
95% CI 0.94 to 3.08; 287 participants; 4 trials; I2 = 25%; very low-
certainty evidence; Analysis 1.4.2). Henderson 1990 did not report
data on hepatic encephalopathy; however, development of acute
hepatic encephalopathy was reported in a preliminary analysis (see
the reference to Warren 1985 in Henderson 1990). We downgraded
the evidence by three levels because all trials were at overall high
risk of bias (-2 levels) and because of imprecision - the OIS as
calculated by GRADE was not met (-1 level) (Summary of findings 3;
Table 8).
Sensitivity analysis
We did not perform sensitivity analyses according to site of
variceal bleeding, modality of endoscopy, or association with beta
blockers because no trials were restricted to prevention of gastric
variceal rebleeding; sclerotherapy was the endoscopic intervention
in all trials, and no trials combined endoscopic intervention with
medical treatment.
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Assessment of imprecision with Trial Sequential Analysis and
comparison with GRADE
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis by using the
default RRR of 25% as suggested in the GRADE Handbook and the
plausible RRR of 20% and 40% for GRADE and for Trial Sequential
Analysis.
Trial Sequential Analysis of this comparison was constructed on
an incidence of acute hepatic encephalopathy of 13.9% in the
endoscopic intervention group; type I error of 1.4%; and type II
error of 20% (80% power). The cumulative Z-curve did not reach
the monitoring boundaries for harm, benefit, and futility when RRR
with DSRS was set to 40% (D2 = 26%, DARIS 1892 participants). When
the RRR was set to 20% (D2 = 26%, DARIS 8382 participants), the
figure could not be constructed because of the small number of
participants (figures not shown).
The optimal information size was not reached by using the default
RRR of 25% as suggested in the GRADE Handbook, by using an RRR
of 20% and 40% for GRADE, or by using an RRR of 40% and 20% for
Trial Sequential Analysis (Table 8).
Chronic hepatic encephalopathy
Chronic hepatic encephalopathy was increased by DSRS (RR 4.87,
95% CI 1.46 to 16.23; 170 participants; 2 trials; I2 = 0%; very low-
certainty evidence; Analysis 1.5.2). We downgraded the evidence
by four levels because all trials were at overall high risk of bias
(-2 levels) and because of imprecision - there were few events and
CI included appreciable benefit and harm (-2 levels) (Summary of
findings 3; Table 8).
Sensitivity analysis
We did not perform sensitivity analyses according to site of
variceal bleeding, modality of endoscopy, or association with beta
blockers because no trials were restricted to prevention of gastric
variceal rebleeding; sclerotherapy was the endoscopic intervention
in all trials, and no trials combined endoscopic intervention with
medical treatment.
Assessment of imprecision with Trial Sequential Analysis and
comparison with GRADE
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis by using the
default RRR of 25% as suggested in the GRADE Handbook and the
plausible RRR of 20% and 40% for GRADE and for Trial Sequential
Analysis.
Trial Sequential Analysis of this comparison was constructed on
an incidence of chronic hepatic encephalopathy of 3.4% in the
endoscopic intervention group; type I error of 1.4%; and type II error
of 20% (80% power). The cumulative Z-curve was not constructed
because too little information was available when the RRR was set
to 40% (D2 = 0%, DARIS 6228 participants) and to 20% (D2 = 0%,
DARIS 27,926 participants) (figures not shown).
The required information size was not reached by using the default
RRR of 25% as suggested in the GRADE Handbook nor when we
used an RRR of 20% or 40% for GRADE and Trial Sequential Analysis
(Table 8).
Complications
Complications are summarised in Table 3. It is apparent that
reporting of complications may be incomplete in all trials.
Shunt occlusion or dysfunction was reported in three trials (Terés
1987; Rikkers 1993; Santambrogio 2006). Shunt occlusion or
dysfunction occurred in 8 out of 113 (7%), 95% CI 3% to 13%)
participants treated by shunts.
Inpatient stay
Terés 1987 reported the number of inpatient days following
randomisation (weighted mean diJerence (WMD) between groups
-3.4 days, 95% CI -13.7 to 6.9 days) and was the only trialist to
do so. Whilst participants treated with DSRS stayed significantly
longer in hospital for initial treatment, participants treated with
endoscopic intervention stayed significantly longer in hospital
undergoing treatment during follow-up aNer initial treatment.
Therefore, overall, there was no significant diJerence in the total
number of days spent in hospital ) (Table 5; Terés 1987).
Cost analysis
One trial provided a cost analysis in the preliminary report, but
it included only participants who were admitted to the University
Hospital and it did not include the full cohort of participants
(Rikkers 1993). Whilst medical costs for the index hospitalisation
were higher for participants treated with DSRS (mean ± SD for
DSRS: USD 22,473 ± USD 3521) versus endoscopic intervention (USD
10,410 ± USD 1893), costs were comparable over a longer follow-up
period: DSRS (mean ± SD for DSRS: USD 34,474 ± USD 5499) versus
endoscopic intervention (USD 37,648 ± USD 6392) (Table 6).
Transjugular intrahepatic portacaval shunt (TIPS) versus
endoscopic intervention
All-cause mortality
We found no evidence of a diJerence between TIPS and endoscopic
intervention with or without medical treatment for all-cause
mortality (RR 1.10, 95% CI 0.92 to 1.31; 1312 participants; 19 trials; I2
= 0%; very low-certainty evidence; Analysis 1.1.3). We downgraded
the evidence by four levels because all trials were at overall high risk
of bias (-2 levels), because of imprecision - the OIS as calculated by
GRADE was not met (-1 level), and because of publication bias (-1
level) (Summary of findings 4; Table 9; Figure 4).
Sensitivity analysis
The results did not change by excluding the trial assessing
prevention of gastric variceal rebleeding (Lo 2007) (RR 1.08, 95% CI
0.90 to 1.29; 1240 participants; 18 trials; I2 = 0%); by including trials
that have used only PTFE-covered stents (RR 1.02, 95% CI 0.70 to
1.49; 292 participants; 5 trials; I2 = 6%) (Ferlitsch 2012; Luo 2015;
Holster 2016; Lv 2018; Dunne 2020); or by including trials that did
not use PTFE-covered stents or did not declare whether PTFE stents
were covered or not (RR 1.13, 95% CI 0.93 to 1.39; 1020 participants;
14 trials; I2 = 0%) (GDEAIH 1995; Cabrera 1996; Cello 1997; Jalan
1997; Rossle 1997; Sanyal 1997; Sauer 1997; Merli 1998; García-
Villarreal 1999; Narahara 2001; Pomier-Layrargues 2001; Gülberg
2002; Sauer 2002; Lo 2007).
We did not observe a diJerence in all-cause mortality when
we excluded trials employing pharmacotherapy in addition to
endoscopic intervention (RR 1.17, 95% CI 0.91 to 1.50; 661
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participants; 10 trials; I2 = 0%) (Cabrera 1996; Cello 1997; García-
Villarreal 1999; Gülberg 2002; Jalan 1997; Lo 2007; Merli 1998;
Narahara 2001; Pomier-Layrargues 2001; Sanyal 1997), nor when we
restricted the analysis to trials that used only endoscopic banding
with or without medical treatment (RR 1.00, 95% CI 0.76 to 1.31; 497
participants; 8 trials; I2 = 0%) (Jalan 1997; Pomier-Layrargues 2001;
Gülberg 2002; Sauer 2002; Ferlitsch 2012; Luo 2015; Lv 2018; Dunne
2020), as well as to trials in which band ligation and beta blockers
were combined (RR 1.02, 95% CI 0.73 to 1.43; 377 participants; 6
trials; I2 = 0%) (Sauer 2002; Ferlitsch 2012; Luo 2015; Holster 2016;
Lv 2018; Dunne 2020).
Assessment of imprecision with Trial Sequential Analysis and
comparison with GRADE
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis using the
default RRR of 25% as suggested in the GRADE Handbook and the
plausible RRR of 10% for GRADE and for Trial Sequential Analysis.
Trial Sequential Analysis of this comparison was constructed on an
all-cause mortality of 25.2% in the endoscopic intervention with or
without medical treatment group; an RRR of 10% with TIPS, type I
error of 2.5%; and type II error of 20% (80% power). There was no
diversity (D2 = 0%). The DARIS was 10,902 participants. The Z-curve
did not cross the sequential boundaries for benefit, harm, or futility
(figure not shown).
The optimal information size was not reached by using the default
RRR of 25% as suggested in the GRADE Handbook, nor when we
used a more realistic RRR of 10% chosen by review authors for
GRADE and Trial Sequential Analysis (Table 9).
Rebleeding
Rebleeding was reduced by TIPS (RR 0.44, 95% CI 0.36 to 0.55;
1312 participants; 19 trials; I2 = 18%; very low-certainty evidence;
Analysis 1.2.3). We downgraded the evidence by three levels
because all trials were at overall high risk of bias (-2 levels), and
because of publication bias (-1 level) (Summary of findings 4; Table
9; Figure 5).
Sensivity analysis
The results did not change by excluding the only trial assessing
prevention of gastric variceal rebleeding (Lo 2007) (RR 0.44, 95%
CI 0.35 to 0.56; 1240 participants; 18 trials; I2 = 22%); by including
trials that specified only use of PTFE-covered stents (RR 0.38, 95%
CI 0.24 to 0.59; 292 participants; 5 trials; I2 = 0%) (Ferlitsch 2012; Luo
2015; Holster 2016; Lv 2018; Dunne 2020); by including trials that
did not specify the use of PTFE-covered stents (RR 0.35, 95% CI 0.19
to 0.64; 234 participants;14 trials; I2 = 15%) (GDEAIH 1995; Cabrera
1996; Cello 1997; Jalan 1997; Rossle 1997; Sanyal 1997; Sauer
1997; Merli 1998; García-Villarreal 1999; Narahara 2001; Pomier-
Layrargues 2001; Gülberg 2002; Sauer 2002; Lo 2007); by excluding
trials employing pharmacotherapy for the endoscopic intervention
group (RR 0.45, 95% CI 0.33 to 0.62; 661 participants; 10 trials; I2
= 26%) (Cabrera 1996; Cello 1997; García-Villarreal 1999; Gülberg
2002; Jalan 1997; Lo 2007; Merli 1998; Narahara 2001; Pomier-
Layrargues 2001; Sanyal 1997); or by including trials that utilised
only endoscopic banding with or without medical treatment (RR
0.43, 95% CI 0.31 to 0.60; 497 participants; 8 trials; I2 = 4%) (Jalan
1997; Pomier-Layrargues 2001; Gülberg 2002; Sauer 2002; Ferlitsch
2012; Luo 2015; Lv 2018; Dunne 2020), as well as trials that used only
band ligation and beta blockers (RR 0.43, 95% CI 0.29 to 0.64; 377
participants; 6 trials; I2 = 0%) (Sauer 2002; Ferlitsch 2012; Luo 2015;
Holster 2016; Lv 2018; Dunne 2020).
Assessment of imprecision with Trial Sequential Analysis and
comparison with GRADE
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis by using the
default RRR of 25% as suggested in the GRADE Handbook and the
plausible RRR of 20% and 40% for GRADE and for Trial Sequential
Analysis.
Trial Sequential Analysis of this comparison was constructed on a
rebleeding risk of 42.5% for the endoscopic intervention with or
without medical treatment group; type I error of 2.5%; and type
II error of 20% (80% power). The cumulative Z-curve crossed the
monitoring boundary for benefit when RRR with TIPS was set to
40% (D2 = 16 %, DARIS 351 participants), and when RRR was set to
20% (D2 = 16%, DARIS 1474 participants) (figures not shown).
The optimal information size was reached by using the default RRR
of 25% as suggested in the GRADE Handbook, and when we used
an RRR of 40% and 20% for GRADE and an RRR of 40% for Trial
Sequential Analysis. It was not reached with an RRR of 20% for Trial
Sequential Analysis (Table 9).
Mortality due to rebleeding
There was no evidence of a diJerence between TIPS and
endoscopic treatment with or without medical treatment (RR 0.65,
95% CI 0.40 to 1.04; 1263 participants; 18 trials; I2 = 0%; very
low-certainty evidence; Analysis 1.3.3). In four trials, it is unclear
whether deaths were due to variceal rebleeding or to other causes
of gastrointestinal haemorrhage (GDEAIH 1995; Merli 1998; Luo
2015; Lv 2018). However exclusion of these trials had no substantial
eJect on results (RR 0.38, 95% CI 0.18 to 0.78; 937 participants; 13
trials; I2 = 0%). We downgraded the evidence by four levels because
all trials were at overall high risk of bias (-2 levels), because of
imprecision - the OIS as calculated by GRADE was not met (-1 level),
and because of publication bias (-1 level) (Summary of findings 4;
Table 9; Figure 6).
Sensitivity analysis
The result was confirmed when we excluded the trial assessing
prevention of rebleeding from gastric varices (Lo 2007) (RR 0.66,
95% CI 0.40 to 1.08; 1191 participants; 17 trials; I2 = 1%); when
we restricted analysis to trials that did not specify use of PTFE-
covered stents (GDEAIH 1995; Cabrera 1996; Jalan 1997; Rossle
1997; Sanyal 1997; Sauer 1997; Merli 1998; García-Villarreal 1999;
Narahara 2001; Pomier-Layrargues 2001; Gülberg 2002; Sauer 2002;
Lo 2007) (RR 0.57, 95% CI 0.31 to 1.03; 971 participants; 13 trials; I2
= 14%); and when we excluded trials employing pharmacotherapy
in the endoscopic intervention group (RR 0.51, 95% CI 0.24 to 1.10;
612 participants; 9 trials; I2 = 11%) (Cabrera 1996; García-Villarreal
1999; Gülberg 2002; Jalan 1997; Lo 2007; Merli 1998; Narahara 2001;
Pomier-Layrargues 2001; Sanyal 1997).
Analysis of trials that utilised only endoscopic banding (not in
combination with other endoscopic therapies) confirmed the
reduction in mortality due to rebleeding with TIPS (RR 0.41, 95% CI
0.17 to 1.00; 497 participants; 8 trials; I2 = 0%) (Jalan 1997; Pomier-
Layrargues 2001; Gülberg 2002; Sauer 2002; Ferlitsch 2012; Luo
2015; Lv 2018; Dunne 2020).
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There were no diJerences in mortality due to rebleeding between
groups when we restricted the analysis to trials that specified use
of PTFE-covered TIPS (RR 0.59, 95% CI 0.18 to 1.99; 292 participants;
5 trials; I2 = 0%) (Ferlitsch 2012; Luo 2015; Holster 2016; Lv 2018;
Dunne 2020), and when we restricted the analysis to trials in which
band ligation associated with beta blockers was used (RR 0.57,
95% CI 0.19 to 1.67; 377 participants; 6 trials; I2 = 0%) (Sauer 2002;
Ferlitsch 2012; Luo 2015; Holster 2016; Lv 2018; Dunne 2020).
Assessment of imprecision with Trial Sequential Analysis and
comparison with GRADE
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis by using the
default RRR of 25% as suggested in the GRADE Handbook and the
plausible RRR of 20% and 40% for GRADE and for Trial Sequential
Analysis.
Trial Sequential Analysis of this comparison was constructed on a
mortality due to rebleeding of 8.2% in the endoscopic intervention
with or without medical treatment group; type I error of 1.4%, and
type II error of 20% (80% power). The cumulative Z-curve reached
the futility area before reaching the required information size when
RRR with TIPS was set to 40% (D2 = 0%, DARIS 2481 participants); the
cumulative Z-curve did not approach the monitoring boundaries
for benefit or harm or futility when the RRR was set to 20% (D2 = 0%,
DARIS 11,073 participants) (figures not shown).
The optimal information size was not reached by using the default
RRR of 25% as suggested in the GRADE Handbook nor when we used
an RRR of 40% and 20% for GRADE and Trial Sequential Analysis
(Table 9).
Acute hepatic encephalopathy
We found evidence of an increase in acute hepatic encephalopathy
with TIPS (RR 1.61, 95% CI 1.29 to 1.99; 1247 participants; 18 trials; I2
= 20%; very low-certainty evidence; Analysis 1.4.3). We downgraded
the evidence by four levels because all trials were at overall high
risk of bias (-2 levels), because of imprecision - the OIS as calculated
by GRADE was not met (-1 level), and because of publication bias
(Summary of findings 4; Table 9; Figure 7) .
Sensitivity analysis
The increase in acute hepatic encephalopathy was confirmed
by excluding the trial assessing prevention of gastric variceal
rebleeding (Lo 2007) (RR 1.55, 95% CI 1.27 to 1.90; 1175 participants;
17 trials; I2 = 9%); by excluding trials employing medical treatment
in the endoscopic intervention group (RR 1.61, 95% CI 1.13 to 2.29;
661 participants; 10 trials; I2 = 33%) (Cabrera 1996; Cello 1997;
García-Villarreal 1999; Gülberg 2002; Jalan 1997; Lo 2007; Merli
1998; Narahara 2001; Pomier-Layrargues 2001; Sanyal 1997); by
restricting analysis to trials that utilised only endoscopic banding
(RR 1.27, 95% CI 0.97 to 1.67; 497 participants; 8 trials; I2 = 0%) (Jalan
1997; Pomier-Layrargues 2001; Gülberg 2002; Sauer 2002; Ferlitsch
2012; Luo 2015; Lv 2018; Dunne 2020); and by restricting the analysis
to trials in which band ligation and beta blockers were used (RR
1.45, 95% CI 1.08 to 1.95; 377 participants; 6 trials; I2 = 0%) (Sauer
2002; Ferlitsch 2012; Luo 2015; Holster 2016; Lv 2018; Dunne 2020).
The diJerences between groups were reduced when we restricted
analysis to trials that specified use of only PTFE-covered stents (RR
1.39, 95% CI 0.98 to 1.98; 292 participants; 5 trials; I2 = 9%) (Ferlitsch
2012; Luo 2015; Holster 2016; Lv 2018; Dunne 2020), and diJerences
were increased when we restricted analysis to trials that did not
specify use of PTFE-covered stents (RR 1.71, 95% CI 1.30 to 2.25;
955 participants; 13 trials; I2 = 24%) (Cabrera 1996; Cello 1997; Jalan
1997; Rossle 1997; Sanyal 1997; Sauer 1997; Merli 1998; García-
Villarreal 1999; Narahara 2001; Pomier-Layrargues 2001; Gülberg
2002; Sauer 2002; Lo 2007).
Assessment of imprecision with Trial Sequential Analysis and
comparison with GRADE
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis, by using the
default RRR of 25% as suggested in the GRADE Handbook and the
plausible RRR of 20% and 40% for modified GRADE and for Trial
Sequential Analysis.
Trial Sequential Analysis of this comparison was constructed on
an incidence of acute hepatic encephalopathy of 20.1% in the
endoscopic intervention with or without medical treatment group;
type I error of 1.4%; and type II error of 20% (80% power). The
cumulative Z-curve crossed the monitoring boundary for harm
when RRR with TIPS was set to 40% (D2 = 25%, DARIS 1217
participants). When the RRR was set to 20% (D2 = 25%, DARIS
5282 participants), the cumulative Z-curve did not approach the
boundaries for benefit, harm, or futility (figures not shown).
The optimal information size was not reached by using the default
RRR of 25% as suggested in the GRADE Handbook,nor by using a
more realistic RRR of 20% for GRADE and 20% for Trial Sequential
Analysis. It was reached with an RRR of 40% for GRADE and TSA
(Table 9).
Chronic hepatic encephalopathy
Chronic hepatic encephalopathy was increased by TIPS (RR 1.88,
95% CI 0.93 to 3.80; 717 participants; 10 trials; I2 = 0%; very low-
certainty evidence; Analysis 1.5.3). We downgraded the evidence
by four levels because all trials were at overall high risk of bias (-2
levels); because of imprecision - the OIS as calculated by GRADE
was not met (-1 level), and because of publication bias (-1 level)
(Summary of findings 4; Table 9; Figure 8).
Sensitivity analysis
The result was confirmed when we excluded trials in which
pharmacotherapy was combined with endoscopic intervention
(RR 2.30, 95% CI 0.75 to 7.02; 301 participants; 5 trials; I2 = 0%)
(Cabrera 1996; García-Villarreal 1999; Gülberg 2002; Jalan 1997;
Pomier-Layrargues 2001). No clear increase in chronic hepatic
encephalopathy was noted when we restricted analysis to trials
that utilised only endoscopic banding (RR 1.52, 95% CI 0.63 to 3.66;
399 participants; 6 trials; I2 = 0%) (Jalan 1997; Pomier-Layrargues
2001; Gülberg 2002; Sauer 2002; Luo 2015; Lv 2018); when we
restricted the analysis to trials in which band ligation and beta
blockers were used (RR 1.54, 95% CI 0.51 to 4.65; 207 participants; 3
trials; I2 = 0%) (Sauer 2002; Luo 2015; Lv 2018), or when we restricted
the analysis only to trials in which PTFE-covered TIPS were used
(RR 1.25, 95% CI 0.35 to 4.46; 122 participants; 2 trials; I2 = 0%) (Luo
2015; Lv 2018).
Assessment of imprecision with Trial Sequential Analysis and
comparison with GRADE
We compared the assessment of imprecision of intervention eJects
as assessed by GRADE and Trial Sequential Analysis by using the
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default RRR of 25% as suggested in the GRADE Handbook and the
plausible RRR of 20% and 40% for GRADE and for Trial Sequential
Analysis.
Trial Sequential Analysis of this comparison was constructed on
an incidence of chronic hepatic encephalopathy of 2.8% in the
endoscopic intervention with or without medical treatment group;
type I error of 1.4%; and type II error of 20% (80% power). The
cumulative Z-curve did not approach the boundaries for benefit,
harm, or futility when RRR with TIPS was set to 40% (D2 = 0%,
DARIS 7600 participants). When RRR was set to 20% (D2 = 0%, DARIS
34,099 participants), the cumulative Z-curve was not constructed
due because we had insuJicient information (2.1% of the DARIS)
(figures not shown).
The required information size was not reached by using the default
RRR of 25% as suggested in the GRADE Handbook, nor when we
used an RRR of 20% and 40% for GRADE and Trial Sequential
Analysis (Table 9).
Complications
Complications are summarised in Table 4.
Shunt occlusion or dysfunction was the most common problem
following TIPS implantation. Rates of shunt occlusion or
dysfunction were recorded in 16 trials, with a reported incidence
varying from 8% to 89% (Cabrera 1996; Cello 1997; Jalan 1997;
Rossle 1997; Sanyal 1997; Sauer 1997; Merli 1998; García-Villarreal
1999; Narahara 2001; Pomier-Layrargues 2001; Sauer 2002; Lo 2007;
Ferlitsch 2012; Luo 2015; Holster 2016; Lv 2018).
Overall, across all trials utilising TIPS, the incidence of shunt
occlusion or dysfunction was 47.1% (95% CI 43% to 51%) (Cabrera
1996; Cello 1997; Jalan 1997; Rossle 1997; Sanyal 1997; Sauer
1997; Merli 1998; García-Villarreal 1999; Narahara 2001; Pomier-
Layrargues 2001; Sauer 2002; Lo 2007; Ferlitsch 2012; Luo 2015;
Holster 2016; Lv 2018). There was substantial variation in shunt
surveillance methods and protocols.
Four trials specified that PTFE-covered stents were used (Ferlitsch
2012; Luo 2015; Holster 2016; Lv 2018); of these, three trials
reported the incidence of shunt dysfunction (Luo 2015; Holster
2016; Lv 2018), and one reported the incidence of thrombosis
(Ferlitsch 2012). Luo 2015 and Holster 2016 reported incidences
of shunt dysfunction of 30% and 5%, respectively, whilst Lv
2018 reported shunt patency rates of 80% at two-year follow-up.
When we pooled results, the incidence of shunt dysfunction or
thrombosis in trials utilising PTFE-covered stents was 17% (95% CI
11.0 to 24%) (Luo 2015; Holster 2016; Lv 2018).
The remaining trials appear to have used bare-metal stents. The
incidence of shunt dysfunction varied from 18% to 89% across trials
that did not specify use of PTFE-covered stents (12 trials) (Table
4). When we pooled results from these 12 trials, 55% (95% CI 50
to 59) of trial participants developed shunt dysfunction (Cabrera
1996; Cello 1997; Jalan 1997; Rossle 1997; Sanyal 1997; Sauer
1997; Merli 1998; García-Villarreal 1999; Narahara 2001; Pomier-
Layrargues 2001; Sauer 2002; Lo 2007).
For the shunt group, few complications are reported, suggesting
potential under-reporting of complications.
For endoscopy, the most common complications were
oesophageal ulcers and stenosis with or without bleeding and
infection (Table 2; Table 3; Table 4).
In-hospital stay
Nine trials reported on length of hospital stay (Cabrera 1996;
García-Villarreal 1999; Cello 1997; Jalan 1997; Rossle 1997; Pomier-
Layrargues 2001; Sauer 2002; Lo 2007; Holster 2016). The data
(when reported) were found to be skewed, with significant
statistical heterogeneity and variation in the time scales measured.
Results are summarised in Table 5.
Cost
Three trials have reported costs of TIPS versus endoscopic
intervention (Cello 1997; Jalan 1997; Holster 2016; Table 6).
Cello 1997 reported total costs from the day of randomisation to
death or last follow-up and reported comparable costs in both
groups.
Jalan 1997 reported that the mean cost for the TIPS procedure was
GBP 5782 per person (excluding personnel costs), and the mean
cost for endoscopic intervention was GBP 4020 per person; Jalan
1997 also reported that the mean cost of inpatient treatment was
GBP 7059 for TIPS and GBP 8432 for endoscopic intervention.
Although Cello 1997 and Jalan 1997 found comparable costs in
both groups, Holster 2016 reported significantly higher financial
costs of TIPS, with a mean cost of EUR 27,746 for TIPS versus a
mean cost of EUR 16,816 for endoscopy over one year of follow-up
(including admissions, consultations, procedures, investigations,
transfusions, and medications). However, it must be noted that
we extracted cost-eJectiveness data from a conference abstract
and noted that these data were not based on the full cohort of
participants (Holster 2016).
Rebleeding from all causes
We added an unplanned analysis of gastrointestinal rebleeding
from all causes (portal hypertension-related and non-portal
hypertension-related).
The rate of rebleeding was lower in the portosystemic shunts
group than in the endoscopic intervention with or without medical
treatment group for all three modalities of treatment: shunt
intervention meta-analysed together (RR 0.42, 95% CI 0.34 to 0.52;
1769 participants; 26 trials; I2 = 42%; Analysis 1.6); TS (RR 0.34, 95%
CI 0.19 to 0.61; 127 participants; 2 trials; I2 = 0%; Analysis 1.6.1);
DSRS (RR 0.35, 95% CI 0.18 to 0.68; 330 participants; 5 trials; I2
= 63%; Analysis 1.6.2); TIPS (RR 0.45, 95% CI 0.35 to 0.56; 1312
participants; 19 trials; I2 = 41%; Analysis 1.6.3).
Subgroup analyses
We were unable to perform subgroup analysis of trials according to
risk of bias because all trials were at overall high risk of bias.
Subgroup analysis regarding funding
We found no evidence of diJerences between the subgroup of trials
without for-profit funding and the subgroup of trials in which the
source of funding was unknown (no trials had definite for-profit
funding; see above for details) for all outcomes.
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The test for subgroup diJerences showed no diJerences in:
• all-cause mortality (P = 0.25; I2 = 24.8): trials without for-profit
funding (RR 1.12, 95% CI 0.85 to 1.49; 754 participants; 11 trials;
I2 = 39%; Analysis 2.1.1), trials with funding unknown (RR 0.93,
95% CI 0.78 to 1.10; 1074 participants; 16 trials; I2 = 0%; Analysis
2.1.2);
• rebleeding (P = 0.37; I2 = 0%): trials without for-profit funding
(RR 0.36, 95% CI 0.25 to 0.51; 732 participants; 11 trials; I2 = 37%;
Analysis 2.2.1), trials with funding unknown (RR 0.44, 95% CI 0.33
to 0.58; 1037 participants; 15 trials; I2 = 29%; Analysis 2.2.2);
• mortality due to rebleeding (P = 0.61; I2 = 0%): trials without for-
profit funding (RR 0.45, 95% CI 0.23 to 0.86; 705 participants; 10
trials; I2 = 1%; Analysis 2.3.1), trials with funding unknown (RR
0.55, 95% CI 0.33 to 0.91; 1074 participants; 16 trials; I2 = 0%;
Analysis 2.3.2);
• acute hepatic encephalopathy (P = 0.59%; I2 = 0%): trials without
for-profit funding (RR 1.52, 95% CI 1.09 to 2.12; 705 participants;
11 trials; I2 = 24%; Analysis 2.4.1), trials with funding unknown
( (RR 1.69, 95% CI 1.36 to 2.11; 944 participants; 13 trials; I2 = 0%;
Analysis 2.4.2); or
• chronic hepatic encephalopathy (P = 0.61; I2 = 0%): trials without
for-profit funding (RR 2.00, 95% CI 0.70 to 5.73; 282 participants;
4 trials; I2 = 0%; Analysis 2.5.1), trials with funding unknown
(RR 2.79, 95% CI 1.35 to 5.75; 674 participants; 9 trials; I2 = 0%;
Analysis 2.5.2).
Assessment for publication bias
The presence of publication bias was assessed by performing a
dichotomous analysis. It was possible to assess it for all treatments
together and for TIPS, given that there were at least 10 trials for TS
and DSRS.
Asymmetry was present in the funnel plot, both for all
portosystemic shunts analysed together, and for TIPS, which
suggests that small trials favouring shunts are missing for analysis
of all-cause mortality (Figure 4), rebleeding (Figure 5), and
mortality due to rebleeding (Figure 6) , and small trials favouring
endoscopy are missing for analysis of development of acute hepatic
encephalopathy (Figure 7) and for development of chronic hepatic
encephalopathy (Figure 8).
D I S C U S S I O N
Summary of main results
In this systematic review we compared portosystemic shunting
procedures (total shunt (TS), distal splenorenal shunt (DSRS),
and transjugular intrahepatic portosystemic shunt (TIPS)) versus
endoscopic interventions (endoscopic sclerotherapy or banding,
or both) with or without medical treatment for prevention of
rebleeding from oesophagogastric varices in people with cirrhosis.
We included 27 trials with up to 1828 participants, which provided
data for analyses.
Overall, we found very low-certainty evidence suggesting that
all modalities of shunt intervention compared with endoscopic
intervention with or without medical treatment may make little or
no diJerence in all-cause mortality.
We found very low-certainty evidence suggesting that shunts
reduced the risk of rebleeding. Estimates for the risk of all-cause
mortality and rebleeding were precise, as optimal information sizes
(OISs) were met and confidence intervals (CIs) were narrow. There
was no heterogeneity. However, the overall high risk of bias of the
included trials and the risk of publication bias are limitations that
reduce the strength of the results of this review.
We found very low-certainty evidence suggesting that shunts
reduced mortality due to rebleeding, and that shunts increased the
risk of acute and chronic hepatic encephalopathy. A summary of
our results is reported in Summary of findings 1.
We found very low-certainty evidence suggesting that DSRS and
TIPS compared with endoscopic treatment with or without medical
treatment may make little or no diJerence in all cause-mortality,
and that TS seemed to reduce mortality. We found very low-
certainty evidence suggesting that each shunt modality reduced
rebleeding and mortality due to rebleeding. Although meta-
analysis did not demonstrate an impact of treatment with total
shunt on the development of acute hepatic encephalopathy (very
low-certainty evidence), risk was increased with DSRS (very low-
certainty evidence) as with TIPS (very low-certainty evidence).
Chronic hepatic encephalopathy was not increased with TS but
was increased with DSRS, and the tendency toward chronic hepatic
encephalopathy was increased with TIPS (very low-certainty
evidence).
DiJerences between types of treatment in eJects on all-cause
mortality and acute and chronic encephalopathy must be
interpreted cautiously because of the low certainty of evidence,
and because of the absence of statistical diJerences between
them. When we analysed TS, DSRS, and TIPS as subgroups, the
test for subgroup diJerences showed no diJerences between the
three treatments on mortality (P = 0.14; I2 = 48.8%; Analysis 1.1),
acute encephalopathy (P = 0.98; I2 = 0%; Analysis 1.4), or chronic
encephalopathy (P = 0.31; I2 = 13.5%; Analysis 1.5).
We found no substantial heterogeneity among the included
trials. This was confirmed by the absence of diJerences in
the main analyses. Sensitivity analysis performed in trials with
TIPS, band ligation, medical treatment (beta blocker), and
polytetrafluoroethylene (PFTE)-covered stent did not show any
changes in results.
Shunt dysfunction was a problem commonly encountered among
individuals treated with TIPS. Summaries of our results comparing
TS, DSRS, and TIPS versus endoscopic treatment with or without
medical treatment are provided in Summary of findings 2,
Summary of findings 3, and Summary of findings 4.
Overall completeness and applicability of evidence
Included trial participants had liver disease ranging from Child's
class A to C, although the mean Child-Pugh score, when reported,
ranged between 6.6 and 9.8. This suggests that trials excluded
participants with initial Child's class A and severe Class C. No
analyses of the results according to liver function or grade of
hypertension (based on variceal size or hepatic venous pressure
gradient (HVPG)) are reported. Results show high variability in the
number of previous bleedings and in time from the index bleeding;
the start of prevention ranged from a few hours to several weeks.
In addition, some of the included trials were conducted more
than 30 years ago. Over the past decades, treatments such as
orthotopic liver transplantation for advanced stages of cirrhosis
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and improved surgical, interventional, and endoscopic procedures
have influenced the natural history of cirrhosis and have reduced
the applicability of the results of old trials (usually assessing
surgical procedures) to patients seen in current practice.
Quality of the evidence
Our current review has identified a number of methodological
concerns. All trials were at overall high risk of bias. The a
priori number of participants required for a meta-analysis to be
conclusive was reached for all-cause mortality and rebleeding as
shown by the meta-analysis of all shunt treatments, and for re-
bleeding with TIPS as shown by the meta-analysis of individual
treatments, but not for the other outcomes nor for other individual
treatments, meaning that risk of random error was high.
Our assessments of risk of bias reflect the lack of, or poor
description of, trial design and performance, as well as incomplete
reporting of results. We oNen failed in our attempts to obtain
missing information from the authors of trial reports.
Regarding lack of blinding of participants and personnel, as we
anticipated, blinding was impossible to perform in light of the
nature of the interventions, but it could have influenced a shiN to
alternative treatments aNer randomisation, not due to medical or
technical reasons.
Blinding of outcome assessors should have been achievable.
Nonetheless, only two trials reported adequate blinding of
outcome assessors (Holster 2016; Lo 2007), leaving the remaining
trials at risk of detection and performance bias. A lack of blinding of
outcome assessor (detection bias) may not aJect the results of all-
cause mortality, but it could influence the results of other outcomes
(e.g. hepatic encephalopathy, cause of mortality, etc), considering
that outcomes can have a subjective component in the judgement
(Savović 2018).
We found high risk of reporting bias. Most trials did not publish
protocols, and not all of the outcomes of interest for the review
were reported; in particular, the incidence of chronic hepatic
encephalopathy was reported by only a relatively small number of
trials.
Very few adverse events were reported in the shunt group in
comparison with the endoscopic group, which could suggest
selective under-reporting of adverse events due to surgical
treatment.
A large number of participants with treatment failure were crossed-
over to the other available treatment (mainly from endoscopic
intervention to portosystemic shunts) aNer failure. In most cases, it
is unclear if and when the data were censored. It is likely that this
bias was relevant for all outcomes except rebleeding (this was the
reason for the switch to alternative treatments). We classified this
bias under 'other bias'.
The funnel plots in our review seem to suggest risk of publication
bias. The visual inspection might give a misleading impression
of the presence or absence of publication bias (Simmonds 2015)
because there is concern that "visual interpretation of funnel plots
is inherently subjective" (Higgins 2019). There is not an agreement
on the use of statistical tools to interpret publication bias (Higgins
2019; Grade Handbook), and alternative hypotheses to explain the
asymmetry in this review does not seem likely because there was
no heterogeneity among the trials, asymmetry was present also for
each type of treatment (TS, DSRS, TIPS), and if the number of trials
for each type of shunt is low. There were no diJerences between
the results with a random-eJects meta-analysis and a fixed-eJect
analysis (data not presented). We cannot exclude the role of chance
completely, but we constructed funnel plots only for analyses with
more than 10 trials. Publication bias seems to be the most likely
explanation of the asymmetry also because a lot of the included
trials are very old, being performed before the implementation
of the trial registration initiative. Thus, a selective publication of
studies was most likely to have taken place, also if it is not possible
to exclude that the apparent asymmetry could be a result of factors
other than publication bias, and that the direction of bias appears
to vary.
All trials included in this review presented methodological
weaknesses that increase bias risk and reduce the certainty
of evidence. All of this has impacted the robustness of our
conclusions.
Through our GRADE assessment, we considered the influence of
the high risk of bias, imprecision, and publication bias in the
trials on the trial outcome results. Whereas the precision of the
results is high for rate of rebleeding (narrow CI and OIS were
met), the limitations due to the overall low quality of trials and
publication bias resulted in very low certainty of evidence rating for
all outcomes and for each shunt modality.
No trial data on health-related quality of life were reported;
therefore, no evidence is available for this outcome. In addition,
we were unable to draw clear conclusions with regards to cost and
length of patient stay because data were variably reported, were
highly heterogeneous, and were inconsistently collected.
It was not possible to perform meta-analyses of complications
because in most trials they were reported as single episodes, and
the number of participants experiencing them was not reported.
Potential biases in the review process
We performed a comprehensive literature search for published and
unpublished studies, and we combined electronic data searches
with manual searches of the reference lists of identified trials as
well as conference proceedings and abstract books from relevant
national and international society meetings. We included trials
regardless of their language of publication, and whether they
reported data on the outcomes we needed. We contacted relevant
study authors to request additional information.
Three review authors independently assessed study eligibility,
extracted data, and assessed risk of bias in included trials, and we
believe that this has reduced potential biases in the review process.
This systematic review represents an update of a previously
published review, based on a protocol from 1997. Every eJort has
been made to update the review with up-to-date methods, whilst
maintaining methods according to the published protocol when
possible, hence avoid reporting bias in the current review. However,
we acknowledge that changes in Cochrane guidance have resulted
in minor deviations from the protocol.
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Agreements and disagreements with other studies or
reviews
The previous version of this review utilised a systematic approach
to assess the eJects of portosystemic shunts (TS, DSRS, and
TIPS) versus endoscopic treatments (Khan 2006). Those review
authors reported no diJerences in all-cause mortality but a reduced
incidence of rebleeding and an increased incidence of hepatic
encephalopathy for all shunt modalities and with analysis of each
modality individually for TIPS. Review results are consistent with
our results.
The current version, updating data to 2020, has included more
trials and, among these, trials that utilised PTFE-covered stents
and band ligation, which are judged better than uncovered
stents and sclerotherapy, respectively. In a sensitivity analysis, the
results did not change when trials using the modality of TIPS
shunt and using endoscopic interventions were added. Second,
more outcomes were assessed: among these, mortality due to
rebleeding, which seems reduced by the portosystemic shunt in
comparison with endoscopy with or without medical treatment.
Whilst it is undoubtedly essential to examine the impact of
treatments on health-related quality of life, unfortunately our
attempts to conduct this evaluation failed because none of the
trials reported on it, suggesting that health-related quality of life
remains to be examined in future trials.
Moreover, although an assessment of risk of bias was reported
in the previous version of this review, the methodological update
of criteria according to Cochrane methods has been applied,
and an assessment of the certainty of evidence via GRADE
recommendations has been added.
Recently, another published meta-analysis compared
portosystemic shunts (including surgical portosystemic shunts and
transjugular intrahepatic portosystemic shunt) versus endoscopic
intervention (Zhou 2019). The authors of this meta-analysis
stated in the methods section that they assessed trials
including participants with "at least one previous episode
of gastroesophageal variceal bleeding that had subsequently
stabilised, either spontaneously or by the use of non-surgical
therapies..."; however, it appears that they also included trials
performed in emergency settings (OrloJ 2009; OrloJ 2015). In
addition, they included trials comparing the surgical shunt to
TIPS (Rosemurgy 2012). Therefore, our results represent a diJerent
clinical context. Our meta-analysis is more homogeneous for
settings of participants (elective prophylaxis of rebleeding) and
comparisons (shunts versus endoscopy).
Two previous meta-analyses compared uncovered TIPS versus
endoscopic intervention (Luca 1999; Papatheodoridis 1999); these
were updated by Burroughs 2002. All these meta-analyses reported
no diJerences in all-cause mortality, a decrease in rebleeding risk,
and an increase in hepatic encephalopathy. However, none of
these meta-analyses evaluated the certainty of evidence following
stringent methods. In addition, these meta-analyses included
fewer trials, and given the years of publications, these meta-
analyses included fewer trials reporting on covered TIPS and/or
band ligation with or without beta blockers.
In a multiple-treatment meta-analysis, Shi 2013 assessed
several treatments to prevent rebleeding, including TIPS. Beta
blockers combined with endoscopic injection sclerotherapy,
and endoscopic banding ligation (EBL) combined with
endoscopic injection sclerotherapy, were superior to beta
blockers and endoscopic injection sclerotherapy in reducing
rebleeding and mortality due to rebleeding; TIPS was more
eJicacious than beta blockers, endoscopic banding ligation,
endoscopic injection sclerotherapy, beta blockers combined
with isosorbide-5-mononitrate (5-ISMN), and beta blockers
combined with endoscopic injection sclerotherapy. TIPS had the
greatest probability of reducing mortality due to rebleeding.
Endoscopic banding ligation combined with endoscopic injection
sclerotherapy was the best choice according to the cumulative
probabilities of being among the three most eJicacious
interventions for the three outcomes examined in this review. In
this meta-analysis, trials in which drugs or treatments have been
previously used were excluded. The list of included trials is not
reported in Shi 2013, nor is it updated. Furthermore, the role of this
method has yet to be validated.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Overall, the very low certainty of evidence on the eJects of shunts in
comparison with endoscopic interventions with or without medical
treatment prevents us from drawing definitive conclusions about
the role of shunts in preventing rebleeding and mortality due to
rebleeding. We are very uncertain whether shunts had an impact
on mortality. Shunts are used at the cost of one having to undergo
major surgery or a radiological interventional procedure (with its
attendant risks) and the need for a specialised team, which could
be diJerent in diJerent countries and between low- and high-
income countries. So, the decision on which treatment should be
used to prevent further bleeding and the choice of the type of
treatment to be used could be based on the physician's and the
patient's values and preferences aNer they have understood the
uncertainty on which these choices are based and the significant
risks of publication bias behind these results.
Implications for research
We propose adequately powered, adequately conducted, properly
reported multi-centre randomised clinical trials in this area. These
trials should stratify patients at high risk of rebleeding and should
consider an 'early' shunt procedure (in the early stage of the
bleeding). The trials should consider to investigate hepatic venous
pressure gradient (HVPG) as a prognostic variable at entry. The
trials need to strive for outcome assessors blinded to intervention
group. The issues of eJects of interventions on quality of life and
costs and their impact on length of hospital stay should also be
adequately addressed. As patient recruitment will continue to be
an impediment, the only way around this is the pooling of resources
across diJerent centres with similar interests. Furthermore, trial
reporting should be done in such a way that it facilitates future
meta-analyses. These recommendations are not specific to the
comparisons addressed here, but they have implications for
randomised clinical trials examining the management of portal
hypertension in general. Future trials should be designed according
to the SPIRIT recommendations (www.spirit-statement.org), and
trial details should be reported in keeping with the CONSORT
recommendations (www.consort-statement.org).
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [author-defined order]
 
Study characteristics
Methods Randomised controlled trial comparing surgical shunt with endoscopic sclerotherapy for prevention of
variceal rebleeding in patients with Child's A cirrhosis
Time from bleeding episode to randomisation: not mentioned
Time from randomisation to treatment in days (mean): not mentioned
Korula 1987 
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Total number of participants evaluated: 55; found eligible: 37
Randomised to surgical shunt: 18; randomised to endoscopic sclerotherapy: 19
Adequate reasons provided for those not randomised: no information
Follow-up period months (mean, SD): surgical shunt group 13.1, 8.8; sclerotherapy group 10.5, 9.5
Deviation from intended interventions: 2 participants were not treated after randomisation (1 in shunt
group and 1 in endoscopic group)
Assessment of suitability for shunt carried out before randomisation: not mentioned
Shunt patency assessed: no mention
Method of Child's grading: Child-Pugh
Method of encephalopathy testing: not mentioned
Rebleeding episodes endoscopically verified: no information
Participants Inclusion criteria: all patients with cirrhotic portal hypertension (Child-Pugh A class, Pugh modification
< 8 points) with minimum of 2 variceal bleeding episodes who received less than 1 session of endoscop-
ic sclerotherapy
Exclusion criteria: not mentioned
Aetiology: alcohol 16 patients in each group
Baseline characteristic: similar in the 2 groups
Interventions Shunt: TS (portacaval) (13 patients), DSRS (3 patients), mesocaval (1 patient)
ET: sclerotherapy






Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information
Allocation concealment
(selection bias)





Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk No loss to follow-up
Selective reporting (re-
porting bias)
High risk Insufficient Information: information only on mortality and rebleeding.
Korula 1987  (Continued)
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Not enough information on all outcomes






Methods Randomised controlled trial comparing distal splenorenal shunt with sclerotherapy for prevention of
esophagogastric variceal rebleeding
Intention-to-treat analysis
Time from bleeding episode to randomisation: 10 to 15 days
Time from randomisation to treatment in days: DSRS group 11 to 65 (mean 32.7, SD 17.2), sclerothera-
py group 10 to 59 (mean 23.5, SD 15.1)
Total number of patients evaluated: 189
Randomised to shunt surgery: 57; randomised to endoscopic sclerotherapy: 55
Deviation from intended interventions: 14 of the 57 patients assigned to the DSRS group (24.5%) and 4
of the 55 assigned to the endoscopic sclerotherapy group (7.3%) were excluded from the trial after ran-
domisation before treatment for clinical reasons. Some reasons involved surgical considerations (i.e.
splenic and vein thrombosis). Other reasons were participant related (4 refused surgery)
Two patients in the endoscopic group were lost to follow-up
Mean follow-up period in months (SD): shunt surgery 27.45 (15.6), endoscopic sclerotherapy 26.57
(16.9)
Follow-up range in months DSRS (1 to 58), endoscopic therapy (1 to 64)
Assessment of suitability for shunt carried out before randomisation: no
Method of Child's grading: Child-Campbell
Method of encephalopathy testing: clinical testing and history
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding episode clinically significant: not specified
Participants Inclusion criteria: Child-Campbell A and B cirrhotic patients with at least 1 episode of oesophageal or
gastric variceal haemorrhage, documented by endoscopy, who were treated by conservative proce-
dures (balloon tamponade or vasopressin) and achieved haemostasis
Exclusion criteria: Child-Campbell C patients, continual variceal bleeding despite medical treatment
and balloon tamponade, early rebleeding between admission and randomisation
Randomisation was done when the patient was stabilised - between 10 and 15 days after cessation of
the haemorrhage
Child-Cambell score: DSRS group 7.07 ± 1.17, sclerotherapy group 7.54 ± 1.38
Aetiology: alcohol 64% (DSRS group 51%, sclerotherapy group 78%)
Child-Campbell score greater and number of alcoholics greater in the endoscopic sclerotherapy group
Interventions Shunt: DSRS (retroperitoneal approach)
Endoscopic therapy: sclerotherapy, technique intravariceal, sclerosant 5% ethanolamine oleate (10 to
20 mL at each session), every week for an average of 4 weeks until varices disappeared or became of
minimal size
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• Days of hospitalisation
Study authors reported complications
Notes Funding: supported by Grants CAICYT (Comisión Asesora de Investigación Científica y Técnica) 1851/82
and 1853/82
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random table
Allocation concealment
(selection bias)





Unclear risk Not feasible
It is unclear if lack of blinding influenced the choice of treatments and the
management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





High risk Study authors reported information on mortality for all randomised partici-
pants. They did not report information on the other outcomes of interest for
excluded participants after randomisation
Selective reporting (re-
porting bias)
High risk No pre-published protocol is available
Study authors report information on all key outcomes of interest in this review
They reported complications in the endoscopic group but not in the shunt
group
Other bias High risk In DSRS, 4 participants/6 who rebled were submitted to an alternative therapy:
1 to stapling transection; 3 to sclerotherapy
In endoscopic group, 3 participants who rebled were treated: 1 by stapling
transection, 2 by portacaval shunt
Participants were not censored at the bleeding episode





Methods Randomised controlled trial comparing distal splenorenal shunt with endoscopic sclerotherapy for
prevention of variceal rebleeding
Time from bleeding episode to randomisation: when the patient achieved haemodynamic stability
Time from randomisation to treatment: no longer than 24 hours
Total number of patients evaluated: 282, of which 140 were eligible
Adequate reasons provided for not randomising: yes
Santambrogio 2006 
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Randomised to shunt surgery: 40; randomised to endoscopic sclerotherapy: 40
Long-term follow-up not complete in 2 DSRS and 3 endoscopic therapy patients
Mean follow-up period in months (mean, SD): shunt surgery group 109 ± 58, sclerotherapy group 87 ±
61
Protocol violation: DSRS group: 2 patients had TS for technical reasons; endoscopic therapy: 3 patients
changed treatment (1 transplant, 2 portacaval shunt)
Assessment of suitability for shunt carried out before randomisation: yes
Method of Child's grading: Child-Pugh
Method of encephalopathy testing: mental status, asterixis, trail-making tests, "cancelling A's" test, EEG
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding episode clinically significant: yes
Participants Inclusion criteria: biopsy-confirmed cirrhosis, endoscopically verified variceal bleed requiring at least 1
unit of blood transfusion, arrest of variceal haemorrhage spontaneously or by the use of drugs and/or
tamponade and/or sclerotherapy, < 70 years old, good or moderate liver function as reflected by Child-
Pugh class A and B, patency of portal venous system and hepatopetal flow (according to Nordlinger's
classification), eligible for shunt or sclerotherapy, absence of life-threatening disease (e.g. tumour) and
willingness to return for regular follow-up
Exclusion criteria: Budd-Chiari syndrome, sclerosing cholangitis, > 70 years old, Child's class C, unsuit-
able splenic vein, gastric varices, chronic encephalopathy, severe ascites, associated disease, previous
sclerotherapy, not willing
Randomisation for assignment to groups was carried out when the patient was stabilized, which oc-
curred no more than 24 hours before treatment
Child-Pugh class A/B (%): 37.5/62.5 (DSRS group 47.5/53.5, sclerotherapy group 27.5/72.5)
Aetiology (%): alcohol 50, no alcohol 50 (DSRS group 35/65, sclerotherapy group 65/35)
Patients in the endoscopic sclerotherapy group were slightly older and a larger number were alcoholics
Interventions Shunt surgery: distal splenorenal shunt (Warren technique) with splenopancreatic disconnection in 18
patients; total shunt in 2 patients
Endoscopic therapy: sclerotherapy, intravariceal and paravariceal technique, sclerosant 0.5% to 1%




Notes Santambrogio 2006 represents update of Spina 1990
Funding: no information
Analysis of time to rebleeding appears to include 4 patients bleeding from duodenal ulcers in the shunt
group and 1 patient bleeding from oesophageal ulcer and 2 from unknown causes in the endoscopic
therapy group. Data for variceal bleeding and hypertensive gastropathy could be extracted only for as-
sessment of raw numbers of patients experiencing rebleeding
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random numbers table
Allocation concealment
(selection bias)
Unclear risk No information
Santambrogio 2006  (Continued)
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
cirrhosis (Review)














Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treat-
ments.and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk Mean follow-up 109 months in DSRS group; 87 in endoscopic therapy group.
Long-term follow-up complete in all patients, except 5. This was judged to be




High risk No pre-published protocol available
Study authors reported information on all key outcomes of interest in this re-
view but provided incomplete reporting of surgical complications
Other bias Low risk Small number of cross-over treatments: 2 participants in endoscopic group





Methods Randomised controlled trial comparing distal splenorenal shunt with endoscopic variceal sclerosis to
prevent variceal rebleeding in cirrhotic patients
Time from bleeding episode to randomisation: not mentioned
Time from randomisation to treatment: therapy was instituted within 48 hours of assignment for all pa-
tients except 2 in the shunt group
Total number of patients evaluated: 420
Randomised to shunt: 35; randomised to endoscopic therapy: 37
Adequate reasons provided for those not randomised: yes
One patient in the shunt group did not receive assigned treatment
Surgical rescue was required in 35% of patients receiving sclerotherapy. Rescue surgery included distal
splenorenal shunt in 8 patients, total portal systemic shunt in 2 patients, and splenectomy with devas-
cularisation in 2 patients
No losses to follow-up
Intention-to-treat analysis
Median (range) follow-up period in months: 61 (30 to 84)
Assessment of suitability for shunt carried out before randomisation: no
Method of Child's grading: single worst Child’s criterion
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding episode clinically significant: yes
(Only 16 patients in the shunt group and 14 in the endoscopic therapy group were discharged alive af-
ter the initial hospitalisation)
Participants Inclusion criteria: biopsy-proven cirrhosis, endoscopic evidence of oesophageal variceal bleeding, suit-
ability for DSRS established with angiography or sclerotherapy
Exclusion criteria: living more than 200 miles from the base hospital, referred for specific therapy
(surgery or sclerosis), previous long-term sclerotherapy, emergent or urgent surgery, non-cirrhotic
variceal bleed
Henderson 1990 
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Acute bleeding episode was managed as clinically indicated. After stabilisation of the patient's bleed-
ing for 24 to 48 hours, the patient and his or her data were reviewed to assess eligibility
Forty-one participants (57%) were in Child's A and B classes (57% in each group); 31 participants (43%)
were in class C (41% in each group)
Aetiology: alcohol 57% in DSRS group and 62% in sclerotherapy group. No mention of HBV and HCV ae-
tiology
Patients comparable in terms of age, Child's class, and alcoholic status
Interventions Surgical shunt: DSRS (Warren technique), with or without splenopancreatic disconnection
Sclerotherapy: intravariceal and paravariceal injections of: 0.75 to 1.0% sodium tetradecyl sulphate or
1.5 to 2.0% sodium morrhuate, following a weekly, biweekly, then monthly schedule




• Haemodynamics and liver and spleen volumes
Encephalopaty is reported in a previous report (Warren 1986)
Notes Funding: supported by Public Health Service Research Grant AM 15736 and General Clinical Research
Center Public Health Service Grant 5M01RR00039
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information
Allocation concealment
(selection bias)





Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treat-
ments.and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk Intention-to-treat analysis. Median follow-up 61 months (range 30 to 84
months). Telephone contact maintained: "in the latter years of the study, not




High risk No pre-published protocol available
"Endpoints were defined at the beginning of the study. Primary endpoints
were death and failure of therapy"; "Secondary endpoints included rebleeding
and a decline in either hepatic function or haemodynamics"
Rates of encephalopathy were reported in preliminary analysis (Warren and
colleagues) but not in final report. Not all key outcomes are reported
Henderson 1990  (Continued)
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Other bias High risk Large number of cross-over treatments. Twelve participants in endoscopic
group received surgery for bleeding: 8 splenorenal shunt, 2 total portal shunt,





Methods Randomised controlled trial comparing portacaval shunt with endoscopic sclerotherapy for prevention
of gastroesophageal variceal rebleeding
Time from bleeding episode to randomisation: between 4 and 11 days in both groups
Time from randomisation to treatment in days (mean, SD): shunt group 14.7, 6.3; endoscopic therapy
group 7.2, 3.4
Total number of patients evaluated: 182
Randomised to shunt: 41; randomised to endoscopic sclerotherapy: 41
Adequate reasons provided for those not randomised: yes
Seven patients in the shunt group and 6 in the endoscopic therapy group did not receive the allocated
treatment
One patient in each group was lost to follow-up
Intention-to-treat analysis
Follow-up period in months (mean, SD): shunt group 20.9, 13.9; endoscopic sclerotherapy group 20.8,
15
Assessment of suitability for shunt carried out before randomisation: no
Method of Child's grading: Child-Campbell
Method of encephalopathy testing: clinical testing and history
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding episode clinically significant: not specified
Participants Inclusion criteria: Child-Campbell A and B cirrhotic patients following endoscopically proven gastroe-
sophageal variceal haemorrhage
Exclusion criteria: Child-Campbell class C, uncontrollable haemorrhage or early rebleeding between
admission and randomisation
Randomisation was performed after the haemorrhage had stopped and the patient had been haemo-
dynamically stable for 3 days
Child-Campbell score: shunt group 8.2 ± 1.3, sclerotherapy group 8.4 ± 1.5. Child-Campbell class A/B
(%): shunt group 39/61, sclerotherapy group 34/66
Aetiology (%): alcohol 61 in shunt group and 73 in sclerotherapy group. No mention of HCB and HBV ae-
tiology
Patient characteristics comparable, age slightly younger in the endoscopic sclerotherapy group
Interventions Shunt: end-to-side portacaval shunt
Sclerotherapy: intravariceal and paravariceal injections of 1% polidocanol (first 2 sessions performed






• Days of hospitalisation and cost
Planas 1991 
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Notes Funding: no information
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information
Allocation concealment
(selection bias)





High risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Deviation from intended interventions: 4 participants in the shunt group re-
fused surgery not for medical or technical reasons
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk 1 patient in each group lost to follow-up, with censorship as appropriate (ac-
ceptable dropout rate < 5%).
Results presented on both an intention-to-treat and a per-protocol basis for all




Low risk No pre-published protocol
All outcomes of interest in this review are presented in the expected forms
Other bias High risk Large number of cross-over treatments. In portacaval shunt group, 1 (2.4%)
participant was crossed over to sclerotherapy and then to mesocaval shunt
for repeated rebleeding. Five participants in endoscopic group (14%) were





Methods Randomised controlled trial comparing elective shunt surgery with endoscopic sclerotherapy for pre-
vention of oesophageal variceal haemorrhage
Time from bleeding episode to randomisation: not specified
Time from randomisation to treatment: not specified
Randomised to shunt surgery: 31; randomised to endoscopic sclerotherapy: 29. One patient switched
to endoscopic sclerotherapy from shunt surgery after he withdrew consent; he was assessed as being
randomised to endoscopic sclerotherapy
Adequate reasons provided for those not randomised: not specified
Deviation from intended interventions, small number: 1 patient who refused surgery was treated with
endoscopic therapy and was included in the endoscopic therapy group for subsequent analysis (per-
protocol analysis)
Two patients in each group lost to follow-up
Per-protocol analysis, non-intention-to-treat
Rikkers 1993 
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
cirrhosis (Review)
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Follow-up period in months (mean, SEM): shunt surgery group 85, 5; endoscopic sclerotherapy group
92, 7
Assessment of suitability for shunt carried out before randomisation: yes, with angiography
Method of Child's grading: modified Child's with 4 parameters (serum albumin level, total bilirubin lev-
el, encephalopathy, ascites)
Method of encephalopathy testing: clinical, EEG, psychometric (number connection test)
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding episode clinically significant: not specified
Participants Inclusion criteria: portal hypertension secondary to cirrhosis, endoscopic documentation of acute or
recent oesophageal variceal haemorrhage requiring a minimum transfusion of 3 U of blood, residence
within 500 miles of Salt Lake City or Omaha, non-operative control of acute variceal haemorrhage, pa-
tency of splenic and portal veins documented by selective angiography
Exclusion criteria: not specified
Child-Pugh score (mean ± SEM): 6.6 ± 0.4 in each group. Child's class C (%): 33% in each group
Aetiology (%): alcohol 83 in shunt group and 90 in sclerotherapy group. No mention of HBV and HCV ae-
tiology
Patients in the 2 groups were comparable at randomisation
Interventions Shunt surgery: DSRS without splenopancreatic disconnection (n = 26), side-to-side portacaval shunt or
Dacron graN interposition shunt (n = 3), end-to-side portacaval (n = 1)
Endoscopic therapy: sclerotherapy, with intravariceal injections of 0.75% sodium tetradecyl sulphate
and 50% dextrose or 5% sodium morrhuate, every 4 to 6 days until most varices were eradicated, then




• Quantitative liver function and haemodynamics
• Encephalopathy
• Cost
Notes Portacaval shunts were performed on 3 patients with medically intractable ascites and on 1 with mas-
sive rebleeding; SPD was not used in any patients
Rikkers 1987 reported early results of the same study
Funding: supported by Public Health Service Grant #5 ROI DK35168 and General Clinical Research Cen-
ter Public Health Service Grant #5MOIRR0004
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Rikkers 1993  (Continued)
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Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Adequate follow-up: survival status of all patients was known; late postopera-





High risk No pre-published protocol available. Study authors did not report all key out-
comes: surgical complications were not reported
Other bias High risk Large number of cross-over treatments. In shunt group, 2 participants (6.7%)
underwent shunt reoperation for rebleeding (1 end-to-side portacaval shunt,
1 interposition meso-renal shunt). In endoscopic group, 5 participants (16.6%)
underwent emergency salvage operations (4 end-to-side portacaval shunts, 1





Methods Randomised controlled trial comparing transjugular intrahepatic portosystemic shunt with sclerother-
apy + propranolol for prevention of variceal rebleeding in patients with Child's C cirrhosis
Randomised to TIPS: 32; endoscopic therapy + propranolol: 33
Time from bleeding episode to randomisation: not specified
Time from randomisation to treatment: TIPS performed within 4 days after bleeding; time to treatment
not specified for sclerotherapy In 2 patients; TIPS could not be performed (1 technical failure, 1 portal
vein thrombosis). These 2 patients were treated with sclerotherapy + propranolol
Adequate reasons provided for those not randomised: no information
Follow-up: 1 year or until death or liver transplantation
53 patients completed the study. All patients were included in analysis
Mean follow-up period in months (SE): not specified
Assessment of suitability for shunt carried out before randomisation: unclear
Method of Child's grading: unclear
Method of encephalopathy testing: not applicable
Rebleeding episodes endoscopically verified: not specified. Rebleeding defined as any digestive haem-
orrhage
Specified whether rebleeding episode clinically significant: yes – necessitating transfusion of 2 or more
units of blood
Participants Inclusion criteria: Child's C cirrhotic patients presenting with oesophageal variceal bleeding
Exclusion criteria: not specified
Aetiology (%): alcohol 94
Patients were treated with emergency sclerotherapy before randomisation
Patients were treated with sclerotherapy before randomisation
Interventions TIPS: type not specified
GDEAIH 1995 
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Endoscopic therapy: sclerotherapy + propranolol





Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information
Allocation concealment
(selection bias)





Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Only preliminary results reported. All randomised patients were included in
the analysis; however study authors stated that "so far 53 patients have com-
pleted the study". No information on remaining participants
Selective reporting (re-
porting bias)
High risk No pre-published protocol available
Study authors reported on not all of the key outcomes of interest in the review
Other bias Unclear risk Abstract only






Methods Randomised controlled trial comparing transjugular intrahepatic portosystemic shunt vs endoscopic
sclerotherapy for prevention of variceal rebleeding after recent variceal haemorrhage
Time from bleeding episode to randomisation: after a period of 24 hours of stability
Time from randomisation to assigned therapy: 3 days; in case of rebleeding after randomisation, as-
signed therapy was applied immediately
Time from variceal bleeding to therapy in days, mean (SD): TIPS 5.4 (2.1), sclerotherapy 5.6 (2.2)
22 patients randomised in TIPS group, 24 patients in endoscopic therapy group
Results presented according to intention-to-treat
Follow-up period in days (mean, SD): TIPS 760, 390; endoscopic therapy 503, 463
García-Villarreal 1999 
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
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Assessment of suitability for shunt carried out before randomisation: not specified
One participant in endoscopic group crossed to TIPS after 2 rebleeding episodes
1 patient lost to follow-up, and 1 patient in each group leN the study
Shunt patency assessed with portography at 1 month and then every 6 months
Method of Child's grading: Child-Pugh
Method of encephalopathy testing: Parson-Smith criteria
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding episode clinically significant: not specified
Participants Inclusion criteria: endoscopically proven oesophageal variceal bleeding; diagnosis of cirrhosis based on
clinical history and laboratory, ultrasonography, and/or liver biopsy findings; age between 18 and 75
years; informed consent from patient or next of kin when encephalopathy was present
Exclusion criteria: history of chronic encephalopathy, portal vein thrombosis, hepatocellular carcino-
ma, end-stage liver disease defined by the presence of more than 1 of the following parameters: pro-
thrombin index < 35%, bilirubin > 5 mg/dL, plasma creatinine > 3 mg/dL, and follow-up not possible
Child-Pugh score (mean ± SD): TIPS group 8.6 ± 2.2, sclerotherapy group 8.8 ± 2.2. Child-Pugh class A/B/
C (%): TIPS group 23/45/32, sclerotherapy group 12/58/30
Aetiology (%): alcohol 68 in TIPS group, 75 in sclerotherapy group. No mention of HBV and HCV aetiolo-
gy
Both groups were comparable with respect to age, gender, aetiology. Endoscopic group had a signifi-
cantly greater proportion of patients with pre-existing encephalopathy who were comparable in terms
of Child-Pugh class and score
All patients presenting with variceal haemorrhage were treated with endoscopic sclerotherapy (within
4 hours of admission) and vasoactive drugs and balloon tamponade when necessary
Interventions TIPS: wall stent endoprosthesis
Sclerotherapy: intravariceal injections of 0.5 to 1 mL of 5% ethanolamine oleate (for a total of 12 to 20






• Days spent as an in-patient
• Causes of death
Notes Funding: no information
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random numbers
Allocation concealment
(selection bias)
Unclear risk No information
García-Villarreal 1999  (Continued)
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Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treat-
ments.and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk One patient lost to follow-up, 1 patient in each group decided to leave the
study
Small number of dropouts (5%)
Selective reporting (re-
porting bias)
High risk No pre-published protocol available
Planned outcomes: "primary endpoint was variceal rebleeding. Secondary
outcomes were survival and hepatic encephalopathy. Other parameters that
reflect the benefit of therapy such as rebleeding index, days spent in hospital
and cause of death were studied". No report of complications for shunt group






Methods Randomised controlled trial comparing transjugular intrahepatic portosystemic shunt vs sclerotherapy
for elective treatment of oesophageal variceal haemorrhage
Time from bleeding episode to randomisation: 3 days after bleeding was controlled
Time from randomisation to treatment in days (mean, SD): TIPS 8.4, 3.6; endoscopic therapy 2.7, 3.2
Total number of patients evaluated and found eligible: 63 (90 evaluated)
Randomised to TIPS: 31 participants; randomised to endoscopic therapy: 32 participants
1 participant from each group died before treatment
Adequate reasons provided for those not randomised: yes
Nine patients in the endoscopic therapy group were crossed over to TIPS during follow-up
There were no losses to follow-up
Intention-to-treat analysis
Follow-up period, days (mean, SD): TIPS 452, 298 (range 30 to 1020); endoscopic therapy 455, 298
(range 70 to 951)
Assessment of suitability for shunt carried out before randomisation: no
Shunt patency assessed with angiography at 6 months or at the time of rebleeding
Method of Child's grading: Child-Pugh
Method of encephalopathy testing: clinical
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding episode clinically significant: yes
Participants Inclusion criteria: all cirrhotic patients admitted with an episode of acute oesophageal variceal bleed-
ing
Exclusion criteria: presence of gastric varices with active bleeding or with stigmata of recent haemor-
rhage at first emergency endoscopy, episodes of chronic hepatic encephalopathy, severe acute alco-
holic hepatitis (prothrombin time < 30%), hepatic encephalopathy and/or functional renal failure in
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an alcoholic cirrhotic patient, end-stage cirrhosis (≥ 2 of the following parameters: prothrombin time <
35%, plasma creatinine > 2 mg/dL, bilirubin > 5 mg/dL, age > 75 years), neoplastic disease, septicaemia,
portal vein thrombosis
Active bleeding episode was treated with intravenous somatostatin infusion (250 microg/h after ini-
tial bolus of 1 microg/kg body weight) for 48 hours. If bleeding was not controlled, a Sengstaken-Blake-
more tube was placed
Child-Pugh score (mean ± SD): TIPS group 7.1 ± 1.59, sclerotherapy group 7.22 ± 1.75. Child-Pugh Class
A/B/C (%): TIPS group 45/42/13, sclerotherapy group 44/50/6
Aetiology (%): alcohol 64.4 in TIPS group and 72 in sclerotherapy group. No mention of HBV and HCV
aetiology
The 2 groups were comparable in terms of age, sex, aetiology of cirrhosis, Child-Pugh classification
Interventions TIPS: Wallstent endoprosthesis (Schneider Europe, Bulach, Switzerland) or Strecker stent (Meditech,
Watertown, MA, USA)
Sclerotherapy: intravariceal and paravariceal injections of 1% polidocanol (2 to 4 mL/injection, with to-
tal injection of sclerosant between 10 and 30 mL) with the use of videoendoscopy, weekly for the first





Notes Long-term follow-up; published as abstract in Hepato-Gastroenterology 1998, Third International Con-
gress of Hepato-Pancreato-Biliary Association
Funding: supported in part by a grant from Fundacíon Universitaria de Las Palmas
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random numbers
Allocation concealment
(selection bias)





Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk No dropouts are reported
Selective reporting (re-
porting bias)
Low risk No pre-published protocol
Study authors report all key outcomes of interest in the review
Cabrera 1996  (Continued)
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Other bias High risk Large number of cross-overs. Nine participants randomised to endoscopic in-





Methods Randomised controlled trial comparing mesocaval shunt with endoscopic sclerotherapy for prevention
of oesophageal variceal rebleeding
Time from bleeding episode to randomisation and treatment: not specified (interval between index
sclerotherapy and subsequent elective therapy was 78 days, not different from interval from index scle-
rotherapy to shunt surgery)
Total number of patients evaluated: 228
Randomised to shunt surgery: 24; randomised to endoscopic sclerotherapy: 21
Adequate reasons provided for those not randomised: yes
No patient was crossed over
No losses to follow-up
Intention-to-treat analysis
Follow-up period in months (mean): shunt group 69.5, endoscopic therapy group 60.2
Assessment of suitability for shunt carried out before randomisation: not specified
Method of Child's grading: Child's (version not specified)
Method of encephalopathy testing: clinical and psychometric testing
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding episode clinically significant: yes
Isaksson and colleagues were unable to assess encephalopathy in 7/24 patients in the shunt group and
in 5/21 patients in the endoscopic therapy group
Participants Inclusion criteria: age between 20 and 75 years, endoscopically verified oesophageal varices as the
source of bleeding, portal hypertension, biopsy-confirmed cirrhosis
Exclusion criteria: not specified
All patients underwent emergency endoscopy to verify bleeding oesophageal varices. Thereafter, pa-
tients were stabilised by vasopressin treatment and usually initial sclerotherapy; In some cases, bal-
loon tamponade was applied
Child-Pugh class A/B/C (%): 15/56/29
Aetiology (%): alcohol 81 in shunt group, 67 in sclerotherapy group
Participants in the two arms were comparable in terms of age and Child's status, but slightly more par-
ticipants with alcohol abuse were included in the endoscopic sclerotherapy group.
Interventions Shunt surgery: interposition polytetrafluoroethylene (Gore-Tex, W.L. Gore & Associates Inc., Medical
Products, Falgstaff, AZ, USA) 14-mm mesocaval shunt
Sclerotherapy: submucosal and paravariceal injections of 1% ethoxy-sclerol (hydroxy-poly-etoxi-dode-





• Cost and hospital stay
Notes Funding: supported by grant number 4X-9489 from the Swedish Medical Research Council
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information
Allocation concealment
(selection bias)





Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





High risk No dropouts, but not all patients were fully assessed for hepatic encephalopa-
thy (no information on 27% of participants)
Selective reporting (re-
porting bias)
Low risk No pre-published protocol. All key outcomes are reported





Methods Randomised controlled trial comparing transjugular intrahepatic portosystemic shunt with endoscopy
+ propranolol for prevention of variceal rebleeding
Time from bleeding episode to randomisation in hours (SD): TIPS group 6.3 (5.5), endoscopic therapy +
propranolol group 4.4 (5.0)
Time from randomisation to treatment: 48 hours
Total number of patients evaluated and found eligible: 126 (assessed patients: 190)
Randomised to TIPS: 61; randomised to endoscopic therapy + propranolol: 65
Adequate reasons provided for those not randomised: not individually specified
One patient in TIPS group and 3 in endoscopic therapy group were lost to follow-up. Nine patients were
crossed over from endoscopic therapy to TIPS during follow-up
Intention-to-treat analysis
Follow-up period in months (median, interquartile range): TIPS group 14, 8 to 23; endoscopic therapy +
propranolol group 13, 8 to 25
Assessment of suitability for shunt carried out before randomisation: not mentioned
Shunt patency assessed with Duplex ultrasound at 1, 3, 6, 9, and 12 months, then every 6 months
Method of Child's grading: Child-Pugh
Method of encephalopathy testing: clinical testing, trail-making test, mental state examination
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding episode clinically significant: yes
Participants Inclusion criteria: liver cirrhosis, variceal bleeding (confirmed endoscopically) within 2 weeks before
randomisation, age over 18 years
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Exclusion criteria: hepatic encephalopathy grades 3 and 4, liver insufficiency (bilirubin > 5 mg/dL - ex-
cept patients with primary biliary cirrhosis), cavernomatous portal vein thrombosis, advanced malig-
nancy, contraindications to propranolol (severe heart insufficiency, obstructive lung disease, severe
hypotension), bleeding emergency
Patients with acute bleeding at admission were treated by injection of polidocanol (59 patients), a mix-
ture of n-butyl-2-cyanoacrilate and lipiodol (5 patients) or fibrin glue (4 patients), or polidocanol + bu-
crylate (8 patients) to stop the bleeding. In 6 patients in whom endoscopic treatment failed, a Sengk-
staken tube was put in place
Treatment was assigned to patients within 24 hours; treatment was started within 28 hours after ad-
mission
Child-Pugh class A/B/C (%): TIPS group 28/54/18, endoscopic group 34/48/18
Aetiology (%): alcohol 69 in TIPS group and 65 in endoscopic group; viral 18 in TIPS group and 15 in
endoscopic group; alcohol + viral 5 in TIPS group and 6 in endoscopic group; miscellaneous 8 in TIPS
group and 15 in endoscopic group
Patients in the 2 groups were comparable
Interventions TIPS: Palmaz stent (n = 39), Memotherm stent (n = 16), Wallstent (n = 6). In patients with huge varices or
in whom variceal perfusion persisted after creation of the shunt, embolisation was done
Endoscopic therapy: sclerotherapy with injections of polidocanol (16 mL per session) or banding lig-
ation (3.2 rubber bands) at intervals of 2 to 5 days until eradication of the varices was achieved or at
least 6 treatment sessions were applied. Gastric varices were treated by intravariceal injection of bucry-
late/lipiodol
Thirty-three patients were treated with sclerotherapy only, 31 had a combination of sclerotherapy and
banding ligation, and 1 patient had banding ligation only. Propranolol was given at a dose of 63 (SD 33)
mg/d to decrease heart rate by 25%; propanolol was taken by 44 of the 65 patients who had endoscop-
ic treatment (17 patients were not compliant, and in 4 patients, medication was withdrawn because of
severe side effects)
Outcomes Planned primary outcome was rebleeding from varices
Secondary endpoints were death, bleeding from non-variceal sources, procedure-related complica-
tions, and hepatic encephalopathy. Hospital stay was reported
Notes Funding: no information
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random numbers
Allocation concealment
(selection bias)
Low risk Study authors stated that "study groups read by person not involved in the





Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Blinding not mentioned. Judgement on all outcomes except mortality could
be biased
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Low risk 1/65 patients in the shunt group and 3/62 in the endoscopic group were lost to




Low risk No pre-published protocol available
All key outcomes are reported as defined in the methods
Other bias High risk Large number of cross-over treatments: 9 out of 61 participants (14.7%) in the





Methods Randomised controlled trial comparing transjugular intrahepatic portosystemic shunt vs sclerotherapy
+ propranolol for variceal rebleeding
Time from bleeding episode to randomisation in days (mean, SD): TIPS group 1.1, 1.1; endoscopic ther-
apy + propranolol group 1.2, 0.9
Time from randomisation to treatment in days (mean, SD): TIPS group 3.4, 2.8; endoscopic therapy +
propranolol group 2.9, 3.8
Total number of patients evaluated and found eligible: 83 (98 assessed for eligibility). Randomised to
TIPS: 42; randomised to endoscopic therapy + propranolol: 41
Adequate reasons provided for those not randomised: yes
No losses to follow-up
Five patients in endoscopic therapy + propranolol group were crossed over to TIPS during follow-up
Intention-to-treat analysis
Method of Child's grading: Child-Pugh
Method of encephalopathy testing: clinical and trail-marking tests
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding episode was clinically significant: no
Median observation time in years: TIPS group 1.6, endoscopic therapy + propranolol group 1.45
Assessment of suitability for shunt carried out before randomisation: not mentioned
Shunt patency assessed with duplex ultrasound and angiography at 3-monthly intervals
Participants Inclusion criteria: cirrhosis and acute oesophageal haemorrhage
Exclusion criteria (≥ 1 of the following): gastric varices, prior endoscopic or surgical treatment of
varices, portal venous thrombosis, neoplastic disease and/or severe comorbid conditions that would
limit patient life span to < 6 months, septicaemia, uncontrolled bleeding requiring emergency TIPS pro-
cedure, contraindications for beta blockers (cardiovascular failure, respiratory failure, insulin-depen-
dent diabetes mellitus)
Active bleeding was primarily treated by injection sclerotherapy. Initial success was defined as cessa-
tion of bleeding longer than 24 hours together with stable vital signs. Patients received a Sengstak-
en-Blakemore tube if active bleeding persisted despite endoscopic treatment, or if there was evidence
of bleeding within 24 hours after a bleeding-free interval. When balloon tamponade failed to control
bleeding, patients additionally received intravenous octreotide
Randomisation was performed within 1 to 3 days after variceal bleeding which was controlled within 24
hours after admission
Child-Pugh score (mean ± SD): TIPS group 7.76 ± 2.29, sclerotherapy group 8.26 ± 2.46. Child-Pugh class
A/B/C (%): TIPS group 36/43/21, sclerotherapy group 29/44/27
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Aetiology (%): alcohol 60 in TIPS group and 63 in sclerotherapy group; viral 31 in TIPS group and 24 in
sclerotherapy group; others 9 in TIPS group and 12 in sclerotherapy group
Both groups were comparable regarding patient data at entry (slightly younger patients in the TIPS
group)
Interventions TIPS: Palmaz stents
Sclerotherapy + beta blocker: intravariceal and paravariceal injections of 5% ethanolamine oleate (2 to
3 mL/injection, with a total injection of sclerosant between 10 and 30 mL), at weekly intervals for the
first month and between 1 and 3 months thereafter until obliteration. Propranolol was given twice dai-





Notes Funding: no information
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random numbers
Allocation concealment
(selection bias)





Unclear risk Not feasibIle. It is unclear if lack of blinding influenced the choice of treat-
ments and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk No loss to follow-up
Selective reporting (re-
porting bias)
Low risk All outcomes reported as defined in methods
Other bias High risk Large number of cross-over treatments: 5 out of 41 participants were crossed





Methods Randomised controlled trial comparing transjugular intrahepatic portosystemic shunt with endoscopic
sclerotherapy for prevention of variceal rebleeding
Sanyal 1997 
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
cirrhosis (Review)









Cochrane Database of Systematic Reviews
Time from bleeding episode to randomisation: clinical stability for at least 72 hours following a variceal
bleed
Time from randomisation to treatment: within 72 hours
Total number of patients evaluated and found eligible: 80 (132 patients evaluated)
Randomised to TIPS: 41, randomised to endoscopic therapy: 39
Adequate reasons provided for those not randomised: yes
Two patients in TIPS group and 1 in endoscopic therapy group lost to follow-up
Six patients in endoscopic therapy group were crossed over to TIPS during follow-up
Five patients in the TIPS group and 3 in the endoscopic therapy group underwent liver transplantation,
censored at the time of transplantation
Intention to treat analysis
Follow-up period in days (median): TIPS 956, endoscopic therapy 990
Assessment of suitability for shunt carried out before randomisation: yes
Shunt patency assessed with duplex ultrasound at 1 week, at 1 and 3 months, then every 3 months; an-
giography carried out at 6-monthly intervals
Method of Child's grading: Child-Pugh
Method of encephalopathy testing: not mentioned
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding episode clinically significant: yes
Participants Inclusion criteria: clinical stability in the absence of rebleeding 72 hours following an oesophageal
variceal bleed
Exclusion criteria: portal venous thrombosis, hepatoma, end-stage cancer or systemic disease that
would limit the patient life span to less than 1 year, failure to obtain informed consent, pregnancy, his-
tory of non-compliance with treatment
Child-Pugh class A/B/C (%): TIPS group 17/32/51, sclerotherapy group 15/38/47
Aetiology (%): alcohol 39 in TIPS group and 44 in sclerotherapy group; HCV 37 in TIPS group and 41 in
sclerotherapy group; HBV 7 in TIPS group and 5 in sclerotherapy group; other 17 in TIPS group and 10 in
sclerotherapy group
Groups were similar with respect to patient characteristics at study entry
Interventions TIPS: Wallstents (Schneider, Inc., Plymouth, MN, USA)
Sclerotherapy: intravariceal injections of 5% sodium morrhuate, 12 to 20 mL per session, then every 2
to 3 weeks until varices obliteration
Patients on beta blocker before randomisation were asked to stop taking it before study entry
Outcomes Planned outcomes
Primary outcomes: rebleeding and survival.
Secondary outcomes: complications (including encephalopathy) and rate of re-hospitalisation
Notes Funding: grant support in part by an award from the National Institutes of Health to the Clinical Re-
search Centre at the Medical College of Virginia (RR-00065) and by an award from the American College
of Gastroenterology
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation code
Sanyal 1997  (Continued)
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Allocation concealment
(selection bias)





Unclear risk Not feasible
It is unclear if lack of blinding influenced the choice of treatments and the
management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk Two patients in TIPS group and 1 in endoscopic therapy group lost to fol-
low-up. Dropout < 5%
Selective reporting (re-
porting bias)
Low risk No pre-published protocol available
All outcomes reported as defined in methods
Other bias High risk Large number of cross-over treatments: 6 out of 30 (15%) participants in endo-





Methods Randomised controlled trial comparing transjugular intrahepatic portosystemic shunt with variceal
band ligation for prevention of rebleeding from oesophageal varices
Time from bleeding episode to randomisation (mean, SD): TIPS group 1.2, 0.3 days; endoscopic group
1.5, 0.5 days
Time from randomisation to treatment in days (mean, SD): TIPS 2.2, 0.2; variceal banding 2.4, 0.2
Total number of patients evaluated and found eligible: 61 (105 evaluated)
Randomised to TIPS: 31, randomised to endoscopic therapy: 27
Adequate reasons provided for those not randomised: yes
Three patients in the TIPS group did not receive the allocated treatment; 6 patients in the endoscopic
therapy group were crossed over to TIPS during follow-up
No losses to follow-up
Intention-to-treat analysis
Follow-up period months (mean, SD): TIPS 15.7, 10.2; endoscopic therapy 16.8, 10.9
Assessment of suitability for shunt carried out before randomisation: yes
Shunt patency assessed with duplex ultrasonography and portography at 1 week and at 1 month, then
every 6 months
Method of Child's grading: Child-Pugh
Method of encephalopathy testing: Parson-Smith criteria
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding episode clinically significant: yes
Participants Inclusion criteria: all cirrhotic patients between 18 and 75 years of age who presented with a first (in-
dex) episode of oesophageal variceal bleeding
Exclusion criteria: age < 18 years, rebleeding from varices within 24 hours of initial endoscopy, bleeding
from ectopic varices, previous endoscopic treatment for variceal bleeding, hepatorenal failure, hepatic
or extrahepatic malignancy, portal vein thrombosis, failure to give informed consent
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Patients with active bleeding underwent an upper gastrointestinal endoscopy within 6 hours of admis-
sion. If patients were bleeding actively from varices, endoscopic variceal sclerotherapy was performed;
otherwise, they underwent variceal band ligation
Patients were randomised 24 hours after their first endoscopic treatment if no further haemorrhage oc-
curred
Aetiology (%): alcohol 84 in TIPS group and 78 in endoscopic group; HCV/HBV 6 in TIPS group and 4 in
endoscopic group; PBC 6 in TIPS group and 11 in endoscopic group; cryptogenetic 3 in TIPS group and
4 in endoscopic group
Child-Pugh class A/B/C (%): TIPS group 6/45/49, endoscopic group 18/33/49
Patient characteristics similar in the 2 groups
Interventions TIPS: Wallstent
Endoscopic therapy: variceal banding ligation, single application, every week until variceal eradication,
then at 3 and 6 months, and at 6-monthly intervals thereafter




• Cost analysis and amount of time spent as in-patient
Notes Funding: no information
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information
Allocation concealment
(selection bias)






Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk No dropouts. Similar length of follow-up in both groups
Selective reporting (re-
porting bias)
Low risk No pre-published protocol available. All key outcomes of interest in the review
are reported as planned in the methods section
Other bias High risk Large number of cross-over treatments: 8 out of 27 participants (30%) in endo-
scopic group were crossed over to TIPS group for failure of treatment during
follow-up (7 participants) or 8 days after randomisation (1 participant)
Jalan 1997  (Continued)
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Study characteristics
Methods Randomised controlled trial comparing transjugular intrahepatic portosystemic shunt with endoscopic
sclerotherapy after initial sclerotherapy in patients with acute large oesophageal variceal haemorrhage
Time from admission to randomisation (mean, SE): TIPS 37.4, 4.7 hours, endoscopic therapy 35.4, 5.6
hours
Time from randomisation to treatment (mean, SE): TIPS 59.5, 6.7 hours
Total number of patients evaluated: 299. Randomised to TIPS 24; randomised to endoscopic therapy 25
Adequate reasons provided for those not randomised. Reasons mentioned but numbers not provided
One patient assigned to TIPS received sclerotherapy because stent placement was technically impossi-
ble
Six patients treated by sclerotherapy were crossed over to TIPS because of recurrent variceal haemor-
rhage that did not respond to sclerotherapy (failure of treatment) during follow-up
Follow-up period in days (mean, SE): TIPS 575, 109; endoscopic therapy 567, 104
Assessment of suitability for shunt carried out before randomisation: yes
Shunt patency assessed with duplex ultrasound
Method of Child's grading: Child-Pugh; however, patients were not stratified according to the Child-
Pugh system
Method of encephalopathy testing: clinical
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding episode clinically significant: yes
Participants Inclusion criteria: all patients with massive or submassive acute gastrointestinal tract haemorrhage
from large oesophageal varices were admitted
Exclusion criteria (≥ 1 of the following): prisoners, < 18 or > 75 years of age, cerebrovascular accident 3
months before the onset of bleeding, refusal to accept blood products, gastric variceal haemorrhage,
ECG changes compatible with myocardial infarction, PO2 < 70 mmHg or arterial pH ≤ 7.20 on room air
at the time of evaluation for eligibility, serum creatinine ≥ micromol/L, serum bilirubin ≥ 7 mg/dL, pro-
thrombin time at least 5 seconds longer than control, platelet count < 50 × 109/L, grade IV encephalopa-
thy, cancer other than skin cancer, AIDS or advanced AIDS complex, sepsis, pneumonia, peritonitis, al-
coholic hepatitis (clinical evidence only), thrombosis of portal, hepatic, or inferior vena caval veins
All patients received endoscopic sclerotherapy at the time of the initial endoscopic procedure that es-
tablished the source of haemorrhage as oesophageal varices
Active haemorrhage at randomisation (%): TIPS group 21, sclerotherapy group 28. Shock (systolic
blood pressure ≤ 80 mmHg) (%): TIPS group 4, sclerotherapy group 20
Child-Pugh score (mean ± SE): TIPS group 9.0 ± 0.4, sclerotherapy group 7.8 ± 0.5
Aetiology (%): alcoholism 67 in TIPS group and 68 in sclerotherapy group
Patients across the 2 strata were comparable in terms of clinical and laboratory variables, except for
Child-Pugh score and blood transfusion requirements, which were higher in the TIPS group than in the
sclerotherapy group
Interventions TIPS: Wall stent (Schneider, Inc., Minneapolis, MN, USA) within 48 hours of randomisation
Sclerotherapy: injection of 0.5 to 2.0 mL ethanolamine oleate solution per varix. Sclerotherapy was re-
peated every 2 to 7 days during initial hospitalisation and weekly after discharge




• Total transfusion requirements
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• Encephalopathy
• Complications of therapy
• Cost analysis
Notes Grant support: in part by National Institutes of Health, National Institute of Diabetes and Digestive and
Kidney Diseases Liver Core Center grant P30 DK26743
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information
Allocation concealment
(selection bias)





Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





Unclear risk Intention-to-treat. Similar length of follow-up in both groups
No information on dropouts
Selective reporting (re-
porting bias)
High risk Not all key outcomes are reported (no chronic hepatic encephalopathy)
Other bias High risk Large number of cross-over treatments: 6 out of 25 (24%) participants treat-
ed by sclerotherapy were crossed over to TIPS because of recurrent variceal





Methods Randomised controlled trial comparing transjugular portosystemic shunt vs endoscopic sclerotherapy
for prevention of recurrent variceal bleeding in cirrhotic patients
Time from bleeding episode to randomisation: patients were randomised to 3 separate strata accord-
ing to the interval between bleeding and the time of randomisation: (I) 1 to 7 days, (II)1 to 6 weeks, (III)
7 weeks to 6 months
Time from randomisation to treatment: active bleeding had to have been controlled for a minimum of
24 hours
Time between index bleeding and randomisation in days (mean, SE): stratum I: TIPS group 3.5, 0.5 vs
sclerotherapy group 3.1, 0.5; stratum II: TIPS group 21, 3.4 vs sclerotherapy group 19, 2.8; stratum III:
TIPS group 63, 16 vs sclerotherapy group 65, 8
Total number of patients evaluated and found eligible: 82 (120 evaluated)
Randomised to TIPS: 39 patients; randomised to endoscopic therapy: 43 patients. One patient in the
TIPS group was erroneously randomised (bleeding had not stopped before randomisation)
Adequate reasons provided for those not randomised: yes
Merli 1998 
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Five patients in TIPS group and 4 patients in endoscopic therapy group did not receive allocated treat-
ment: 1 participant in each group refused treatment, 1 in TIPS group and 2 in endoscopic group died
before treatment was provided after randomisation; 3 in TIPS group and 1 in sclerotherapy group could
not be treated for technical reasons
One patient in each group lost to follow-up
In the TIPS group, 2 participants were crossed over to endoscopic therapy and 1 to portacaval shunt.
During follow-up for treatment failure In the endoscopic group, 6 participants were crossed over to
TIPS and 1 to portacaval shunt during follow-up for treatment failure
Intention-to-treat analysis but 1 patient erroneously assigned to TIPS and excluded from analysis
Follow-up period in weeks (mean, SE): TIPS 73.9, 7.3; endoscopic therapy 77.7, 7.12
Assessment of suitability for shunt carried out before randomisation: yes
Shunt patency assessed with duplex ultrasound at 6 months, or when shunt malfunction was suspect-
ed
Method of Child's grading: Child-Pugh
Method of encephalopathy testing: Parsons-Smith criteria
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding episode clinically significant: yes
Participants Inclusion criteria: cirrhotic patients with active or recent (< 24 weeks) oesophageal variceal bleeding
(proven or presumed)
Exclusion criteria: complete portal vein thrombosis, previous episode(s) of chronic recurrent hepatic
encephalopathy, advanced hepatocellular carcinoma, previous multiple sessions of sclerotherapy, on-
going pharmacological prophylaxis of rebleeding (1 emergency session during acute bleeding phase
was permissible), severe cardiovascular contraindications, concomitant morbid condition(s) with life
expectancy < 1 year
Patients admitted for active bleeding were included only after bleeding had stopped for at least 24
hours, and when they were haemodynamically stable
Aetiology (%): alcohol 16 in TIPS group and 35 in sclerotherapy group; alcohol + HCV 5 in TIPS group
and 5 in sclerotherapy group; alcohol + HBV 3 in TIPS group and 0 in sclerotherapy group; viral (HBV or
HCV or HBV + HCV) 71 in TIPS group and 44 in sclerotherapy group
Child-Pugh class A/B/C (%): TIPS group 34/53/13, sclerotherapy group 30/58/12
Patient characteristics comparable other than for alcoholics, which were more numerous in the endo-
scopic group
Interventions TIPS: Wallstent (Schneider Europe AG, Zurich, Switzerland) or Nitinol Strecker stent (Ultraflex Biliry
Stent System, Meditech, Boston Scientific Co., Natick, MA, USA)





Notes Funding: no information
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information
Merli 1998  (Continued)
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Allocation concealment
(selection bias)






Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk Small number of dropouts: 1 patient lost to follow-up in each group
Selective reporting (re-
porting bias)
Low risk No published protocol available
All key outcomes of interest in the review were planned and reported
Other bias High risk Large number of cross-over treatments during follow-up for treatment failure.
In the TIPS group, 3 out of 31 (9.6%) participants were crossed over to alter-
native treatment (2 to endoscopic therapy and 1 to portacaval shunt). In the
endoscopic group, 7 out of 43 (16%) participants were crossed over (6 to TIPS





Methods Randomised controlled trial comparing transjugular intrahepatic portosystemic shunt with endoscopic
sclerotherapy for long-term management of patients with cirrhosis after recent variceal haemorrhage
Time from bleeding episode to randomisation in days (mean, SEM): TIPS 19.1, 2; endoscopic therapy
17.9, 1.9
Time from randomisation to treatment (mean, SD): not clear
Total number of patients evaluated: 101
Randomised to TIPS 38; randomised to endoscopic therapy 40
Adequate reasons provided for those not randomised: yes
One patient in the TIPS group had to be treated by endoscopic sclerotherapy during follow-up. Two pa-
tients in endoscopic therapy group were crossed over to TIPS during follow-up
Follow-up period in days (mean, SEM): TIPS 1116, 92; endoscopic therapy 1047, 102
Assessment of suitability for shunt carried out before randomisation: no
Shunt patency assessed with duplex ultrasonography every 3 months
Method of Child's grading: Child-Pugh; however, patients were not stratified according to the Child-
Pugh system
Method of encephalopathy testing: Parson-Smith criteria
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding episode clinically significant: not stated
Participants Inclusion criteria: cirrhosis with recent variceal haemorrhage, clinical stability at randomisation (no he-
matemesis and melena, stable haemoglobin concentration, and no need for transfusion for at least 5
days), age between 20 and 69 years
Exclusion criteria: hepatocellular carcinoma, episodes of chronic encephalopathy, complete portal
vein thrombosis with cavernomatous transformation, Child-Pugh ≥ 13, serum creatinine ≥ 2.5 mg/dL,
serum bilirubin ≥ 5 mg/dL, active infection, severe cardiopulmonary disease
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Active bleeding was treated with intravenous vasopressin + nitroglycerin infusion and/or a single ses-
sion of endoscopic sclerotherapy or endoscopic variceal ligation. Balloon tamponade with a Sengstak-
en-Blackemore tube was used when necessary
Aetiology (%): alcohol 24 in TIPS group and 42 in sclerotherapy group; HCV 53 in TIPS group and 40 in
sclerotherapy group; HBV 10 in TIPS group and 10 in sclerotherapy group
Child-Pugh score (mean ± SEM): TIPS group 6.8 ± 0.3, sclerotherapy group 7.4 ± 0.3
Interventions TIPS: Gianturco-Rösch biliary expandable Z-stents (Cook) in 21 patients, Spiral-Z stents (Cook) in 4 pa-
tients, Wallstents (Schneider, Inc., Plymouth, MN, USA) in 13 patients with final stent diameters of 8 and
10 mm







• Causes of hospitalisation
Notes Funding: no information
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random number table
Allocation concealment
(selection bias)





Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk No patients were lost to follow-up
Selective reporting (re-
porting bias)
Low risk No published protocol was available. Study authors reported all planned key
outcomes of interest for this review
Other bias Low risk Small number of participants (< 5%) were crossed over during follow-up for
treatment failure: 1 out of 38 participants in the TIPS group was treated by en-
doscopic sclerotherapy during follow-up, 2 out of 40 participants in the endo-
scopic therapy group were crossed over to TIPS
Narahara 2001  (Continued)
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Study characteristics
Methods Randomised controlled trial comparing transjugular intrahepatic portosystemic shunt with endoscopic
variceal ligation for prevention of variceal rebleeding in patients with cirrhosis
Time from bleeding to randomisation (hours): TIPS: 44, endoscopic therapy: 42
Time from randomisation to TIPS procedure (mean, SD): 13, 11 hours
158 patients evaluated, reasons provided for those excluded: yes
Patients randomised to TIPS 41; patients randomised to endoscopic therapy 39
Follow-up period in days (mean): TIPS 678, endoscopic therapy 581
Assessment of suitability for shunt carried out before randomisation: yes
Shunt patency assessed with duplex doppler ultrasonography at 24 hours, then 3-monthly
Two patients in the TIPS group and 4 in the endoscopic therapy group underwent liver transplantation.
Eight patients were crossed over from endoscopic therapy to TIPS for uncontrolled rebleeding
Intention-to-treat analysis
Method of Child's grading: Child-Pugh
Method of encephalopathy testing: clinical
Rebleeding episodes endoscopically verified: yes
Specified whether clinically significant: yes
Participants Inclusion criteria: cirrhosis (according to clinical findings, laboratory data, ultrasonography, and/or liv-
er biopsy), Child-Pugh score 7 to 12 (TIPS 9.6, endoscopy 9.8), age between 18 and 75 years, episode of
variceal bleeding demonstrated by upper gastrointestinal endoscopy performed within 72 hours of the
bleeding episode
Exclusion criteria: portal vein thrombosis, previous endoscopic therapy within 3 months, previous
shunt surgery, bleeding from large fundal varices, hepatocellular carcinoma, cardiac failure, renal fail-
ure, respiratory failure, non-compliance, sepsis, uncontrolled bleeding, wait list for emergency liver
transplantation, neurologic comorbidities, anticoagulation, extrahepatic biliary obstruction, refusal to
participate
Initial control of bleeding episode was obtained by 1 session of endoscopic ligation or sclerotherapy
and/or balloon tamponade and/or octreotide infusion
Randomisation was carried out only after the initial haemorrhagic episode had been controlled and
haemodynamic status had been stable for at least 24 hours
Severity of index bleed and clinical and biochemical parameters were non-significantly different in the
2 groups with the exception of serum bilirubin level, which was significantly higher in the ligation group
Aetiology (%): alcohol 61 in TIPS group and 61 in endoscopic group; HCV 2 in TIPS group and 8 in endo-
scopic group; HBV 7 in TIPS group and 5 in endoscopic group; PBC 2 in TIPS group and 8 in endoscopic
group; sclerosing cholangitis 7 in TIPS group and 3 in endoscopic group; haemochromatosis 12 in TIPS
group and 3 in endoscopic group; cryptogenetic 7 in TIPS group and 10 in endoscopic group
Interventions TIPS: type not specified





• Duration of hospital stay
Notes (P-Layrargues 1997 represents duplicate publication of P-Layragues 2001)
Funding: supported in part by a grant from the Medical Research Council of Canada (UI 11508)
Pomier-Layrargues 2001 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information
Allocation concealment
(selection bias)






Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





Unclear risk No information on dropouts
Selective reporting (re-
porting bias)
High risk No pre-published protocol. Not all key outcomes of interest for the review are
reported
Other bias High risk Large number of cross-over treatments: 8 out of 39 (20%) participants were





Methods Randomised controlled trial comparing transjugular intrahepatic portosystemic shunt with endoscopic
variceal band ligation for prevention of variceal rebleeding in cirrhotic patients
Time from bleeding episode to randomisation in days (mean, SE): TIPS group 13, 3; endoscopic therapy
group 14, 3
Time from randomisation to treatment: unclear
Total number of patients evaluated: 86
Randomised to TIPS: 28; randomised to endoscopic therapy: 26
Adequate reasons provided for those not randomised: yes
Two patients in TIPS group did not receive the allocated treatment (TIPS not feasible); 1 of them was
treated endoscopically; in the other, band ligation failed to prevent early rebleeding and the patient
underwent shunt surgery. Four patients in endoscopic therapy group were crossed over to TIPS
Follow-up period in years (median): TIPS group 1.8; endoscopic therapy group 2.0
Assessment of suitability for shunt carried out before randomisation: yes
Shunt patency assessed with duplex ultrasound
Method of Child's grading: Child-Pugh (patients were stratified according to the Child-Pugh system)
Method of encephalopathy testing: clinical
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding episode clinically significant: yes
Participants Inclusion criteria: age > 18 years, endoscopic evidence of oesophageal variceal bleeding within 2
months before randomisation, stable haemodynamic condition, no transfusions during the preceding
24 hours
Gülberg 2002 
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
cirrhosis (Review)









Cochrane Database of Systematic Reviews
Exclusion criteria: isolated gastric varices, index bleeding from gastric varices, large or diffuse liver tu-
mours, hepatocellular carcinoma, liver transplantation intended in 6 months, hepatic encephalopa-
thy ≥ grade 2 before the bleeding episode, severely compromised liver function (Child Pugh score ≥
13 or bilirubin > 5 mg/dL with the exception of cholestatic liver disease, where a prothrombin index >
40% and serum albumin > 2.8 mg/dL were required for inclusion in the study), extrahepatic cholestasis,
heart failure NYHA III or IV, sepsis, multi-organ failure, anticipation of technical contraindications to one
of the procedures before randomisation
Child-Pugh class A/B/C (%): TIPS group 39/55/7, endoscopic group 38/46/16
Aetiology (%): alcohol 76 in TIPS group and 89 in endoscopic group; viral 11 in TIPS group and 11 in en-
doscopic group; other 13 in TIPS group and 0 in endoscopic group
Interventions TIPS: expandable 8 to 10 mm stents
Endoscopic therapy: variceal band ligation, every week
The 2 groups were comparable regarding baseline characteristics except for number of previous bleed-







Notes Funding: no information
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information
Allocation concealment
(selection bias)






Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes









Unclear risk No pre-published protocol. All planned primary and secondary outcomes plus
procedure-related complications are reported. Liver-related complications are
not reported
Other bias High risk Large number of cross-over treatments: 4 out of 26 (15.3%) participants in en-
doscopic therapy group were crossed over to TIPS: 1 participant before the
Gülberg 2002  (Continued)
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
cirrhosis (Review)









Cochrane Database of Systematic Reviews
first ligation as an emergency procedure, 2 for recurrent bleeding, the fourth





Methods Randomised controlled trial comparing transjugular intrahepatic portosystemic shunt with endoscopic
variceal ligation + propranolol for prevention of recurrent variceal bleeding
Time from bleeding episode to randomisation in days, mean (SD): TIPS group 1.2 (1.3), endoscopic
group + propranolol 1.3 (0.9)
Time from randomisation to treatment in days, mean (SD): TIPS group 3.1 (2.1), endoscopic group +
propranolol 2.4 (1.8)
Total number of patients evaluated and found eligible: 85 (assessed for eligibility 112)
Randomised to TIPS: 43 patients; randomised to endoscopic therapy + propranolol: 42 patients
Adequate reasons provided for those not randomised: yes
One patient in the shunt group and 2 in the endoscopic group were lost to follow-up. Data were cen-
sored at time of last examination
One patient in the TIPS group was crossed over to endoscopic therapy + propranolol. Three patients in
the endoscopic therapy group were crossed over to TIPS during follow-up
Intention-to-treat analysis
Assessment of suitability for shunt carried out before randomisation: no
Shunt patency assessed with duplex ultrasound or angiography at 3-monthly intervals
Method of Child's grading: Child-Pugh
Method of encephalopathy testing: clinical
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding episode clinically significant: yes
Mean (SD) observation time in years: TIPS 4.1 (0.26), endoscopic therapy + propranolol 3.6 (0.25)
Assessment of suitability for shunt carried out before randomisation: not mentioned
Participants Inclusion criteria: cirrhosis and acute first oesophageal haemorrhage controlled within 24 hours after
admission
Exclusion criteria: gastric varices, prior endoscopic or surgical treatment of varices, portal vein throm-
bosis, neoplastic disease and/or systemic disease that would limit the patient's life span to less than
6 months, hepatic encephalopathy grade 3 or 4, septicaemia, uncontrolled bleeding that required an
emergency TIPS procedure, contraindications for propranolol (such as severe heart insufficiency, ob-
structive pulmonary disease, severe hypotension)
Active bleeding was primarily treated by sclerotherapy. Control of bleeding was defined as cessation of
bleeding for longer than 24 hours. If active bleeding persisted despite endoscopic treatment, patients
received a Sengstaken-Blakemore tube and/or intravenous octreotide
The accepted interval after control of variceal bleeding was up to 3 days
Both groups were comparable regarding clinical characteristics
Child-Pugh score (mean ± SD): TIPS group 7.9 ± 2.1, endoscopic group 8.2 ± 2.0. Child-Pugh class A/B/C
(%): TIPS group 35/37/28, endoscopic group 24/45/31
Aetiology (%): alcohol 67 in TIPS group and 57 in endoscopic group; viral 21 in TIPS group and 29 in en-
doscopic group; others 12 in TIPS group and 14 in endoscopic group
Interventions TIPS: Palmaz stents (Johnson and Johnson Interventional Systems, Warren, NJ, USA) or Wallstents
(Schneider, Minneapolis, MN, USA)
Sauer 2002 
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Endoscopic therapy: variceal band ligation at intervals of 1 to 2 weeks until disappearance of varices +





Notes Personal communication with Peter Sauer via email 14/03/2016
Funding: no information
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random numbers
Allocation concealment
(selection bias)





Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk Intention-to-treat analysis. Mean follow-up 4.1 years for TIPS and 3.64 for en-
doscopic band ligation. One patient in shunt group and 2 in endoscopic band
ligation group lost to follow-up, with censoring appropriate. Data were cen-
sored at the time of last examination
Selective reporting (re-
porting bias)
Unclear risk All primary and secondary outcomes plus procedure-related complications are
reported. Liver-related complications are not reported
Other bias Unclear risk One out of 43 (2.5%) participants in TIPS group were crossed over to endo-
scopic therapy + propranolol. Three out of 42 (7%) participants in endoscopic
therapy group were crossed over to TIPS during follow-up. It is not clear if the
data were censored at the time of cross-over. The total number of participants






Methods Randomised controlled trial of transjugular intrahepatic portosystemic shunt vs cyanoacrylate injec-
tion for prevention of gastric variceal rebleeding
Time from bleeding episode to randomisation in days: once bleeding had been controlled for 3 days
Time from randomisation to treatment in days (SD): not mentioned
Lo 2007 
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Total number of patients evaluated and found eligible: 77 (460 assessed for eligibility), 3 patients eligi-
ble but not randomised (refusal to participate)
Randomisation: 37 randomised to TIPS, 37 randomised to endoscopic therapy; 2 randomised to TIPS
refused allocated intervention - not included in evaluation
Loss to follow-up: 1 patient in TIPS group, 6 patients in endoscopic therapy group. Telephone contact
maintained, included in analysis
Assessment of suitability for shunt carried out before randomisation: not mentioned
Shunt patency assessed using doppler ultrasound before discharge and every 3 months, or when clini-
cally indicated
Method of Child's grading: Child-Pugh score
Method of encephalopathy testing: clinical (altered consciousness and elevated arterial ammonia lev-
els requiring treatment)
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding episode clinically significant: yes
Median observation time in months: TIPS 33 (range 3 to 46), endoscopic therapy 32 (range 1 to 50)
Note: time to rebleeding was presented for both gastric variceal rebleeding and upper gastrointestinal
rebleeding. Gastric variceal rebleeding was used
Participants Inclusion criteria: liver cirrhosis (diagnosis based on liver biopsy or clinical, laboratory, and imaging
studies); acute gastric variceal bleeding with haematemesis or melaena (or both) and fall in haemoglo-
bin level
Exclusion criteria: age < 20; age > 75; acute bleeding from oesophageal varices; serum bilirubin > 10 mg/
dL; hepatic encephalopathy; hepatocellular carcinoma, uraemia or other debilitating disease; previous
specific treatment of gastric varices; uncontrolled acute gastric variceal bleeding; portal vein thrombo-
sis; pregnancy; refusal to participate; death within 72 hours of admission
Child-Pugh score (mean ± SD): TIPS group 7.8 ± 1.8, endoscopic group 7.6 ± 1.7. Child-Pugh class A/B/C
(%): TIPS group
26/57/17, endoscopic group 32/51/17
Aetiology (%): alcohol 11 in TIPS group and 22 in endoscopic group; HBV 34 in TIPS group and 32 in en-
doscopic group; HCV 37 in TIPS group and 30 in endoscopic group; HBV + HCV 14 in TIPS group and 8 in
endoscopic group; cryptogenetic 3 in TIPS group and 8 in endoscopic group
Patients suspected of gastroesophageal variceal bleeding received somatostatin. Endoscopy was per-
formed within 24 hours of admission, and cyanoacrylate glue injection was instituted when acute gas-
tric variceal bleeding was noted. Randomisation was performed after acute gastric variceal bleeding
had been controlled for 3 days
Interventions TIPS: metallic endoprosthesis 10 × 68 to 91 mm (Wallstent, Boston Scientific, Galway, Ireland)
Endoscopic therapy: n-butyl-2-cyanoacrylate injection (Histoacril; B. Braun, Melsungen AG, Germany)
mixed with lipiodol (Lipiodol Ultra-Fluid, Guerbet, Aulnay sos Bois, France), followed by banding if
concomitant prominent oesophageal varices. Endoscopic obturation was performed at intervals of 4
weeks until obliteration
Outcomes Pre-planned outcomes
• Gastric variceal rebleeding
• Complications (any untoward events that required active treatment or prolonged hospitalisation)
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Notes Funding: supported by internal hospital grant (VGHKS 90-14)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Table of random numbers. A study nurse generated the allocation sequence
Allocation concealment
(selection bias)





Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Six participants in the endoscopic group and 1 in the TIPS group were lost to-
follow-up (included in analysis; telephone contact maintained). The 2 partici-
pants randomised to TIPS who refused the allocated intervention were not in-
cluded in the evaluation
Selective reporting (re-
porting bias)
Low risk No pre-published protocol
All key primary and secondary outcomes were reported





Methods Randomised controlled trial comparing transjugular intrahepatic portosystemic shunt with endoscopic
band ligation in cirrhotic patients with recurrent variceal bleeding not responding to pharmacological
therapy
Time from bleeding episode to randomisation: median to inclusion 20 days in clinical non-responders,
87 days in HVPG non-responders
Time from randomisation to treatment: not reported
Total number of patients evaluated: not reported
Randomised to TIPS: 21; randomised to endoscopic + medical therapy: 19
For 1 participant, TIPS placement was impossible and endoscopic treatment was applied
Two participants were crossed over to endoscopic + medical therapy group for rebleeding from stent
thrombosis 3 months after TIPS implantation (1) and for encephalopathy that required TIPS occlusion
during follow-up. Three participants in endoscopic + medical therapy group were crossed over to TIPS
during follow-up (1 participant for rebleeding and 2 for ascites)
Intention-to-treat analysis
Ferlitsch 2012 
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Rebleeding episodes endoscopically verified: unclear
Specified whether rebleeding episode clinically significant: not mentioned
Median follow-up: 30 months (95% CI 20 to 40)
Assessment of suitability for shunt carried out before randomisation: not mentioned
Shunt patency assessment: not mentioned
Method of Cirrhosis grading: Child-Pugh
Method of encephalopathy testing: not mentioned
Participants Inclusion criteria: rebleeding from oesophageal varices under sufficient pharmacological therapy (clini-
cal non-responders); recurrent variceal bleeding as hepatic venous pressure gradient (HVPG) in non-re-
sponders to minimum of 80 mg propranolol and 40 mg isosorbide mononitrate (ISMN) (HVPG non-re-
sponders)
In the pre-published protocol: NCT00570973
Inclusion criteria: age ≥ 18 years, liver cirrhosis, bleeding from oesophageal varices within last 6
months, sufficient medical therapy (≥ 80 mg propranolol per day), signed written informed consent
Exclusion criteria: bleeding of gastric varices, poral vein thrombosis, insufficient medical therapy (< 80
mg propranolol per day), exclusion criteria for TIPS/band ligation (anatomy; impaired coagulation pa-
rameters; severe encephalopathy; severe liver failure (bilirubin > 10 mg/dL); congestive heart failure;
pulmonary hypertension; polycystic liver disease; presence or suspicion of active systemic, biliary, or
ascitic fluid infection; known cavernous portal vein occlusion; Budd-Chiari syndrome
Child-Pugh score and class not reported
Aetiology not reported
Interventions TIPS: PTFE-coated stent
Endoscopic band ligation repeated until eradication of varices + continuation of medical therapy
Outcomes Pre-published protocol
Primary outcome: variceal rebleeding (time frame: 2 years)





Notes Clinicaltrials.gov NCT 00570973
No study results posted on ClinicalTrials.gov
Study start date: November 2004
Abstract only
Funding: no information - trials registry states sponsor is University of Vienna
Risk of bias
Bias Authors' judgement Support for judgement
Ferlitsch 2012  (Continued)
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Random sequence genera-
tion (selection bias)
Unclear risk No information
Allocation concealment
(selection bias)





Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





Unclear risk No information
Selective reporting (re-
porting bias)
Unclear risk Pre-published protocol. All planned outcomes reported. Complications of in-
terest for the review not reported
Other bias High risk Abstract only
Large number of participants were crossed over during follow-up. Three out of
21 (14%) participants in TIPS group were crossed over to endoscopic + medical
therapy group (reasons given). Three out of 19 (15.7%) participants in endo-
scopic + medical therapy group were crossed over to TIPS group (reasons giv-





Methods Randomised controlled trial comparing transjugular portosystemic shunt with or without variceal em-
bolisation with endoscopic band ligation + propranolol for prevention of oesophageal variceal rebleed-
ing in patients with advanced cirrhosis and portal vein thrombosis
Time from bleeding episode to randomisation: unclear
Time from randomisation to treatment: unclear
Total number of patients evaluated and found eligible: 73 (114 assessed for eligibility)
Randomised to TIPS: 37; randomised to endoscopic therapy + propranolol: 36
Nine participants in endoscopic therapy + propranolol group were crossed over to TIPS during fol-
low-up
One participant in TIPS group and 2 in endoscopic therapy + propranolol group lost to follow-up
Intention-to-treat analysis
Follow-up period in months (mean ± SD): TIPS 22.8 ± 7.7, endoscopic therapy + propranolol 20.9 ± 8.9
Assessment of suitability for shunt carried out before randomisation: unclear
Shunt patency assessment: angiography (direct portography)
Luo 2015 
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Unclear whether routine assessment of shunt patency was undertaken
Method of Child's grading: Child-Pugh
Method of encephalopathy testing: not specified
Rebleeding episodes endoscopically verified: ? yes - variceal bleeding specified
Specified whether rebleeding episode clinically significant: not specified
Participants Inclusion criteria: advanced cirrhosis (Child-Pugh score 7 to 13), portal vein thrombosis, age 18 to 70
years, previous episode of variceal bleeding
Exclusion criteria: portal vein thrombosis ≤ 25% within vessel lumen, limited thrombosis within intra-
hepatic portal branch, portal cavernoma, gastric varices, hepatocellular carcinoma, previous endo-
scopic treatment of varices within 3 months, contraindications to TIPS, endoscopic band ligation or
propranolol
Child-Pugh class B/C (%): TIPS group 68/32, endoscopic group 67/33. Child-Pugh score (mean ± SD):
TIPS group 8.76 ± 1.70, endoscopic group 8.89 ± 1.77. MELD score (mean ± SD): TIPS group 14.2 ± 6.5,
endoscopic group 15.9 ± 5.7
Aetiology (%): HBV 73 in TIPS group and 67 in endoscopic group; HCV 8 in TIPS group and 6 in endo-
scopic group; alcohol 5 in TIPS group and 11 in endoscopic group; other 13 in TIPS group and 17 in en-
doscopic group
Interventions TIPS: polytetrafluoroethylene-covered stents (Fluency; C.R. Bard, Murray Hill, NJ, USA) with embolisa-
tion with coils of portosystemic collateral veins if observed at post-TIPS portography. Warfarin was ad-
ministered for 6 months after recanalisation of the portal venous system, with a target international
normalised ratio of 2 to 3
Endoscopic therapy: band ligation every 4 to 6 weeks until varices were eradicated + propranolol (start-
ing dose 20 mg/d, with increase by 20 to 40 mg/d every week, either until reduction of resting heart
rate of 25% was achieved or up to the maximum dose was tolerated). Immediately after variceal erad-
ication, warfarin was prescribed and was continued for an additional 6 months after recanalisation of




• Recanalisation of portal venous system
• Hepatic encephalopathy
• Mortality
Notes Randomised clinical trial registered in the Chinese Clinical Trial Registry: ChiCTR-TRC-11001577
Funding: no information
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Consecutive numbers generated by computer
Allocation concealment
(selection bias)
Low risk Allocated random digit numbers
Luo 2015  (Continued)
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Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk 73 participants randomised; 3 lost to-follow-up after a mean of 7 months (1 in
TIPS group, 2 in endoscopic band ligation group)
Selective reporting (re-
porting bias)
High risk Trial registered (ChiCTR-TRC-11001577). All primary and secondary outcomes
reported as pre-specified
Complications are not pre-defined. Study authors reported only major com-
plications for TIPS, while reporting minor complications for endoscopic treat-
ment + propranolol
Other bias High risk The number of participants who were crossed over during follow-up is high: 9
out of 37 (25%) participants in endoscopic therapy + propranolol group were





Methods Randomised controlled trial comparing covered transjugular intrahepatic portosystemic shunt vs en-
doscopic therapy + beta blocker for prevention of variceal rebleeding
Time from bleeding episode to randomisation: median 4 days (IQR 1 to 7)
Time from randomisation to treatment: median time from bleeding to TIPS 6 days (IQR 3 to 9)
Total number of patients evaluated and found eligible: 72 (174 patients were admitted for acute
variceal bleeding and evaluated: 40 did not fulfil the inclusion criteria; 62 met 1 or more exclusion crite-
ria; of these, 24 were unable/unwilling to give informed consent)
Randomised to TIPS 37; randomised to endoscopic therapy + beta blocker 35
Four patients randomised to TIPS were treated by endoscopic therapy + beta blocker (advanced HCC
diagnosed after randomisation; technical infeasibility due to Budd-Chiari syndrome; peri-procedural
ventricular fibrillation). Two participants were crossed over to endoscopy because of closure of TIPS
due to severe untreatable hepatic encephalopathy. Six patients randomised to endoscopic therapy
+ beta blocker were crossed over to TIPS (recurrent/uncontrollable variceal rebleeding; refractory as-
cites)
Two patients in the TIPS group and 4 in the endoscopic therapy + beta blocker group were lost to fol-
low-up. Twelve patients were censored due to liver transplantation
Note that original sample size was calculated at 124 patients; study authors stated that due to a greater
than expected benefit of early TIPS in rebleeding, the sample size was reduced to 72 patients
Intention-to-treat analysis and per-protocol presented
Follow-up period in months (median): 23.4 months (IQR 6.9 to 38.5)
Assessment of suitability for shunt carried out before randomisation: unclear
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Shunt patency assessment: TIPS function assessed by clinical evaluation every 6 weeks to 3 months.
Duplex ultrasound undertaken when signs of possible dysfunction were present (new onset/progres-
sive hepatic encephalopathy or ascites). Liver ultrasound every 6 months
Method of Child's grading: Child-Pugh
Method of encephalopathy testing: not specified
Rebleeding episodes endoscopically verified: not specified
Specified whether rebleeding clinically significant: yes
Participants Inclusion criteria: patients with cirrhosis, age 18 to 75 years, first or second episode of endoscopically
documented oesophageal or gastric variceal bleeding
Exclusion criteria: serious or refractory hepatic encephalopathy unrelated to gastrointestinal bleeding;
history of significant heart failure (NYHA III and IV); portal hypertension from cause other than liver dis-
ease (e.g. portal or splenic vein thrombosis); previous TIPS; advanced HCC; Child-Pugh score > 13; sep-
sis and/or multi-organ failure; inability/unwillingness to give informed consent
After stabilisation and successful endoscopic haemostasis, patients were randomly assigned to TIPS
placement or long-term endoscopic therapy (variceal ligation or injection therapy) + beta blocker,
preferably within 1 to 2 days after admission. Initial stabilisation included broad-spectrum antibiotics,
vasoactive drugs (octreotide, terlipressin, or somatostatin), fluid and packed cell administration, and
endoscopic treatment according to international consensus guidelines. Endoscopic treatment of oe-
sophageal varices consisted of endoscopic variceal ligation; gastric varices were injected with cyano-
acrylate glue with lipiodol
Child-Pugh score (mean ± SD): TIPS group 7.5 ± 2.0, endoscopic group 7.3 ± 1.9. Child-Pugh class A/B/C
(%): TIPS group 35/51/14, endoscopic group 37/51/11. MELD score (mean ± SD): TIPS group 13.5 ± 6.3,
endoscopic group 12.7 ± 3.8
Aetiology (%): alcohol 35 in TIPS group and 51 in endoscopic group; HBV/HCV 19 in TIPS group and 3
in endoscopic group; alcohol + HBV/HCV 8 in TIPS group and 8 in endoscopic group; autoimmune liv-
er/biliary disease 24 in TIPS group and 26 in endoscopic group; other 14 in TIPS group and 11 in endo-
scopic group
Interventions TIPS: PTFE-covered stents (Viatorr; W.L. Gore and Associates, FlagstaJ, AZ, USA); embolisation of leN
gastric (coronary) vein or other collaterals was considered when there was evidence of active variceal
bleeding and marked collateral filling on portography
Endoscopic therapy: endoscopic band ligation of oesophageal varices; cyanolacrylate injection of gas-
tric varices + non-selective beta blocker (preferably slow-release propranolol, titrated to maximum tol-
erated dose aiming to decrease the heart rate in rest by 25%, with a lower limit of 50 beats per minute)
unless a contraindication was present
Outcomes Protocol planned outcomes
• Rebleeding




• Quality of life
• Cost
Notes Dutch trial register: www.trialregister.nl; No.: NTR973 (https://www.trialregister.nl/trial/948)
Study authors emailed 29/05/2016 and 26/06/2016. Reply received 05/07/2016
Funding: financial support provided by ZON-MW, The Netherlands Organization for Health Research
and Development (project no.: 80-007029-98-07046). Study authors stated that "the funding source did
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not have influence on study design, data collection, analysis, and interpretation of the data, writing of
the report, nor the decision to submit for publication"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Randomisation assigned through a permanently available central telephone





Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Outcomes scored centrally by 2 physicians blinded to allocated treatment,




Low risk Two patients in the TIPS group and 4 in the endoscopic therapy + beta blocker
group were lost to-follow-up (< 10%)
Study authors performed intention-to-treat analysis and as-treated analysis
Selective reporting (re-
porting bias)
Low risk Study authors reported all pre-planned outcomes. Cost-effectiveness was re-
ported in conference abstracts but not for full cohort in the final paper
Other bias Low risk Two out of 37 (5.4%) participants in TIPS group were crossed over to en-
doscopy + beta blocker because of closure of TIPS due to severe untreatable
hepatic encephalopathy. Six out of 35 (17%) participants in the endoscopic
group were crossed over to TIPS because of recurrent/uncontrollable variceal
rebleeding or refractory ascites. These participants were censored at the mo-





Methods Randomised controlled trial comparing transjugular intrahepatic portosystemic shunt vs endoscopic
band ligation + propranolol for prevention of variceal rebleeding in patients with cirrhosis and portal
vein thrombosis
Inclusion of all randomised participants at evaluation: no (3 patients excluded early after randomisa-
tion due to non-cirrhotic portal hypertension)
Time from bleeding episode to randomisation: patients with endoscopy-proven variceal bleeding in
past 6 weeks included
Time from randomisation to treatment: within 48 hours
Total number of patients evaluated and found eligible: 52 (156 patients assessed for eligibility; 67 did
not meet the inclusion criteria and 46 met the exclusion criteria)
Randomised to TIPS: 25; randomised to endoscopic band ligation + drug: 27. One TIPS patient excluded
after randomisation due to non-cirrhotic hypertension; 2 endoscopic band ligation + drug patients ex-
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cluded after randomisation due to non-cirrhotic hypertension (excluded from intention-to-treat analy-
sis)
One participant randomised to endoscopy withdrew consent and was treated by TIPS
One participant allocated to TIPS group was treated by endoscopic band ligation + drug due to techni-
cal failure of TIPS
Four participants treated with endoscopy were crossed over to TIPS due to uncontrolled variceal bleed-
ing or refractory ascites (included in intention-to-treat analysis) (extensive thrombosis)
Rebleeding episodes endoscopically verified: no, according to Baveno V consensus
Specified whether rebleeding episode clinically significant: not specified, but possible because study
authors refer to Baveno V
Assessment of suitability for shunt carried out before randomisation: at enrolment, doppler ultra-
sound, abdominal CT
Shunt patency assessment: doppler ultrasound and CT evaluations
Method of cirrhosis grading: Child-Pugh
Method of encephalopathy testing: clinical
Follow-up, months (median, IQR): TIPS group 30.9, 21.6 to 42.5; endoscopic band ligation + drug group
30.4, 24.6 to 39.0. No participants were lost to follow-up
Participants Inclusion criteria: liver cirrhosis (diagnosed by clinical finding, laboratory tests, imaging, or liver biop-
sy); portal vein thrombosis; > 50% portal vein trunk lumen; history of endoscopy-proven variceal bleed-
ing (gastric or oesophageal) in the past 6 weeks; age 18 to 75 years
Exclusion criteria: uncontrolled active variceal bleeding; fibrotic cord; previous endoscopic bad ligation
+ non-selective beta blockers, TIPS or shunt surgery; renal insufficiency (serum creatinine > 170 micro-
mol/L); severe liver insufficiency; severe cardiopulmonary disease; uncontrolled systemic infection or
sepsis; hepatocellular carcinoma or other extrahepatic malignancy; contraindications to propranolol,
anticoagulation, or TIPS; HIV infection; pregnant or breastfeeding
Patients presenting with acute bleeding were screened on day 6 after successful treatment of the index
bleeding with vasoactive drugs (terlipressin or somatostatin), antibiotics, and endoscopic treatment
for 5 days. Those who failed to achieve primary haemostasis during acute bleeding were excluded. Pa-
tients with a history of recent variceal bleeding were screened on day 1 after hospital admission, and
those who previously had received more than 1 session of ligation/sclerotherapy and non-selective be-
ta blocker were excluded
Baseline characteristics comparable between study groups
Child-Pugh score (median, IQR): TIPS group 7, 6 to 8; endoscopic group 7, 6 to 8. Child-Pugh class A/B/C
(%): TIPS group 38/55/8, endoscopic group 40/56/4
Aetiology (%): alcohol 4 in TIPS group and 0 in endoscopic group; HBV 83 in TIPS group and 88 in endo-
scopic group; HCV 4 in TIPS group and 0 in endoscopic group; autoimmune 4 in TIPS group and 4 in en-
doscopic group; HBV + autoimmune 0 in TIPS group and 4 in endoscopic group; cryptogenetic 4 in TIPS
group and 4 in endoscopic group
Interventions TIPS group: polytetrafluoroethylene-covered stents (Fluency; Bard Peripheral Vascular, Tempe, AZ,
USA). Local thrombolysis with bolus infusion of urokinase was performed for 3 days in patients with oc-
clusive thrombus remaining in the superior mesenteric vein and/or the splenic vein after stent inser-
tion. TIPS + anticoagulants (5 patients had local thrombolysis; 7 patients had collateral embolisation)
Endoscopic band ligation + drug group: endoscopic band ligation scheduled every 1 to 2 weeks until
variceal eradication + propranolol at initial dose of 20 mg twice daily, then with increasing doses until
55 beats per minute or a 25% decrease in heart rate was achieved
Lv 2018  (Continued)
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In both groups, anticoagulant therapy was given
TIPS group: intravenous heparin for 5 days, followed by warfarin for 6 months or until portal vein
thrombosis complete recanalisation achieved
EBL + drug group: intravenous heparin for 5 days followed by warfarin for 6 months or until portal
vein thrombosis complete recanalisation. Warfarin was commenced when variceal eradication was
achieved or "risk of variceal bleeding was thought to be low after careful evaluation by the investiga-
tors"
Outcomes Planned outcomes in the published protocol
• Variceal rebleeding
• Mortality
• Portal vein recanalisation
• Complications of portal hypertension
• Change in degree of portal vein thrombosis
• Patients without portal vein recanalisation
• Number of complications. For TIPS procedural complications, shunt dysfunction, hepatic en-
cephalopathy. For the endoscopic group, complications related to endoscopy and drugs
Notes Amendments to study protocol
• Drugs pre-planned as encephalopathy prophylactics and oral aspirin not used in TIPS group because
efficacy was not definitive
• Non selective beta blockers administered immediately after randomisation
• Endoscopic sclerotherapy was not used (endoscopic sclerotherapy and glue injection or a combina-
tion planned in protocol for gastric varices, but only banding used)
Trial registered with ClinicalTrials.gov under NCT01326949
Funding: supported by grants from the Optimized Overall Project of Shaanxi Province (2013KTCL03-05)
and the Boost Program of Xijing Hospital (XJZT11Z07)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Eligible patients were randomised in a 1:1 ratio, stratified according to Child-
Pugh class (A or B/C) and degree of PVT (partial or complete obstruction) using




Low risk Randomisation performed within 24 hours after enrolment by a clinical re-






Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk No participants lost at follow-up
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Selective reporting (re-
porting bias)
Low risk All outcomes reported as specified in protocol and trial registry
Other bias High risk The number of participants who were crossed over is high: 4 out of 25 (16%)
participants treated with endoscopy were crossed to TIPS due to uncontrolled





Methods Randomised clinical trial evaluating early transjugular intrahepatic portosystemic shunt (TIPSS) vs
standard of care in patients with cirrhosis and oesophageal variceal bleeding
Time from bleeding episode to randomisation and time from randomisation to treatment: for those pa-
tients randomised to early TIPSS, the aim was to perform TIPSS within 72 hours after initial endoscopy.
Mean time from endoscopy to TIPSS placement for all participants was 65 ± 37 hours. Ten participants
received TIPSS placement outside the 72-hour window due to a delay in randomisation, with mean
time from endoscopy to randomisation of 37 ± 22 hours. In comparison, the remaining 13 participants
who received TIPSS placement within the 72-hour window had mean time from endoscopy to randomi-
sation of 18 ± 12 hours. Of the 23 participants who received TIPSS placement, 22 received it within 72
hours of randomisation, rather than from endoscopy
Total number of patients evaluated and found eligible: 59 (206 patients assessed for eligibility; 147
were excluded); 1 withdrew consent
Randomised to TIPS: 29; randomised to endoscopic therapy + beta blocker. Of the 29 participants ran-
domised to the early TIPSS group, 6 participants did not undergo TIPSS placement due to logistical and
practical issues. Of the 29 participants randomised to the standard of care group, 1 underwent liver
transplantation and 2 underwent rescue TIPSS because of rebleeding during follow-up
Intention-to-treat analysis and per-protocol presented
No participants were lost to follow-up
Assessment of suitability for shunt carried out before randomisation: not specified
Shunt patency assessment: TIPSS patency was checked at 6 months and at 1 year using doppler ultra-
sonography or TIPSS venography. If TIPSS dysfunction was confirmed, balloon angioplasty was per-
formed or a further e-PTFE-covered stent was placed
Method of Child's grading: Child-Pugh
Method of encephalopathy testing: not reported
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding clinically significant: not specified
Participants Inclusion criteria: patients with liver cirrhosis presenting with acute oesophageal variceal bleeding and
subsequent haemostasis following treatment with vasoactive drugs and endoscopic band ligation
Exclusion criteria: younger than 18 or older than 75 years of age, pregnancy, Child-Pugh score < 8 and
> 13, inability to control bleeding at index endoscopy, previous porto-systemic shunt or TIPSS, previ-
ous pharmacotherapy and endoscopic band ligation, bleeding from isolated gastric or ectopic varices,
known portal vein thrombosis, active cancer including hepatocellular carcinoma, recurrent hospital
admissions with encephalopathy
After endoscopic haemostasis was achieved, consenting participants were randomised 1:1 to early
TIPSS or to standard of care (continued endoscopic band ligation sessions ± pharmacotherapy)
Dunne 2020 
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Pre-endoscopic management included use of antibiotics and vasoactive drugs (terlipressin 2 mg QDS)
unless contraindicated. Policy was to perform endoscopy within 12 hours of presentation. During en-
doscopy, band ligation was performed to gain haemostasis for actively bleeding varices or to treat pre-
existing varices with high-risk stigmata of recent bleeding such as red spots or fibrin plugs
There were no differences in baseline characteristics between the 2 treatment groups at study entry
Causes of cirrhosis (%): ALD 97 and 90, NAFLD 3 and 7, viral 0 and 3
Child-Pugh score, mean (SD): 9.8 (1.2) and 9.8 (1.5). Child-Pugh class B/C (%): 45/55 and 41/59. MELD
score, mean (SD): 17 (3.4) and 17 (3.8)
Interventions Early TIPSS group: TIPSS (e-polytetrafluoroethylene (e-PTFE)-covered stents (Viatorr TIPSS endopros-
thesis; W.L. Gore & Associates, Inc., Newark, NJ, USA)) within 72 hours after initial endoscopy. Terli-
pressin was continued until TIPSS was performed, and antibiotics were continued for 5 to 7 days. TIPSS
were initially dilated to 8 or 9 mm. If the portal pressure gradient did not decrease to below 12 mmHg,
the stent was dilated further to 9 or 10 mm
Endoscopic intervention with medical therapy group: terlipressin continued for up to 5 days + antibi-
otics for 5 to 7 days + outpatient endoscopic variceal band ligation programme (endoscopy at 2- to
4-weekly intervals until variceal eradication, then repeat endoscopy in 3-, then 6-monthly intervals).
Carvedilol was commenced before discharge from hospital at a dose of 6.25 mg and was titrated there-
after, depending on participant tolerability
Outcomes Primary outcome was 1-year survival
Secondary outcomes included survival at 6 weeks; rates of early rebleeding (within 6 weeks); late re-
bleeding (between 6 weeks and 1 year); development of hepatic encephalopathy
Subsidiary outcomes: development of new ascites, number of days in the intensive care unit, hospital
attendances (including to the endoscopy unit), use of alternative treatments including beta blockers,
safety profile
Notes ClinicalTrials.gov reference: NCT02377141
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A 24-hour web-based randomisation service [https://www. aleaclinical.eu
(ALEA Clinical, Abcoude, The Netherlands)] was used
Allocation concealment
(selection bias)
Low risk A 24-hour web-based randomisation service [https://www. aleaclinical.eu





Unclear risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients
Blinding of outcome as-
sessment (detection bias)
All outcomes





Low risk All outcome data are reported
Selective reporting (re-
porting bias)
Unclear risk A pre-published protocol was available. Protocol-planned outcomes were re-
ported. Not all key outcomes of interest in the review were reported
Dunne 2020  (Continued)
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Other bias High risk In the TIPS groups, 6 participants did not undergo TIPSS placement due to lo-





Methods Randomised controlled trial comparing distal splenorenal shunt (DSRS), propranolol (P), and endo-
scopic sclerotherapy (ES) for prevention of oesophageal variceal rebleeding in alcoholic cirrhosis
Time from bleeding episode to randomisation: no later than 4 weeks after discharge from hospital for
the bleeding episode
Time from randomisation to treatment: no later than 2 weeks after randomisation
Total number of patients evaluated and found eligible: 43 (58 patients evaluated for eligibility; 15 pa-
tients excluded: 10 refused participation and 5 did not return for further evaluation)
Randomised to DSRS (only patients in Child's class A or B): 15; randomised to P: 15; randomised to ES:
13
Four participants randomised to DSRS group refused and opted for ES group
Intention-to-treat analysis and per-protocol presented
Follow-up period in months (mean): 23.2 (16.4).
Lost to follow-up: DSRS group 5, ES group 6, P group 8
Assessment of suitability for shunt carried out before randomisation: yes
Shunt patency assessment: not specified
Method of Child's grading: Child-Pugh
Method of encephalopathy testing: not reported
Rebleeding episodes endoscopically verified: yes
Specified whether rebleeding clinically significant: yes
Participants Inclusion criteria: alcoholic cirrhosis, previous episode of endoscopically proven oesophageal variceal
bleeding for which no treatment was applied
Exclusion criteria: not specified
Baseline characteristics:
Child class A/B/C: DSRS group 11/4/0, ES group 6/6/1.
Interventions DSRS group - distal splenorenal shunt after splenoportogram documented a patent and adequate vas-
cular system
ES group - endoscopic sclerotherapy using a solution of 1:1 3% sodium tetradecyl sulfate and 5% dex-
trose, intravariceal injection in distal 6 cm of the oesophagus using a 23 G needle, 1 to 2 mL of scle-
rosant per injection with a total of 12 to 16 mL per session. Sclerotherapy was performed twice the
first week, then weekly until total obliteration of the varices was achieved. After total obliteration, en-
doscopy was repeated every 3 months for the first year, and every 6 months for the duration of the
study. If non-bleeding varices were found, sclerotherapy was performed again until re-obliteration fol-
lowing the same weekly scheme
Urbistondo 1996 
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P group - patients underwent hepatic-portal pressure gradient measurement. Propranolol was given
orally at a starting dose of 60 mg/d (single dose), and was titrated to obtain a 25% reduction in heart
rate from the baseline or less than 60 beats per minute. Hepatic-portal pressure gradient was measured
again at 90 to 120 days after start of therapy. Response to propranolol was defined as a 10% decrease
in the gradient
Outcomes • Death
• Rebleeding from varices
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Table of random numbers
Allocation concealment
(selection bias)





High risk Not feasible. It is unclear if lack of blinding influenced the choice of treatments
and the management of patients. 4 (26%) participants randomised to surgery
refused it and opted for sclerotherapy
Blinding of outcome as-
sessment (detection bias)
All outcomes









High risk Not all outcomes of interest in the review are reported
Other bias High risk Unbalanced randomisation between the 2 groups: participants in Child's class
A and B were randomised to surgery, sclerotherapy, or propranolol (third arm
not of interest in this review). Participants in Child's class C were randomised
only to sclerotherapy or propranolol. So there is bias in selection of partici-
pants
Urbistondo 1996  (Continued)
ALD: alcoholic liver disease.
CT: computed tomography.
DSRS: distal splenorenal shunt.
ECG: electrocardiogram.
EEG: electroencephalogram.
HBV: hepatitis B virus.
HCC: hepatocellular carcinoma.
HCV: hepatitis C virus.
HVPG: hepatic venous pressure gradient.
IQR: interquartile ratio.
ISMN: isosorbide mononitrate.
MELD: Model for End-Stage Liver Disease.
NAFLD: non-alcoholic fatty liver disease.
NYHA: New York Heart Association.
OLT: ortotopic liver transplantation.
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P: propranolol.
PBC: braided power shunt.
PO2: partial pressure of oxygen.
PTFE: polytetrafluoroethylene.
PVT: portal vein thrombosis.
SD: standard deviation.
SE: standard error.
SEM: standard error of the mean.
TIPS: transjugular intrahepatic portosystemic shunt.
TS: total shunt.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Cello 1982 Thirteen Child's class C patients with variceal haemorrhage requiring 6 or more units of blood were
randomly assigned to 2 groups: endoscopic sclerotherapy using 5% sodium morrhuate and oe-
sophageal transection/re-anastomosis employing the EEA Auto Suture stapling instrument. Results
were compared retrospectively to those of a separate group of 20 patients who had received total
shunts
Cello 1987 Randomised controlled trial comparing portacaval shunt with endoscopic sclerotherapy for pa-
tients with severe cirrhosis and acute variceal haemorrhage. Variceal bleeding not controlled be-
fore randomisation
Escorsell 2002 Ninety-one Child-Pugh class B/C cirrhotic patients surviving their first episode of variceal bleeding
were randomised to receive TIPS or medical therapy (propranolol + isosorbide-5-mononitrate) to
prevent variceal rebleeding. Endoscopic therapy (banding ligation preferably) was used only acute-
ly to treat index bleeding
Garcia-Pagan 2010 Sixty-three patients with cirrhosis and acute variceal bleeding who had been treated with vasoac-
tive drugs + endoscopic therapy were randomly assigned within 24 hours after admission to treat-
ment with a polytetrafluoroethylene-covered stent within 72 hours after randomisation (early-TIPS
group, 32 patients) or continuation of vasoactive drug therapy, followed after 3 to 5 days by treat-
ment with propranolol or nadolol and long-term endoscopic band ligation, with insertion of a TIPS
if needed as rescue therapy (pharmacotherapy–EBL group, 31 patients). Variceal bleeding not con-
trolled before randomisation
Kitano 1992 Ninety-six patients with good liver function (Child class A or B) and oesophageal varices were ran-
domly assigned to 1 of 3 groups given different treatments: endoscopic sclerotherapy (n = 32), oe-
sophageal transection (n = 32), or distal splenorenal shunt (n = 32). Patients who had not previous-
ly bled from varices were included. Only 35/96 (36%) participants had had at least 1 endoscopically
proven episode of variceal bleeding
Li 2015 Non-randomised prospective study enrolling 109 cirrhotic patients with oesophageal variceal
bleeding non-responders to pharmacological therapy based on HVPG measurement who were di-
vided into 2 groups: 55 patients were treated with endoscopic variceal ligation and non-selective
beta blocker; 54 patients were treated with endoscopic variceal ligation and non-selective beta
blocker if HVPG ≤ 16 mmHg, with percutaneous transhepatic variceal embolisation if HVPG > 16
mmHg and ≤ 20 mmHg, or with transjugular intrahepatic portosystemic shunt if HVPG > 20 mmHg
Meddi 1999 Cost analysis study comparing the cumulative cost of the first 18-month period in a group of partic-
ipants selected from a multi-centre randomised controlled trial comparing transjugular intrahepat-
ic portosystemic shunt vs endoscopic sclerotherapy to prevent variceal rebleeding. Possible over-
lap of previously published results
OrloJ 1994 Prospective randomised trial conducted in unselected, consecutive patients with bleeding oe-
sophageal varices resulting from cirrhosis comparing emergency portacaval shunt performed with-
in 8 hours of initial contact (21 patients) with emergency medical therapy (intravenous vasopressin
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Study Reason for exclusion
and oesophageal balloon tamponade) followed in 9 to 30 days by elective portacaval shunt in sur-
vivors (22 patients). Variceal bleeding not controlled before randomisation. Endoscopic therapy
not used in the medically treated group of patients
OrloJ 2009 Randomised trial that compared endoscopic sclerotherapy with emergency portacaval shunt in cir-
rhotic patients with acute variceal haemorrhage. Variceal bleeding not controlled before randomi-
sation
OrloJ 2015 Randomised trials of endoscopic therapy and transjugular intrahepatic portosystemic shunt vs
portacaval shunt for emergency and elective treatment of bleeding gastric varices in cirrhosis
Paquet 1990 Non-randomised study comparing endoscopic sclerotherapy and surgical shunt (narrow-lumen
mesocaval interposition shunt and distal splenorenal shunt) for treatment of acute or recurrent
haemorrhage from oesophagogastric varices
Resnick 1974 Prospective controlled trial comparing medical therapy, end-side portacaval shunt, and side-side
portacaval shunt. Endoscopic therapy not employed in the medically treated group
Reynolds 1981 Randomised controlled trial of medical therapy vs end-to-side portacaval shunt in 89 patients with
alcoholic liver disease and at least 1 severe upper gastrointestinal haemorrhage thought to be from
oesophageal varices. Endoscopic therapy not employed in the medically treated group
Sanyal 1994 Non-randomised study evaluating prospectively portosystemic encephalopathy in 30 patients un-
dergoing transjugular intrahepatic portosystemic shunts, compared with 25 patients concurrently
undergoing sclerotherapy. Study outcome measures are not a subject of this review
Sauerbruch 2015 Multi-centre, open-label randomised clinical trial of patients with cirrhosis (92% Child's class A or
B, 70% alcoholic) comparing more than 5 days after variceal haemorrhage the insertion of a small
covered transjugular intrahepatic portosystemic stent shunt (TIPS) (8 mm; n = 90) with medical
therapy (propranolol and isosorbide-5-mononitrate; n = 95). In the medical group, patients with an
adequate reduction in HVPG (responders) remained on the drugs, whereas non-responders under-
went only variceal band ligation
Terés 1987a Randomised controlled trial in 70 consecutive cirrhotic patients with persistent or recurrent
variceal bleeding comparing portacaval shunt with stapler transection in patients with low surgical
risk, and stapler transection with endoscopic sclerotherapy in patients with high surgical risk
Tripathi 2001 Randomised controlled trial comparing transjugular intrahepatic portosystemic stent-shunt vs
transjugular intrahepatic portosystemic stent-shunt and variceal band ligation for prevention of
variceal rebleeding
Wang 2015 Non-randomised trial. Retrospective study comparing transjugular intrahepatic portosystemic
shunt and endoscopic band ligation in patients with cirrhosis and portal vein thrombosis
HVPG: hepatic venous pressure gradient.
RCT: randomised clinical trial.
TIPS: transjugular intrahepatic portosystemic shunt.
 
Characteristics of studies awaiting classification [ordered by study ID]
 
Methods Randomised controlled trial comparing early TIPS with covered stents vs standard treatment for
acute variceal bleeding in patients with advanced cirrhosis
Time from bleeding episode to randomisation (hours): TIPS group 24.3 (16.1), endoscopic interven-
tion with NSBB 24.7 (19.5)
Lv 2019 
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Time from randomisation to treatment: early TIPS performed within 72 hours (preferably within
the first 24 hours) after diagnostic endoscopy (45 patients within 24 hours, 28 in 24 to 48 hours, and
10 in 48 to 72 hours)
Total number of patients evaluated and found eligible: 132 (317 assessed for eligibility: 101 did not
meet inclusion criteria; 140 met exclusion criteria)
Randomised to TIPS: 86; randomised to endoscopic therapy + beta blocker: 46. After randomisa-
tion, 3 patients were excluded due to non-cirrhotic portal hypertension (1 in each group) and hepa-
tocellular carcinoma (1 in the early TIPS group). Therefore, the intention-to-treat population con-
sisted of 84 patients in the early TIPS group and 45 in the control group. One patient allocated to
the early TIPS group died before TIPS placement, and 1 patient assigned to the control group with-
drew consent before administration of propranolol; thus, 83 patients in the early TIPS group and 44
in the control group were included in the per-protocol population
Intention-to-treat analysis and per-protocol analysis presented
Follow-up period in months (median): 24.0 (IQR 18.1 to 24.0) in the early TIPS group and 24.0 (9.0 to
24.0) in the control group
No participants were lost to follow-up
Assessment of suitability for shunt carried out before randomisation: not specified
Shunt patency assessment: TIPS revision with angioplasty or another stent placement was done
when portal hypertensive complications re-emerged or when doppler ultrasonography indicated
shunt dysfunction (i.e. reduction in portal blood flow velocity > 50% or < 28 cm/s, or reversion of
blood flow direction within the intrahepatic branches)
Method of Child's grading: Child-Pugh
Method of encephalopathy testing: West-Haven criteria
Participants Inclusion criteria: liver cirrhosis (diagnosed based on clinical presentation, laboratory tests, im-
ages, or liver biopsies); age 18 to 75 years; endoscopy-proven acute variceal bleeding according to
Baveno 2 definitions; Child-Pugh class B or C (< 14 points)
Exclusion criteria: uncontrolled bleeding before randomisation; bleeding from isolated gastric or
ectopic varices; severe cardiopulmonary disease; spontaneous recurrent hepatic encephalopathy;
complete portal vein thrombosis or cavernoma; creatinine > 3 mg/dL; hepatocellular carcinoma or
other extrahepatic malignancy; uncontrolled infection or sepsis; previous treatment with a surgi-
cal shunt, TIPS, or combined therapy with non-selective beta blockers + endoscopic band ligation;
contraindications to TIPS; pregnancy or breastfeeding; declining to participate or unable to give in-
formed consent
Baseline characteristics were comparable between study groups
Interventions TIPS group: an 8-mm covered stent (Fluency; Bard Peripheral Vascular, Tempe, AZ, USA) dilated to
8 mm
Control group: vasoactive drugs for up to 5 days. At day 6, propranolol was started at an initial
dose of 20 mg twice daily, then was titrated to reduce the resting heart rate by 25% but not be-
low 55 beats per minute. An elective session of endoscopic band ligation was done within 7 to 14
days after initial endoscopic treatment, then every 14 days (plus or minus 3 days) thereafter un-
til variceal eradication was achieved. Endoscopic band ligation was done with multi-band devices
(Wilson-Cook Medical; Winston-Salem, NC, USA). Once variceal eradication was achieved, monitor-
ing endoscopy was done every 6 months. Additional sessions of ligation were done if varices reap-
peared
In both groups, vasoactive drugs (octreotide, somatostatin, or terlipressin) or endoscopic band lig-
ation (sclerotherapy if technically difficult or not feasible) within 12 hours of admission and pro-
phylactic antibiotics were used to control the initial bleeding episode
Lv 2019  (Continued)
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Outcomes Primary endpoint: transplantation-free survival
Secondary endpoints: failure to control bleeding or rebleeding defined as per recommendations of
the Baveno V workshop; new or worsening ascites defined as an increase of ≥ 1 point in the ultra-
sound ascites score (0 = none, 1 = mild, 2 = moderate, 3 = massive) or sustained ascites up to a vol-
ume requiring paracentesis; overt hepatic encephalopathy, diagnosed and graded according to the
West Haven criteria; other complications of portal hypertension and adverse events
Notes This study is registered with ClinicalTrials.gov, number NCT01370161, and is completed.
Funding: National Natural Science Foundation of China, National Key Technology R&D Program,
Optimized Overall Project of Shaanxi Province, Boost Program of Xijing Hospital
This study is under evaluation, because in the title it is reported that it is:"A randomised controlled
trial comparing early-TIPS with covered stents versus standard treatment for acute variceal bleed-
ing in patients with advanced cirrhosis". But it is not clear if they treat only patients with a con-
trolled bleeding or not
Lv 2019  (Continued)
IQR: interquartile ratio.
NSBB: non-selective beta blocker.
TIPS: transjugular intrahepatic portosystemic shunt.
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name A randomised, controlled trial comparing 8 mm transjugular intrahepatic portosystemic shunt vs
endoscopic variceal ligation + propranolol for prevention of variceal rebleeding
Methods Study type: interventional
Study phase: not applicable
Study design: parallel assignment, open label
Estimated enrolment: 100 participants
Participants Inclusion criteria: cirrhosis, patients who have bled from oesophageal varices (≥ 5 days and ≤ 28
days), Child-Pugh B or Child-Pugh C ≤ 13
Exclusion criteria: gastric varices, non-cirrhotic portal hypertension, portal vein thrombosis, hepat-
ic encephalopathy, total bilirubin ≥ 51.3 μmol/L, previous treatment of TIPS or surgery, malignan-
cy including hepatocellular carcinoma, contraindications to TIPS, contraindications to EVL, con-
traindications to propranolol, renal replacement therapy, cardiorespiratory failure, pregnancy, pa-
tients not giving informed consent for endoscopic procedures
Interventions Active comparator: 8 mm TIPS
Patients in this group would have undergone TIPS placement with 8-mm-diameter ePTFE-covered
stents
Interventions:
Procedure: 8 mm TIPS
Device: 8 mm ePTFE-covered stent
Active comparator: EVL + propranolol
Patients in this group would have undergone sequential endoscopic variceal ligation and propra-
nolol treatment
Interventions:
Procedure: endoscopic variceal ligation
Drug: propranolol
Outcomes Primary outcome: variceal rebleeding rate (time frame: 3 years)
NCT02477384 
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Secondary outcomes: hepatic encephalopathy rate (time frame: 3 years), number of participants
with improving or worsening hepatic function (time frame: 3 years), TIPS dysfunction rate (time
frame: 3 years), incidence of complications (time frame: 3 years), number of participants with im-
proving or worsening quality of life (time frame: 3 years), mortality rate (time frame: 3 years)
Starting date June 2015
Contact information Luo Xuefeng, MD
West China Hospital




Study name Randomised, controlled trial comparing 8-mm TIPS vs endoscopic variceal ligation + propranolol
for prevention of variceal rebleeding in patients with Child's A cirrhosis
Methods Study type: interventional
Study phase: not applicable
Study design: parallel assignment, single masking (care provider)
Estimated enrolment: 72 participants
Participants Inclusion criteria: cirrhosis patients who had bled from oesophageal varices (≥ 5 days and ≤ 28
days), Child-Pugh A
Exclusion criteria: gastric varices; non-cirrhotic portal hypertension; portal vein thrombosis; hepat-
ic encephalopathy; total bilirubin ≥ 51.3 micromol/L; previous TIPS or surgery; malignancy includ-
ing hepatocellular carcinoma; contraindications to TIPS, EVL, or propranolol; renal replacement
therapy; cardiorespiratory failure; pregnancy; patients not giving informed consent for endoscopic
procedure
Interventions Active comparator: 8-mm TIPS




Active comparator: EVL + propranolol
Patients in this group would have undergone sequential endoscopic variceal ligation and propra-
nolol treatment
Interventions:
Procedure: endoscopic variceal ligation (EVL)
Drug: propranolol
Outcomes Primary outcome: variceal rebleeding rate (time frame: 3 years)
Secondary outcomes: hepatic encephalopathy rate (time frame: 3 years), TIPS dysfunction rate
(time frame: 3 years), incidence of complications (time frame: 3 years), mortality rate (time frame: 3
years)
Starting date 28 April 2017
Contact information Iuo Xuefeng, MD
West China Hospital
NCT03094234 
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Notes Estimated study completion date: 28 March 2020
NCT03094234  (Continued)
EVL: endoscopic variceal ligation.
PTFE: polytetrafluoroethylene.
TIPS: transjugular intrahepatic portosystemic shunt.
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Comparison 1.   Portosystemic shunts versus endoscopic intervention with or without medical treatment





Statistical method Effect size
1.1 All-cause mortality 27 1828 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.86, 1.13]
1.1.1 TS vs endoscopic interven-
tion
3 164 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.19, 1.13]
1.1.2 DSRS vs endoscopic interven-
tion
5 352 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.65, 1.33]
1.1.3 TIPS vs endoscopic interven-
tion
19 1312 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.92, 1.31]
1.2 Rebleeding 26 1769 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.33, 0.50]
1.2.1 TS vs endoscopic interven-
tion
2 127 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.14, 0.56]
1.2.2 DSRS vs endoscopic interven-
tion
5 330 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.11, 0.65]
1.2.3 TIPS vs endoscopic interven-
tion
19 1312 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.36, 0.55]
1.3 Mortality due to rebleeding 26 1779 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.34, 0.76]
1.3.1 TS vs endoscopic interven-
tion
3 164 Risk Ratio (M-H, Random, 95% CI) 0.25 [0.06, 0.96]
1.3.2 DSRS vs endoscopic interven-
tion
5 352 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.13, 0.74]
1.3.3 TIPS vs endoscopic interven-
tion
18 1263 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.40, 1.04]
1.4 Acute hepatic encephalopathy 24 1649 Risk Ratio (M-H, Random, 95% CI) 1.60 [1.33, 1.92]
1.4.1 TS vs endoscopic interven-
tion
2 115 Risk Ratio (M-H, Random, 95% CI) 1.66 [0.70, 3.92]
1.4.2 DSRS vs endoscopic interven-
tion
4 287 Risk Ratio (M-H, Random, 95% CI) 1.70 [0.94, 3.08]
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Statistical method Effect size
1.4.3 TIPS vs endoscopic interven-
tion
18 1247 Risk Ratio (M-H, Random, 95% CI) 1.61 [1.29, 1.99]
1.5 Chronic hepatic encephalopa-
thy
13 956 Risk Ratio (M-H, Random, 95% CI) 2.51 [1.38, 4.55]
1.5.1 TS vs endoscopic interven-
tion
1 69 Risk Ratio (M-H, Random, 95% CI) 7.20 [0.39, 134.36]
1.5.2 DSRS vs endoscopic interven-
tion
2 170 Risk Ratio (M-H, Random, 95% CI) 4.87 [1.46, 16.23]
1.5.3 TIPS vs endoscopic interven-
tion
10 717 Risk Ratio (M-H, Random, 95% CI) 1.88 [0.93, 3.80]
1.6 Rebleeding from all causes 26 1769 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.34, 0.52]
1.6.1 TS vs endoscopic interven-
tion
2 127 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.19, 0.61]
1.6.2 DSRS vs endoscopic interven-
tion
5 330 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.18, 0.68]
1.6.3 TIPS vs endoscopic interven-
tion
19 1312 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.35, 0.56]
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Analysis 1.1.   Comparison 1: Portosystemic shunts versus endoscopic
intervention with or without medical treatment, Outcome 1: All-cause mortality
Study or Subgroup






Heterogeneity: Tau² = 0.01; Chi² = 2.02, df = 2 (P = 0.36); I² = 1%
Test for overall effect: Z = 1.69 (P = 0.09)








Heterogeneity: Tau² = 0.08; Chi² = 9.04, df = 4 (P = 0.06); I² = 56%
Test for overall effect: Z = 0.39 (P = 0.70)






















Heterogeneity: Tau² = 0.00; Chi² = 10.52, df = 18 (P = 0.91); I² = 0%
Test for overall effect: Z = 1.07 (P = 0.28)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 26.81, df = 26 (P = 0.42); I² = 3%
Test for overall effect: Z = 0.17 (P = 0.86)




































































































































































M-H, Random, 95% CI
0.08 [0.00 , 1.37]
0.35 [0.04 , 3.08]
0.63 [0.22 , 1.75]
0.46 [0.19 , 1.13]
1.76 [1.02 , 3.04]
0.65 [0.43 , 0.98]
0.84 [0.63 , 1.11]
0.84 [0.44 , 1.59]
1.73 [0.18 , 16.99]
0.93 [0.65 , 1.33]
1.24 [0.42 , 3.64]
1.04 [0.47 , 2.33]
0.86 [0.33 , 2.24]
1.38 [0.43 , 4.40]
1.18 [0.70 , 2.00]
0.41 [0.12 , 1.35]
0.93 [0.26 , 3.34]
1.26 [0.61 , 2.62]
1.13 [0.60 , 2.15]
1.53 [0.75 , 3.12]
0.69 [0.38 , 1.23]
2.08 [0.72 , 6.02]
1.27 [0.55 , 2.97]
1.65 [0.72 , 3.82]
1.01 [0.60 , 1.71]
1.07 [0.43 , 2.66]
1.63 [0.72 , 3.71]
0.91 [0.49 , 1.69]
1.12 [0.44 , 2.80]
1.10 [0.92 , 1.31]
0.99 [0.86 , 1.13]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours shunts Favours endoscopy
Footnotes
(1) The data were double checked, and they are correct.
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Analysis 1.2.   Comparison 1: Portosystemic shunts versus endoscopic
intervention with or without medical treatment, Outcome 2: Rebleeding
Study or Subgroup





Heterogeneity: Tau² = 0.00; Chi² = 0.02, df = 1 (P = 0.90); I² = 0%
Test for overall effect: Z = 3.57 (P = 0.0004)








Heterogeneity: Tau² = 0.64; Chi² = 11.83, df = 4 (P = 0.02); I² = 66%
Test for overall effect: Z = 2.90 (P = 0.004)






















Heterogeneity: Tau² = 0.04; Chi² = 21.89, df = 18 (P = 0.24); I² = 18%
Test for overall effect: Z = 7.51 (P < 0.00001)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.09; Chi² = 36.19, df = 25 (P = 0.07); I² = 31%
Test for overall effect: Z = 8.35 (P < 0.00001)































































































































































M-H, Random, 95% CI
0.29 [0.11 , 0.77]
0.27 [0.10 , 0.74]
0.28 [0.14 , 0.56]
0.05 [0.01 , 0.34]
0.28 [0.12 , 0.65]
0.07 [0.01 , 0.52]
0.38 [0.17 , 0.87]
0.87 [0.32 , 2.34]
0.26 [0.11 , 0.65]
0.45 [0.22 , 0.94]
0.26 [0.08 , 0.81]
0.38 [0.11 , 1.27]
0.28 [0.03 , 2.26]
0.67 [0.41 , 1.11]
0.18 [0.05 , 0.72]
0.93 [0.38 , 2.29]
0.05 [0.00 , 0.74]
0.19 [0.06 , 0.58]
0.42 [0.21 , 0.83]
0.46 [0.26 , 0.84]
0.30 [0.11 , 0.78]
0.47 [0.22 , 1.00]
0.57 [0.25 , 1.27]
0.35 [0.18 , 0.68]
0.33 [0.17 , 0.64]
0.95 [0.45 , 2.03]
0.28 [0.13 , 0.62]
0.68 [0.29 , 1.63]
0.44 [0.36 , 0.55]
0.40 [0.33 , 0.50]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours shunts Favours endoscopy
Footnotes
(1) In Teres 1987, rebleeding is reported in participants followed-up for a long period. The total number is lower than that of the randomised participants and for whom mortality is reported.
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Analysis 1.3.   Comparison 1: Portosystemic shunts versus endoscopic intervention
with or without medical treatment, Outcome 3: Mortality due to rebleeding
Study or Subgroup






Heterogeneity: Tau² = 0.00; Chi² = 0.82, df = 2 (P = 0.66); I² = 0%
Test for overall effect: Z = 2.02 (P = 0.04)








Heterogeneity: Tau² = 0.00; Chi² = 1.51, df = 4 (P = 0.83); I² = 0%
Test for overall effect: Z = 2.64 (P = 0.008)





















Heterogeneity: Tau² = 0.00; Chi² = 14.37, df = 15 (P = 0.50); I² = 0%
Test for overall effect: Z = 1.79 (P = 0.07)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 20.05, df = 23 (P = 0.64); I² = 0%
Test for overall effect: Z = 3.31 (P = 0.0009)





























































































































































M-H, Random, 95% CI
0.08 [0.00 , 1.37]
0.35 [0.04 , 3.08]
0.33 [0.04 , 3.07]
0.25 [0.06 , 0.96]
0.35 [0.01 , 8.36]
0.13 [0.02 , 0.94]
0.20 [0.02 , 1.64]
0.48 [0.13 , 1.83]
0.43 [0.04 , 4.25]
0.31 [0.13 , 0.74]
0.15 [0.01 , 2.74]
1.00 [0.07 , 15.24]
Not estimable
1.18 [0.48 , 2.87]
0.08 [0.00 , 1.40]
0.46 [0.04 , 4.82]
Not estimable
0.10 [0.01 , 1.73]
0.35 [0.04 , 3.23]
0.32 [0.04 , 2.97]
0.69 [0.13 , 3.80]
1.13 [0.30 , 4.22]
0.35 [0.01 , 8.35]
0.14 [0.01 , 2.55]
0.21 [0.01 , 4.35]
1.59 [0.41 , 6.19]
0.09 [0.01 , 1.56]
0.49 [0.05 , 5.19]
0.65 [0.40 , 1.04]
0.51 [0.34 , 0.76]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours shunts Favours endoscopy
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Analysis 1.4.   Comparison 1: Portosystemic shunts versus endoscopic intervention
with or without medical treatment, Outcome 4: Acute hepatic encephalopathy
Study or Subgroup





Heterogeneity: Tau² = 0.00; Chi² = 0.28, df = 1 (P = 0.60); I² = 0%
Test for overall effect: Z = 1.15 (P = 0.25)







Heterogeneity: Tau² = 0.09; Chi² = 3.98, df = 3 (P = 0.26); I² = 25%
Test for overall effect: Z = 1.76 (P = 0.08)





















Heterogeneity: Tau² = 0.04; Chi² = 21.13, df = 17 (P = 0.22); I² = 20%
Test for overall effect: Z = 4.29 (P < 0.0001)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.02; Chi² = 25.48, df = 23 (P = 0.33); I² = 10%
Test for overall effect: Z = 4.99 (P < 0.00001)





















































































































































M-H, Random, 95% CI
2.82 [0.33 , 24.43]
1.50 [0.59 , 3.83]
1.66 [0.70 , 3.92]
1.40 [0.37 , 5.30]
0.88 [0.36 , 2.11]
2.60 [1.02 , 6.61]
2.86 [0.97 , 8.44]
1.70 [0.94 , 3.08]
2.58 [0.90 , 7.37]
1.14 [0.63 , 2.06]
2.40 [0.97 , 5.95]
1.52 [0.78 , 2.96]
0.91 [0.32 , 2.56]
1.86 [0.18 , 19.29]
1.66 [0.79 , 3.45]
1.45 [0.38 , 5.52]
9.51 [1.27 , 71.27]
0.91 [0.53 , 1.56]
2.08 [0.42 , 10.34]
2.38 [1.29 , 4.39]
2.11 [0.88 , 5.04]
0.89 [0.51 , 1.55]
1.95 [1.06 , 3.60]
2.28 [0.89 , 5.88]
3.58 [1.08 , 11.91]
1.84 [0.93 , 3.67]
1.61 [1.29 , 1.99]
1.60 [1.33 , 1.92]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours shunts Favours endoscopy
Footnotes
(1) In Isaksson 1995, encephalopathy was not evaluated in all randomised participants. The number of evaluated participants is lower than that reported for the other outcomes
(2) In Henderson 1990, there are no data on acute hepatic encephalopathy. The data on hepatic encephalopathy for this trial is reported in a previous report (Warren 1986), in which the number of participants treated was smaller than in the Henderson trial.
(3) In Teres encephalopaty is reported in participants followed-up for a long period. The total number is lower than that of randomised participants and for whom mortality is reported
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Analysis 1.5.   Comparison 1: Portosystemic shunts versus endoscopic intervention
with or without medical treatment, Outcome 5: Chronic hepatic encephalopathy
Study or Subgroup





Test for overall effect: Z = 1.32 (P = 0.19)





Heterogeneity: Tau² = 0.00; Chi² = 0.03, df = 1 (P = 0.86); I² = 0%
Test for overall effect: Z = 2.57 (P = 0.01)













Heterogeneity: Tau² = 0.00; Chi² = 3.43, df = 9 (P = 0.94); I² = 0%
Test for overall effect: Z = 1.75 (P = 0.08)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 5.81, df = 12 (P = 0.93); I² = 0%
Test for overall effect: Z = 3.02 (P = 0.003)






























































































M-H, Random, 95% CI
7.20 [0.39 , 134.36]
7.20 [0.39 , 134.36]
4.50 [1.04 , 19.54]
5.71 [0.70 , 46.98]
4.87 [1.46 , 16.23]
7.22 [0.39 , 134.25]
3.27 [0.37 , 29.18]
2.79 [0.12 , 65.66]
2.63 [0.11 , 61.88]
1.46 [0.26 , 8.23]
1.04 [0.16 , 6.81]
0.95 [0.14 , 6.43]
1.07 [0.15 , 7.33]
6.84 [0.36 , 128.37]
2.93 [0.32 , 27.06]
1.88 [0.93 , 3.80]
2.51 [1.38 , 4.55]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours shunts Favours endoscopy
Footnotes
(1) In Planas 1991, the authors excluded seven and six participants after randomisation respectively in the two groups. They report data on chronic hepatic encephalopathy only for the participants treated according to the randomisation.
(2) In Teres 14 and 4 participants were excluded after randomisation. The authors reported acute encephalopaty only in the participants treated according to the randomisation.They assessed chronic hepatic encephalopaty only in 42 participants randomised to shunts and in 48 participants randomized to endoscopy
(3) In Teres encephalopaty is reported in participants followed-up for a long period. The total number is lower than that of randomised participants and for whom mortality is reported
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Analysis 1.6.   Comparison 1: Portosystemic shunts versus endoscopic intervention
with or without medical treatment, Outcome 6: Rebleeding from all causes
Study or Subgroup





Heterogeneity: Tau² = 0.00; Chi² = 0.14, df = 1 (P = 0.71); I² = 0%
Test for overall effect: Z = 3.59 (P = 0.0003)








Heterogeneity: Tau² = 0.33; Chi² = 10.72, df = 4 (P = 0.03); I² = 63%
Test for overall effect: Z = 3.11 (P = 0.002)






















Heterogeneity: Tau² = 0.10; Chi² = 30.60, df = 18 (P = 0.03); I² = 41%
Test for overall effect: Z = 6.87 (P < 0.00001)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.11; Chi² = 42.95, df = 25 (P = 0.01); I² = 42%
Test for overall effect: Z = 8.28 (P < 0.00001)































































































































































M-H, Random, 95% CI
0.29 [0.11 , 0.77]
0.37 [0.17 , 0.78]
0.34 [0.19 , 0.61]
0.04 [0.01 , 0.31]
0.28 [0.12 , 0.65]
0.29 [0.13 , 0.63]
0.50 [0.28 , 0.89]
0.87 [0.32 , 2.34]
0.35 [0.18 , 0.68]
0.34 [0.17 , 0.69]
0.26 [0.08 , 0.81]
0.70 [0.31 , 1.59]
0.28 [0.03 , 2.26]
0.67 [0.41 , 1.11]
0.18 [0.05 , 0.72]
0.93 [0.38 , 2.29]
0.07 [0.01 , 0.53]
0.17 [0.06 , 0.54]
0.72 [0.45 , 1.15]
0.42 [0.24 , 0.76]
0.35 [0.15 , 0.81]
0.46 [0.24 , 0.88]
0.46 [0.21 , 0.99]
0.43 [0.27 , 0.68]
0.33 [0.17 , 0.64]
1.06 [0.48 , 2.32]
0.20 [0.09 , 0.43]
0.57 [0.25 , 1.31]
0.45 [0.35 , 0.56]
0.42 [0.34 , 0.52]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours shunts Favours endoscopy
Footnotes
(1) In Teres 1987, rebleeding from all causes is reported in participants followed-up for a long period. The total number is lower than that of the randomised participants and for whom mortality is reported.
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Comparison 2.   Portosystemic shunts versus endoscopic intervention with or without medical treatment regarding
funding





Statistical method Effect size
2.1 All-cause mortality 27 1828 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.86, 1.13]
2.1.1 Trials without for-profit funding 11 754 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.85, 1.49]
2.1.2 Trials with for-profit funding or
unknown
16 1074 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.78, 1.10]
2.2 Rebleeding 26 1769 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.33, 0.50]
2.2.1 Trials without for-profit funding 11 732 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.25, 0.51]
2.2.2 Trials with for-profit funding or
unknown
15 1037 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.33, 0.58]
2.3 Mortality due to rebleeding 26 1779 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.34, 0.76]
2.3.1 Trials without for-profit funding 10 705 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.23, 0.86]
2.3.2 Trials with for-profit funding or
unknown
16 1074 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.33, 0.91]
2.4 Acute hepatic encephalopathy 24 1649 Risk Ratio (M-H, Random, 95% CI) 1.60 [1.33, 1.92]
2.4.1 Trials without for-profit funding 11 705 Risk Ratio (M-H, Random, 95% CI) 1.52 [1.09, 2.12]
2.4.2 Trials with for-profit funding or
unknown
13 944 Risk Ratio (M-H, Random, 95% CI) 1.69 [1.36, 2.11]
2.5 Chronic hepatic encephalopathy 13 956 Risk Ratio (M-H, Random, 95% CI) 2.51 [1.38, 4.55]
2.5.1 Trials without for-profit funding 4 282 Risk Ratio (M-H, Random, 95% CI) 2.00 [0.70, 5.73]
2.5.2 Trials with for-profit funding or
unknown
9 674 Risk Ratio (M-H, Random, 95% CI) 2.79 [1.35, 5.75]
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Analysis 2.1.   Comparison 2: Portosystemic shunts versus endoscopic intervention
with or without medical treatment regarding funding, Outcome 1: All-cause mortality
Study or Subgroup














Heterogeneity: Tau² = 0.08; Chi² = 16.46, df = 10 (P = 0.09); I² = 39%
Test for overall effect: Z = 0.82 (P = 0.41)



















Heterogeneity: Tau² = 0.00; Chi² = 9.25, df = 15 (P = 0.86); I² = 0%
Test for overall effect: Z = 0.87 (P = 0.38)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 26.81, df = 26 (P = 0.42); I² = 3%
Test for overall effect: Z = 0.17 (P = 0.86)































































































































































M-H, Random, 95% CI
1.24 [0.42 , 3.64]
1.04 [0.47 , 2.33]
1.76 [1.02 , 3.04]
1.26 [0.61 , 2.62]
0.08 [0.00 , 1.37]
1.53 [0.75 , 3.12]
2.08 [0.72 , 6.02]
1.01 [0.60 , 1.71]
0.65 [0.43 , 0.98]
1.63 [0.72 , 3.71]
0.84 [0.44 , 1.59]
1.12 [0.85 , 1.49]
0.86 [0.33 , 2.24]
1.38 [0.43 , 4.40]
1.18 [0.70 , 2.00]
0.41 [0.12 , 1.35]
0.93 [0.26 , 3.34]
1.13 [0.60 , 2.15]
0.35 [0.04 , 3.08]
0.69 [0.38 , 1.23]
1.27 [0.55 , 2.97]
1.65 [0.72 , 3.82]
0.63 [0.22 , 1.75]
1.07 [0.43 , 2.66]
0.84 [0.63 , 1.11]
0.91 [0.49 , 1.69]
1.12 [0.44 , 2.80]
1.73 [0.18 , 16.99]
0.93 [0.78 , 1.10]
0.99 [0.86 , 1.13]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours shunts Favours endoscopy
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Analysis 2.2.   Comparison 2: Portosystemic shunts versus endoscopic intervention
with or without medical treatment regarding funding, Outcome 2: Rebleeding
Study or Subgroup














Heterogeneity: Tau² = 0.12; Chi² = 15.92, df = 10 (P = 0.10); I² = 37%
Test for overall effect: Z = 5.70 (P < 0.00001)


















Heterogeneity: Tau² = 0.08; Chi² = 19.70, df = 14 (P = 0.14); I² = 29%
Test for overall effect: Z = 5.90 (P < 0.00001)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.09; Chi² = 36.98, df = 25 (P = 0.06); I² = 32%
Test for overall effect: Z = 8.22 (P < 0.00001)


























































































































































M-H, Random, 95% CI
0.45 [0.22 , 0.94]
0.26 [0.08 , 0.81]
0.05 [0.01 , 0.34]
0.05 [0.00 , 0.74]
0.29 [0.11 , 0.77]
0.42 [0.21 , 0.83]
0.30 [0.11 , 0.78]
0.35 [0.18 , 0.68]
0.28 [0.12 , 0.65]
1.06 [0.48 , 2.32]
0.38 [0.17 , 0.87]
0.36 [0.25 , 0.51]
0.38 [0.11 , 1.27]
0.28 [0.03 , 2.26]
0.67 [0.41 , 1.11]
0.18 [0.05 , 0.72]
0.93 [0.38 , 2.29]
0.19 [0.06 , 0.58]
0.46 [0.26 , 0.84]
0.47 [0.22 , 1.00]
0.57 [0.25 , 1.27]
0.27 [0.10 , 0.74]
0.33 [0.17 , 0.64]
0.07 [0.01 , 0.52]
0.28 [0.13 , 0.62]
0.68 [0.29 , 1.63]
0.87 [0.32 , 2.34]
0.44 [0.33 , 0.58]
0.40 [0.33 , 0.50]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours shunts Favours endoscopy
Footnotes
(1) In Teres 1987, rebleeding is reported in participants followed-up for a long period. The total number is lower than that of the randomised participants and for whom mortality is reported.
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Analysis 2.3.   Comparison 2: Portosystemic shunts versus endoscopic intervention with
or without medical treatment regarding funding, Outcome 3: Mortality due to rebleeding
Study or Subgroup













Heterogeneity: Tau² = 0.01; Chi² = 8.11, df = 8 (P = 0.42); I² = 1%
Test for overall effect: Z = 2.40 (P = 0.02)



















Heterogeneity: Tau² = 0.00; Chi² = 11.67, df = 14 (P = 0.63); I² = 0%
Test for overall effect: Z = 2.32 (P = 0.02)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 20.05, df = 23 (P = 0.64); I² = 0%
Test for overall effect: Z = 3.31 (P = 0.0009)
























































































































































M-H, Random, 95% CI
0.15 [0.01 , 2.74]
0.35 [0.01 , 8.36]
Not estimable
0.08 [0.00 , 1.37]
0.35 [0.04 , 3.23]
0.69 [0.13 , 3.80]
0.14 [0.01 , 2.55]
0.13 [0.02 , 0.94]
1.59 [0.41 , 6.19]
0.48 [0.13 , 1.83]
0.45 [0.23 , 0.86]
1.00 [0.07 , 15.24]
Not estimable
1.18 [0.48 , 2.87]
0.08 [0.00 , 1.40]
0.46 [0.04 , 4.82]
0.10 [0.01 , 1.73]
0.35 [0.04 , 3.08]
0.32 [0.04 , 2.97]
1.13 [0.30 , 4.22]
0.35 [0.01 , 8.35]
0.33 [0.04 , 3.07]
0.21 [0.01 , 4.35]
0.20 [0.02 , 1.64]
0.09 [0.01 , 1.56]
0.49 [0.05 , 5.19]
0.43 [0.04 , 4.25]
0.55 [0.33 , 0.91]
0.51 [0.34 , 0.76]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours shunts Favours endoscopy
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Analysis 2.4.   Comparison 2: Portosystemic shunts versus endoscopic intervention with or
without medical treatment regarding funding, Outcome 4: Acute hepatic encephalopathy
Study or Subgroup














Heterogeneity: Tau² = 0.07; Chi² = 13.18, df = 10 (P = 0.21); I² = 24%
Test for overall effect: Z = 2.46 (P = 0.01)
















Heterogeneity: Tau² = 0.00; Chi² = 11.46, df = 12 (P = 0.49); I² = 0%
Test for overall effect: Z = 4.66 (P < 0.00001)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.02; Chi² = 25.48, df = 23 (P = 0.33); I² = 10%
Test for overall effect: Z = 4.99 (P < 0.00001)
















































































































































M-H, Random, 95% CI
2.58 [0.90 , 7.37]
1.14 [0.63 , 2.06]
1.40 [0.37 , 5.30]
1.66 [0.79 , 3.45]
2.82 [0.33 , 24.43]
9.51 [1.27 , 71.27]
2.08 [0.42 , 10.34]
0.89 [0.51 , 1.55]
0.88 [0.36 , 2.11]
2.28 [0.89 , 5.88]
2.86 [0.97 , 8.44]
1.52 [1.09 , 2.12]
2.40 [0.97 , 5.95]
1.52 [0.78 , 2.96]
0.91 [0.32 , 2.56]
1.86 [0.18 , 19.29]
1.45 [0.38 , 5.52]
0.91 [0.53 , 1.56]
2.38 [1.29 , 4.39]
2.11 [0.88 , 5.04]
1.50 [0.59 , 3.83]
1.95 [1.06 , 3.60]
2.60 [1.02 , 6.61]
3.58 [1.08 , 11.91]
1.84 [0.93 , 3.67]
1.69 [1.36 , 2.11]
1.60 [1.33 , 1.92]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours shunts Favours endoscopy
Footnotes
(1) In Henderson 1990, there are no data on acute hepatic encephalopathy. The data on hepatic encephalopathy for this trial is reported in a previous report (Warren 1986), in which the number of participants treated was smaller than in the Henderson trial.
(2) In Isaksson, encephalopathy was evaluated not in all randomised participants. The number of the evaluated participants is lower than that reported for the other outcomes.
(3) In Teres encephalopaty is reported in participants followed-up for a long period. The total number is lower than that of randomised participants and for whom mortality is reported
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
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Analysis 2.5.   Comparison 2: Portosystemic shunts versus endoscopic intervention with or
without medical treatment regarding funding, Outcome 5: Chronic hepatic encephalopathy
Study or Subgroup







Heterogeneity: Tau² = 0.00; Chi² = 2.84, df = 3 (P = 0.42); I² = 0%
Test for overall effect: Z = 1.29 (P = 0.20)












Heterogeneity: Tau² = 0.00; Chi² = 2.73, df = 8 (P = 0.95); I² = 0%
Test for overall effect: Z = 2.78 (P = 0.005)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 5.81, df = 12 (P = 0.93); I² = 0%
Test for overall effect: Z = 3.02 (P = 0.003)

























































































M-H, Random, 95% CI
7.22 [0.39 , 134.25]
1.04 [0.16 , 6.81]
0.95 [0.14 , 6.43]
5.71 [0.70 , 46.98]
2.00 [0.70 , 5.73]
3.27 [0.37 , 29.18]
2.79 [0.12 , 65.66]
2.63 [0.11 , 61.88]
1.46 [0.26 , 8.23]
7.20 [0.39 , 134.36]
1.07 [0.15 , 7.33]
4.50 [1.04 , 19.54]
6.84 [0.36 , 128.37]
2.93 [0.32 , 27.06]
2.79 [1.35 , 5.75]
2.51 [1.38 , 4.55]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours shunts Favours endoscopy
Footnotes
(1) In Teres 1987, encephalopathy is reported in participants followed-up for a long period. The total number is lower than that of the randomised participants and for whom mortality is reported.
(2) In Planas, the authors excluded seven and six participants after randomisation respectively in the two groups.. They report data on chronic hepatic encephalopathy only for the participants treated according to the randomisation
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Comparison of imprecision by GRADE based on the GRADE Handbook, with GRADE based on our choice of plausible relative risk reduction (RRR) and multiplicity
correction, and according to our Trial Sequential Analysis (TSA) based on our similar choice of plausible relative risk reduction and multiplicity correction while al-















All-cause mortality - GRADE Handbook 28.8% 25% 5% 20% Not used 1140 Not
down-
graded
All-cause mortality - GRADE plausible RRR 28.8% 10% 2.5% 20% Not used 9108 Down-
graded
1 level




Rebleeding - GRADE Handbook 43.2% 25% 5% 20% Not used 632 Not
down-
graded
Rebleeding - GRADE plausible RRR 43.2% 20% 2.5% 20% Not used 1208 Not
down-
graded
Rebleeding - GRADE plausible RRR 43.2% 40% 2.5% 20% Not used 286 Not
down-
graded




Table 1.   Comparison of imprecision by GRADE and Trial Sequential Analysis (TSA) in the comparison of portosystemic shunts versus endoscopic


















































































































































































Health-related quality of life - GRADE Handbook No data
Health-related quality of life - GRADE plausible RRR No data
Health-related quality of life - TSA No data
Mortality due to rebleeding - GRADE Handbook 9.5% 25% 5% 20% Not used 4222 Down-
graded
1 level
Mortality due to rebleeding - GRADE plausible RRR 9.5% 20% 1.4% 20% Not used 9426 Down-
graded
1 level
Mortality due to rebleeding - GRADE plausible RRR 9.5% 40% 1.4% 20% Not used 2116 Down-
graded
1 level








Acute hepatic encephalopathy - GRADE Handbook 18.5% 25% 5% 20% Not used 1986 Down-
grade 1
level
Acute hepatic encephalopathy - GRADE plausible RRR 18.5% 20% 1.4% 20% Not used 4410 Down-
grade 1
level
Table 1.   Comparison of imprecision by GRADE and Trial Sequential Analysis (TSA) in the comparison of portosystemic shunts versus endoscopic














































































































































































Acute hepatic encephalopathy - GRADE plausible RRR 18.5% 40% 1.4% 20% Not used 972 Not
down-
graded
Acute hepatic encephalopathy - TSA 18.5% 20% 1.4% 20% 14% 5108 Not
down-
gradedd
Acute hepatic encephalopathy - TSA 18.5% 40% 1.4% 20% 14% 1160 Not
down-
gradedd
Chronic hepatic encephalopathy - GRADE Handbook 2.7% 25% 5% 20% Not used 15,644 Down-
graded
1 level
Chronic hepatic encephalopathy - GRADE plausible RRR 2.7% 20% 1.4% 20% Not used 35,392 Down-
graded
1 level
Chronic hepatic encephalopathy - GRADE plausible RRR 2.7% 40% 1.4% 20% Not used 7886 Down-
graded
1 level








Table 1.   Comparison of imprecision by GRADE and Trial Sequential Analysis (TSA) in the comparison of portosystemic shunts versus endoscopic
intervention with or without medical therapy for prevention of rebleeding in patients with cirrhosis  (Continued)
aThe Z-curve did not reach 50% of the diversity-adjusted required information size and did not cross any of the sequential boundaries for benefit, harm, or futility.
bThe Z-curve reached the monitoring boundary for benefit.
cThe Z-curve reached the monitoring boundary for futility.
dThe Z- curve reached the monitoring boundary for harm.




































































Cochrane Database of Systematic Reviews
 




Other reported shunt compli-
cations or adverse eventsa
Other reported endoscopic or med-










centage and 95% CI
4.2%, 0.7% to 20%)













surgery or at the




and 95% CI 2.4%,
0.4% to 13%)
Bleeding from lesions other
than oesophageal or gastric
varices 3 patients
Other complications 7 patients
(wound abscess 2, sepsis 1,
pneumonia 2, chylous pleural
effusion 1, cholestasis 1)
Bleeding from lesions other than oe-
sophageal or gastric varices 4 patients
Other complications 12 patients (deep
oesophageal ulcers 3, stenosis 1, pneu-
monia 1, transient dysphagia 4, fever 2,
pleural effusion 1)
Table 2.   Total shunt versus endoscopic intervention: shunt surveillance and complications 












Other reported endoscopic or medical thera-





Insufficient information Bleeding from deep oesophageal ulcers 2 pa-
tients
Insufficient information on other complica-
















day, then at 1, 3, and 6
months after discharge,













Bleeding from oesophageal ulcers 5 patients
Bleeding from unknown sources 2 patients
Dyspagia due to oesophageal ulcers 8 patients
Oesophageal stenosis 5 patients
Pleural effusion 1 patient
Ascites 19 patients
Liver failure 1 patient
Table 3.   Distal splenorenal shunt versus endoscopic intervention: shunt surveillance and complications 
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
cirrhosis (Review)
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Terés 1987 Angiography, ultra-
sound, and/or isotopic
splenoportography 7 to
10 months after surgery











other than varices (peptic
ulcers or gastritis) 5 pa-
tients
Bleeding from sources other than varices (pep-
tic ulcers or gastritis) 7 patients
Oesophageal ulcers 2 patients
Oesophageal stenosis 3 patients





Insufficient information Insufficient information
Table 3.   Distal splenorenal shunt versus endoscopic intervention: shunt surveillance and complications  (Continued)













Other reported shunt complica-
tions or adverse eventsa
Other reported endoscopic or
























Complications 7 patients (portal
vein thrombosis 2, spontaneous
bacterial peritonitis 2, haemobilia
1, sepsis 1, pneumonia 2, conges-
tive heart failure 2)
Complications 11 patients (bleeding
oesophageal ulcers 5, oesophageal
stenosis 4, pneumonia 2, sepsis 1,






































No technical failures or major
complications of the TIPSS proce-
dure




Portal hypertensive gastropathy 1
Seizure 2, fractured bone 3, celluli-
tis 1, arrhythmia 1, urinary tract in-
fection 1, alcohol hepatitis 1, leN
ventricular thrombus 1, pneumo-
nia 2, spontaneous bacterial peri-
tonitis 1, spontaneous retroperi-
No information on procedure-relat-
ed complications




Fractured bone 2, arrhythmia 1, ab-
scess 1, compartment syndrome
1, urinary tract infection 1, alcohol
hepatitis 2, spontaneous bacterial
peritonitis 2
Table 4.   Transjugular intrahepatic portosystemic shunt versus endoscopic intervention with and without medical
treatments: shunt surveillance and complications 
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
cirrhosis (Review)
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Insufficient information Chest discomfort almost all patients
Oesophageal ulcer 5 patients





























Perforation of liver capsule with
peritoneal haemorrhage (death) 1
patient




























Severe adverse events 24
Number of complications or ad-
verse eventsc:
Bleeding from banding ulcer 1







Acute-on-chronic liver failure 4
Severe adverse events 24 patients
Number of complications or adverse
eventsc:
Bleeding from banding ulcer 2
Bleeding from other upper gastroin-
testinal sources 1
Intra-abdominal bleeding from col-
laterals 1
Laceration of hepatic artery (during
TIPS placement) 1
Ascites 13
Spontaneous bacterial peritonitis 3
Table 4.   Transjugular intrahepatic portosystemic shunt versus endoscopic intervention with and without medical
treatments: shunt surveillance and complications  (Continued)
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
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Sepsis 3 patients (aspiration pneu-
monia 1 patient, staphylococcal
septicaemia 2 patients)
Perforation of liver capsule 1 pa-
tient
Respiratory depression caused by
sedation 1 patient
Oesophageal ulcer 12 patients
Bleeding from oesophageal ulcer 1
patient
Aspiration pneumonia 2 patients
Sepsis 4 patients (aspiration pneu-
monia 2 patients, spontaneous bac-
terial peritonitis 1 patient, central


















Hepatic failure 2 patients




Refractory ulcer on gastric varices 3
patients
Bacteraemia 10 patients
Spontaneous bacterial peritonitis 1
patient
Bleeding from peptic ulcer 1 patient

























No 'major' complications Transient retrosternal pain 11 pa-
tients




Table 4.   Transjugular intrahepatic portosystemic shunt versus endoscopic intervention with and without medical
treatments: shunt surveillance and complications  (Continued)
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Number of patients with complica-













Mispuncture of bile duct 1
Number of patients with complica-




Spontaneous bacterial peritonitis 1
Hepatorenal syndrome 1
Hepatocellular carcinoma 1
Bleeding from banding ulcer 1
Dysphagia 3
Deep venous thrombosis 1
Oesophageal stenosis 1
Haematuria 1

































Intrahepatic haematoma 1 patient
Cardiac arrest 1 patient
Pulmonary embolism 1 patient
Sclerotherapy-induced ulcer 2 pa-
tients
Oesophageal stenosis 2 patients
Aspiration pneumonia 1 patient





























Transient pleural effusion 6 patients
Bleeding ulcer secondary to scle-
rotherapy 3 patients
Oesophageal stenosis 1 patient
Table 4.   Transjugular intrahepatic portosystemic shunt versus endoscopic intervention with and without medical
treatments: shunt surveillance and complications  (Continued)
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
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Causes of non-variceal gastroin-
testinal rebleedingb:






No information on other complica-
tions or adverse events
Bleeding from non-variceal sources
9 patients
Causes of non-variceal gastrointesti-
nal rebleedingb:
Oesophageal ulcer due to ligation 7
Mallory-Weiss 2
Oesophagitis 2
No information on other complica-



















sound at 1, 3,



















Transient abdominal pain 6 pa-
tients
Bradyarrhytmia due to stent mi-
gration into the right ventricle re-




Hypopyon with eye enucleation







sound at day 1,










Haemolysis TIPS-associated 5 pa-
tients (severe in 1 patient)
Sepsis 6 patients
Renal failure 1 patient
Chest discomfort
Oesophageal ulcer 22 patients





Renal failure 2 patients
Table 4.   Transjugular intrahepatic portosystemic shunt versus endoscopic intervention with and without medical
treatments: shunt surveillance and complications  (Continued)
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Study authors did not report num-
ber of patients with adverse events






Study authors did not report num-
ber of patients with adverse events









































Post-therapeutic haemorrhage 2 pa-
tients
Severe side effects (type non-speci-
fied) propranolol-related 2 patients
Table 4.   Transjugular intrahepatic portosystemic shunt versus endoscopic intervention with and without medical
treatments: shunt surveillance and complications  (Continued)
aAcute hepatic encephalopathy, chronic hepatic encephalopathy, mortality, and shunt dysfunction not included, as reported elsewhere
in this review.
bData for other complications and adverse events were extracted as numbers of events across all time points (< 2 years and ≥ 2 years
combined).cData for other complications and adverse events were extracted as numbers of adverse events across all time points (< 6
months and > 2 months until end of follow-up combined).






















Index hospitalisation for treatment 34.9 (14.1) 22.3 (7.1) 0.0001
Table 5.   Duration of hospital stay 
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
cirrhosis (Review)
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Total hospitalisation due to treatment or complications during
follow-up
41.2 (13.1) 38.1 (12.2) NS
Isaksson
1995
Total hospital stay including operation and readmission
ICU stay
34.5 (9 to 122)
4 (0 to 41)
33 (15 to 64)
3.3 (0 to 16)
NS
NS
Distal splenorenal shunt (DSRS)
Terés 1987 Index hospitalisation for treatment
Hospital stay for treatment of rebleeding and encephalopathy
(shunt group)/treatment of rebleeding and sclerosis (sclerother-
apy group) during follow-up










Transjugular intrahepatic portosystemic shunt (TIPS)
Cabrera
1996
Index hospitalisation for treatment
Hospitalisation for rebleeding










Cello 1997 Hospitalisation for variceal rebleeding
Hospitalisation for any rebleeding













Hospitalisation for any reason after initial discharge


































Index hospitalisation (after randomisation) 27 (17) 34 (28) NS
Sauer
2002
Hospital stays per patient per year 34.1 (30.2) 19.8 (21.9) < 0.05
Lo 2007 Index hospitalisation 7.2 (5.3) 8.7 (6.5) NS
Holster
2016
Index hospitalisation 12.4 (11.2) 8.8 (5.4) 0.095
Table 5.   Duration of hospital stay  (Continued)
Data for length of hospital stay have been presented in a narrative/tabular format due to variation in time points measured between studies
and resultant substantial heterogeneity.
Results are given as mean and SE.
ICU: intensive care unit.
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
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NS: not statistically significant.
 
 


















Hospital costs included laboratory and X-ray examinations, transfusions,
drugs, graNs, hotel service, endoscopy investigations and treatment, and costs














Distal splenorenal shunt (DSRS)
Rikkers
1993
Both initial and total medical costs for each therapy were calculated and com-
pared. Initial medical costs were defined as those incurred during the hospi-
talisation in which shunt surgery was performed or sclerotherapy initiated.
Total costs included initial hospitalisation, all subsequent hospitalisations re-
quired for treatment of recurrent haemorrhage and complications of therapy
or chronic liver disease, and outpatient endoscopic evaluation with or without
variceal sclerosis. Analysis included only patients treated at University hospi-
tals.
Data from Rikkers LF, Burnett DA, Volentine GD, Buchi KN, Cormier RA. Shunt
surgery vs endoscopic sclerotherapy for long-term treatment of variceal bleed-























Transjugular intrahepatic portosystemic shunt (TIPS)
Cello 1997 Total cost of health care per patient calculated as the sum of all real costs for
inpatient and outpatient hospital care, including hospital expenditures and
costs for professional services, and all outpatient costs for endoscopic scle-
rotherapy, doppler ultrasonography, and stent revision from day of randomi-



































Table 6.   Cost of treatment: shunt versus endoscopic intervention with or without medical treatment 
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
cirrhosis (Review)
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Holster
2016
Costs for admissions, consultations, initial treatment, imaging, diagnostics,
transfusions, medications in the first year
Abstract only: Harki J, Holster IL, Polinder S, Moelker A, van Buuren HR,
Kuipers EJ, et al. Cost effectiveness of covered transjugular intrahepatic por-
tosystemic shunt vs endoscopic treatment for secondary prevention of gas-









Table 6.   Cost of treatment: shunt versus endoscopic intervention with or without medical treatment  (Continued)
SD: standard deviation.
SE: standard error.
SEM: standard error of the mean.
 
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
cirrhosis (Review)




















































































































Comparison of imprecision evaluation with GRADE based on the GRADE Handbook, with GRADE based on our choice of plausible relative risk reduction (RRR) and
multiplicity correction, and according to our Trial Sequential Analysis (TSA) based on our similar choice of plausible relative risk reduction and multiplicity correc-










































Table 7.   Comparison of imprecision by GRADE and Trial Sequential Analysis (TSA) in the comparison of total shunt (TS) versus endoscopic




































































































































































































Health-related quality of life - GRADE Handbook No data
Health-related quality of life - GRADE plausible RRR No data
Health-related quality of life - TSA No data










Table 7.   Comparison of imprecision by GRADE and Trial Sequential Analysis (TSA) in the comparison of total shunt (TS) versus endoscopic


















































































































































































































Table 7.   Comparison of imprecision by GRADE and Trial Sequential Analysis (TSA) in the comparison of total shunt (TS) versus endoscopic




























































































































































































Chronic hepatic encephalopathy - GRADE Handbookd
Chronic hepatic encephalopathy - GRADE plausible RRRd
Chronic hepatic encephalopathy - GRADE plausible RRRd
Chronic hepatic encephalopathy - TSAd
Chronic hepatic encephalopathy - TSAd
 
Table 7.   Comparison of imprecision by GRADE and Trial Sequential Analysis (TSA) in the comparison of total shunt (TS) versus endoscopic
intervention for prevention of rebleeding in people with cirrhosis  (Continued)
aThe TSA curve was not constructed due to too little information.
bThe Z-curve did not did not reach 50% of the diversity-adjusted required information size and did not cross any of the sequential boundaries for benefit, harm, or futility.
cThe Z-curve reached the monitoring boundary for benefit.
dThere was a single trial with 3/34 events in the TS group and 0/35 in the endoscopy with or without drugs group.
 
 
Comparison of imprecision evaluation with GRADE based on the GRADE Handbook, with GRADE based on our choice of plausible relative risk reduction (RRR) and
multiplicity correction, and according to our Trial Sequential Analysis (TSA) based on our similar choice of plausible relative risk reduction and multiplicity correc-









Table 8.   Comparison of imprecision by GRADE and Trial Sequential Analysis in the comparison of DSRS versus endoscopic intervention for prevention

















































































































































































All-cause mortality - GRADE Handbook 46.8% 25% 5% 20% Not used 554 Down-
graded 1
level
All-cause mortality - GRADE plausible RRR 46.8% 10% 2.5% 20% Not used 4284 Down-
graded 1
level
All-cause mortality - TSA 46.8% 10% 2.5% 20% 68% 13,538 Down-
graded 2
levelsa
Rebleeding - GRADE Handbook 45.8% 25% 5% 20% Not used 574 Down-
graded 1
level
Rebleeding - GRADE plausible RRR 45.8% 20% 2.5% 20% Not used 1096 Down-
graded 1
level
Rebleeding - GRADE plausible RRR 45.8% 40% 2.5% 20% Not used 262 Not down-
graded
Rebleeding - TSA 45.8% 20% 2.5% 20% 72% 3878 Down-
graded 2
levelsb
Rebleeding - TSA 45.8% 40% 2.5% 20% 72% 928 Down-
graded 2
levelsb
Health-related quality of life - GRADE Handbook No data
Health-related quality of life - GRADE plausible RRR No data
Health-related quality of life - TSA No data
Table 8.   Comparison of imprecision by GRADE and Trial Sequential Analysis in the comparison of DSRS versus endoscopic intervention for prevention














































































































































































Mortality due to rebleeding - GRADE Handbook 12.6% 25% 5% 20% Not used 3102 Down-
graded 1
level
Mortality due to rebleeding - GRADE plausible RRR 12.6% 20% 1.4% 20% Not used 6890 Down-
graded 1
level
Mortality due to rebleeding - GRADE plausible RRR 12.6% 40% 1.4% 20% Not used 1552 Down-
graded 1
level
Mortality due to rebleeding - TSA 12.6% 20% 1.4% 20% 0% 6892 Down-
graded 2
levelsb
Mortality due to rebleeding - TSA 12.6% 40% 1.4% 20% 0% 1554 Down-
graded 2
levelsb
Acute hepatic encephalopathy - GRADE Handbook 13.9% 25% 5% 20% Not used 2768 Down-
graded 1
level
Acute hepatic encephalopathy - GRADE plausible
RRR
13.9% 20% 1.4% 20% Not used 6164 Down-
graded 1
level
Acute hepatic encephalopathy - GRADE plausible
RRR
13.9% 40% 1.4% 20% Not used 1390 Down-
graded 1
level
Acute hepatic encephalopathy - TSA 13.9% 20% 1.4% 20% 26% 8382 Down-
graded 2
levelsa
Acute hepatic encephalopathy - TSA 13.9% 40% 1.4% 20% 26% 1892 Down-
graded 2
levelsb
Table 8.   Comparison of imprecision by GRADE and Trial Sequential Analysis in the comparison of DSRS versus endoscopic intervention for prevention














































































































































































Chronic hepatic encephalopathy - GRADE Handbook 3.4% 25% 5% 20% Not used 12,542 Down-
graded 2
levels
Chronic hepatic encephalopathy - GRADE plausible
RRR
3.4% 20% 1.4% 20% Not used 27,924 Down-
graded 2
levels
Chronic hepatic encephalopathy - GRADE plausible
RRR
3.4% 40% 1.4% 20% Not used 6226 Down-
graded 2
levels
Chronic hepatic encephalopathy - TSA 3.4% 20% 1.4% 20% 0% 27,926 Down-
graded 2
levelsa
Chronic hepatic encephalopathy - TSA 3.4% 40% 1.4% 20% 0% 6228 Down-
graded 2
levelsa
Table 8.   Comparison of imprecision by GRADE and Trial Sequential Analysis in the comparison of DSRS versus endoscopic intervention for prevention
of rebleeding in people with cirrhosis  (Continued)
aThe TSA curve was not constructed due to too little information.
bThe Z-curve did not did not reach 50% of the diversity-adjusted required information size and did not cross any of the sequential boundaries for benefit, harm, or futility.
 
 
Comparison of imprecision evaluation with GRADE based on the GRADE Handbook, with GRADE based on our choice of plausible relative risk reduction (RRR) and
multiplicity correction, and according to our Trial Sequential Analysis (TSA) based on our similar choice of plausible relative risk reduction and multiplicity correc-














All-cause mortality - GRADE Handbook 25.2% 25% 5% 20% Not used 1358 Down-
graded 1
level
Table 9.   Comparison of imprecision by GRADE and Trial Sequential Analysis in the comparison of TIPS versus endoscopic intervention with or














































































































































































All-cause mortality - GRADE plausible RRR 25.2% 10% 2.5% 20% Not used 10,900 Down-
graded 1
level
All-cause mortality - TSA 25.2% 10% 2.5% 20% 0% 10,902 Down-
graded 2
levelsa
Rebleeding - GRADE Handbook 42.5% 25% 5% 20% Not used 648 Not
down-
graded
Rebleeding - GRADE plausible RRR 42.5% 20% 2.5% 20% Not used 1242 Not
down-
graded
Rebleeding - GRADE plausible RRR 42.5% 40% 2.5% 20% Not used 294 Not
down-
graded
Rebleeding - TSA 42.5% 20% 2.5% 20% 16% 1474 Not
down-
gradedb
Rebleeding - TSA 42.5% 40% 2.5% 20% 16% 351 Not
down-
gradedb
Health-related quality of life - GRADE Handbook No data
Health-related quality of life - GRADE plausible RRR No data
Health-related quality of life - TSA No data
Mortality due to rebleeding - GRADE Handbook 8.2% 25% 5% 20% Not used 4974 Down-
graded 1
level
Mortality due to rebleeding - GRADE plausible RRR 8.2% 20% 1.4% 20% Not used 11,062 Down-
graded 1
level
Table 9.   Comparison of imprecision by GRADE and Trial Sequential Analysis in the comparison of TIPS versus endoscopic intervention with or














































































































































































Mortality due to rebleeding - GRADE plausible RRR 8.2% 40% 1.4% 20% Not used 2478 Down-
graded 1
level
Mortality due to rebleeding - TSA 8.2% 20% 1.4% 20% 0% 11,063 Down-
graded 2
levelsa
Mortality due to rebleeding - TSA 8.2% 40% 1.4% 20% 0% 2481 Not
down-
gradedc
Acute hepatic encephalopathy - GRADE Handbook 20.1% 25% 5% 20% Not used 1798 Down-
graded 1
level
Acute hepatic encephalopathy - GRADE plausible RRR 20.1% 20% 1.4% 20% Not used 3990 Down-
graded 1
level
Acute hepatic encephalopathy - GRADE plausible RRR 20.1% 40% 1.4% 20% Not used 906 Not
down-
graded
Acute hepatic encephalopathy - TSA 20.1% 20% 1.4% 20% 25% 5282 Down-
graded 2
levelsa
Acute hepatic encephalopathy - TSA 20.1% 40% 1.4% 20% 25% 1217 Not
down-
gradedd
Chronic hepatic encephalopathy - GRADE Handbook 2.8% 25% 5% 20% Not used 15,312 Down-
graded 1
level
Chronic hepatic encephalopathy - GRADE plausible
RRR
2.8% 20% 1.4% 20% Not used 34,096 Down-
graded 1
level
Table 9.   Comparison of imprecision by GRADE and Trial Sequential Analysis in the comparison of TIPS versus endoscopic intervention with or














































































































































































Chronic hepatic encephalopathy - GRADE plausible
RRR
2.8% 40% 1.4% 20% Not used 7598 Down-
graded 1
level
Chronic hepatic encephalopathy - TSA 2.8% 20% 1.4% 20% 0% 34,099 Down-
graded 2
levelse
Chronic hepatic encephalopathy - TSA 2.8% 40% 1.4% 20% 0% 7600 Down-
graded 2
levelsa
Table 9.   Comparison of imprecision by GRADE and Trial Sequential Analysis in the comparison of TIPS versus endoscopic intervention with or
without medical treatment for prevention of rebleeding in people with cirrhosis  (Continued)
aThe Z-curve did not did not reach 50% of the diversity-adjusted required information size and did not cross any of the sequential boundaries for benefit, harm, or futility.
bThe Z-curve reached the monitoring boundary for benefit.
cThe Z-curve reached the monitoring boundary for futility.
dThe Z-curve reached the monitoring boundary for harm.
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A P P E N D I C E S
Appendix 1. Search strategies
 




June 2020 (40 records)
(shunt* OR dsrs OR tips) AND (sclerotherap* OR band*) AND ('portal hypertension*'






2020, Issue 6 (46 records)
#1 MeSH descriptor: [Portasystemic Shunt, Surgical] explode all trees
#2 ((surgical or total or distal splenorenal or transjugular intrahepatic portosys-
temic) and shunt) or dsrs or tips
#3 #1 or #2
#4 MeSH descriptor: [Sclerotherapy] explode all trees
#5 endoscopic and (sclerotherap* or band*)
#6 #4 or #5
#7 MeSH descriptor: [Hypertension, Portal] explode all trees
#8 MeSH descriptor: [Liver Cirrhosis, Biliary] explode all trees
#9 MeSH descriptor: [Esophageal and Gastric Varices] explode all trees
#10 portal hypertension* or cirrho* or varic*
#11 #7 or #8 or #9 or #10
#12 prevent* and rebleed*
#13 #3 and #6 and #11 and #12
MEDLINE Ovid 1946 to June 2020 (47 records)
1. exp Portasystemic Shunt, Surgical/
2. (((surgical or total or distal splenorenal or transjugular intrahepatic portosys-
temic) and shunt) or dsrs or tips).mp. [mp=title, abstract, original title, name of sub-
stance word, subject heading word, floating sub-heading word, keyword heading
word, organism supplementary concept word, protocol supplementary concept
word, rare disease supplementary concept word, unique identifier, synonyms]
3. 1 or 2
4. exp Sclerotherapy/
5. (endoscopic and (sclerotherap* or band*)).mp. [mp=title, abstract, original title,
name of substance word, subject heading word, floating sub-heading word, key-
word heading word, organism supplementary concept word, protocol supplemen-
tary concept word, rare disease supplementary concept word, unique identifier,
synonyms]
6. 4 or 5
7. exp Hypertension, Portal/
 
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
cirrhosis (Review)
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8. exp Liver Cirrhosis, Biliary/
9. exp "Esophageal and Gastric Varices"/
10. (portal hypertension* or cirrho* or varic*).mp. [mp=title, abstract, original title,
name of substance word, subject heading word, floating sub-heading word, key-
word heading word, organism supplementary concept word, protocol supplemen-
tary concept word, rare disease supplementary concept word, unique identifier,
synonyms]
11. 8 or 7 or 10 or 9
12. (prevent* and rebleed*).mp. [mp=title, abstract, original title, name of sub-
stance word, subject heading word, floating sub-heading word, keyword heading
word, organism supplementary concept word, protocol supplementary concept
word, rare disease supplementary concept word, unique identifier, synonyms]
13. 6 and 11 and 3 and 12
14. (randomized controlled trial or controlled clinical trial).pt. or clinical trials as
topic.sh. or trial.ti.
15. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, origi-
nal title, name of substance word, subject heading word, floating sub-heading word,
keyword heading word, organism supplementary concept word, protocol supple-
mentary concept word, rare disease supplementary concept word, unique identifi-
er, synonyms]
16. 13 and (14 or 15)
Embase Ovid 1974 to June 2020 (98 records)
1. exp Portosystemic Anastomosis/
2. (((surgical or total or distal splenorenal or transjugular intrahepatic portosys-
temic) and shunt) or dsrs or tips).mp. [mp=title, abstract, heading word, drug trade
name, original title, device manufacturer, drug manufacturer, device trade name,
keyword, floating subheading word, candidate term word]
3. 1 or 2
4. exp SCLEROTHERAPY/
5. (endoscopic and (sclerotherap* or band*)).mp. [mp=title, abstract, heading word,
drug trade name, original title, device manufacturer, drug manufacturer, device
trade name, keyword, floating subheading word, candidate term word]
6. 4 or 5
7. exp Portal Hypertension/
8. exp Liver Cirrhosis/
9. exp Esophagus Varices/
10. (portal hypertension* or cirrho* or varic*).mp. [mp=title, abstract, heading word,
drug trade name, original title, device manufacturer, drug manufacturer, device
trade name, keyword, floating subheading word, candidate term word]
11. 8 or 7 or 10 or 9
12. (prevent* and rebleed*).mp. [mp=title, abstract, heading word, drug trade name,
original title, device manufacturer, drug manufacturer, device trade name, keyword,
floating subheading word, candidate term word]
  (Continued)
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13. 6 and 11 and 3 and 12
14. Randomized controlled trial/ or Controlled clinical study/ or trial.ti.
15. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, head-
ing word, drug trade name, original title, device manufacturer, drug manufacturer,
device trade name, keyword, floating subheading word, candidate term word]
16. 13 and (14 or 15)
LILACS (Bireme) 1982 to June 2020 (3 records)
(((surgical or total or distal splenorenal or transjugular intrahepatic portosystemic)
and shunt) or dsrs or tips) AND (endoscopic and (sclerotherap$ or band$)) [Words]




(1900 to June 2020)
and Conference Pro-
ceedings Citation In-
dex – Science (1990
to June 2020) (Web
of Science)
1900 to June 2020 (108 records)
#7 #6 AND #5
#6 TI=(random* or blind* or placebo* or meta-analys* or trial*) OR TS=(random* or
blind* or placebo* or meta-analys*)
#5 #4 AND #3 AND #2 AND #1
#4 TS=(prevent* and rebleed*)
#3 TS=(portal hypertension* or cirrho* or varic*)
#2 TS=(endoscopic and (sclerotherap* or band*))
#1 TS=(((surgical or total or distal splenorenal or transjugular intrahepatic portosys-
temic) and shunt) or dsrs or tips)
  (Continued)
 
W H A T ' S   N E W
 
Date Event Description
22 June 2020 New search has been performed This systematic review and meta-analysis is an update of a pre-
vious version of the review, published in 2006 (Khan 2006). We
used updated Cochrane methods during our work on the review.
We added and analysed 2 additional outcomes: health-related
quality of life, and death due to rebleeding. We performed more
sensitivity analyses, among these assessment of imprecision
with Trial Sequential Analysis, and we compared the results with
the assessment of imprecision with GRADE
22 June 2020 New citation required but conclusions
have not changed
The conclusions in the current review and in the Khan 2006 re-
view overlap regarding no differences between treatments in all-
cause mortality, reduction in rebleeding risk with portosystemic
shunts, and increased acute and chronic hepatic encephalopa-
thy with portosystemic shunts, but our assessment of the cer-
tainty of evidence is very low which means that the we are very
uncertain in the results
22 June 2020 New search has been performed We found 4 ongoing trials
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Date Event Description
25 February 2019 New search has been performed Last search 22 June 2020. This updated review version includes
27 randomised clinical trials with 1828 participants compared to
Khan 2006, which included 22 trials with 1409 participants. One
trial included in the previous version was excluded from the cur-
rent version because of the large number of participants with un-
controlled bleeding, and 2 trial references were confirmed to be
reports of the same trial. One trial excluded in the previous ver-
sion was included in the current version because it was judged
eligible
 
H I S T O R Y
Protocol first published: Issue 4, 1997
Review first published: Issue 4, 2006
C O N T R I B U T I O N S   O F   A U T H O R S
RGS updated the protocol according to recent Cochrane methods and instructions, selected trials for inclusion, rechecked data extracted
and extracted further data, added and analysed two additional outcomes, modified and added information, performed meta-analysis and
Trial Sequential Analysis (TSA), updated references, and rewrote the review.
GP updated the protocol, selected trials for inclusion, rechecked data extracted and extracted further data, added and analysed the two
additional outcomes, modified and added information, performed meta-analysis and TSA analysis, updated references, and revised the
review.
HLR performed the literature search (2018 and 2019), identified relevant studies, used the trial data extraction protocol, extracted data for
individual trials, and performed and updated all meta-analyses as well as time-to-event meta-analyses according to previously published
guidance (developed by the group who published the the last review in 2006). This manuscript was rewritten and updated.
NRB assisted in the literature search (2014), extracted data, identified developments since the last review, and assisted in updating the
current manuscript.
MOW assisted in preparing the manuscript and critically reviewing the outcomes, meta-analyses, and methods.
RS was responsible for placing the current version in its true context with regards to the most recently published literature (including
observational and randomised or synthesised evidence). RS was instrumental in updating the whole text and determining implications for
future research and applicability to practice sections.
SK conceived the current version (2014-2019), developed and updated data extraction protocols for individual trials, extracted data for
surgical shunt comparisons, provided liaison between study authors, acted as the final arbiter of interpretation and directed the team, and
was responsible for overall organisation and oversight of the project.
D E C L A R A T I O N S   O F   I N T E R E S T
RGS: nothing to declare.
GP: nothing to declare.
HLR: nothing to declare.
NRB: nothing to declare.
MOW: nothing to declare.
RS: nothing to declare.
SK: nothing to declare.
S O U R C E S   O F   S U P P O R T
Internal sources
• RS is supported by a National Institute for Health Research Senior Investigator Award, UK
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
cirrhosis (Review)









Cochrane Database of Systematic Reviews
External sources
• European Commission (BMH4-CT96-0373), Belgium
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
This systematic review represents an update of a previously published review, based on a protocol from 1997. Changes in Cochrane
guidance have resulted in minor deviations from the protocol, which were necessary to bring the current review up to current standards.
In addition, several analyses have been added in response to feedback received during the peer review process.
The protocol portion of the review was updated according to updated Cochrane and CHBG methods and requirements and GRADE
methods.
• We changed the title of the review from "Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with
cirrhosis" to "Portosystemic shunts versus endoscopic intervention with or without medical intervention for prevention of rebleeding
in people with cirrhosis" to outline that endoscopic treatment was associated with medical treatment in some trials.
• We added outcomes (health-related quality of life, death due to rebleeding) following comments made by editors during the review
process.
• In response to comments by editors during the review process, we have reported all time-to-event outcomes as dichotomous outcomes
(mortality was planned to be presented as a time-to-event outcome alone).
• We promoted mortality to a primary outcome in accordance with Cochrane guidelines, and we renamed 'all-cause mortality' to
diJerentiate if from death due to rebleeding.
• We used risk ratios (RRs) instead of odds ratios (ORs) because the RR is more appropriate when there are not few events, and because
it is more easily understandable.
• We updated risk of bias assessments in keeping with updated Cochrane guidelines.
• We added risk of bias summary figures in keeping with updated Cochrane guidelines.
• We added 'Summary of findings' tables in accordance with updated Cochrane guidelines, including calculation of optimal information
size.
• We added GRADE assessment in accordance with updated Cochrane guidelines, including calculation of optimal information size.
• We added information about study participants (age, sex, alcohol status) according to updated Cochrane guidelines.
• We added Trial Sequential Analysis in accordance with updated Cochrane Hepato-Biliary Group guidelines, which we used to compare
imprecision according to GRADE instructions.
• We added a study flow diagram in line with updated Cochrane guidelines.
• We searched LILACS and the Conference Proceedings Citation Index in line with updated Cochrane Hepato-Biliary Group guidelines.
• We performed additional sensitivity analyses of included trials,
• We reported financial costs and length of hospital stay as raw outcomes, as reported by trialists, in light of considerable variability of
methods and definitions used by trial authors.
• We performed subgroup analysis according to for-profit funding.
N O T E S
As new trials addressing the questions in the review are unlikely to be published within the next two years, if not significantly longer, we
plan to update this review not before 2024. However, if contrary to our expectations, we identify trials that fulfil the inclusion criteria of
this review before 2024, we will produce an updated version sooner.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Endoscopy  [*methods];  Esophageal and Gastric Varices  [prevention & control]  [*therapy];  Gastrointestinal Hemorrhage  [prevention
& control]  [*therapy];  Hepatic Encephalopathy  [etiology];  Liver Cirrhosis  [*complications];  Portasystemic Shunt, Surgical  [adverse
eJects]  [*methods];  Portasystemic Shunt, Transjugular Intrahepatic  [adverse eJects];  Randomized Controlled Trials as Topic; 
Secondary Prevention;  Splenorenal Shunt, Surgical  [adverse eJects]
MeSH check words
Humans
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with
cirrhosis (Review)
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